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RÉSUMÉ  
 
L’hypercholestérolémie familiale (FH) est un désordre lipidique associé aux maladies 
cardiovasculaires les plus fréquentes. La FH est causée par des mutations dans les 
gènes LDLR, APOB et PCSK9. Toutefois, chez 20% des patients souffrant de FH, 
aucune mutation dans ces gènes n'a été détectée et ceci suggère que d’autres gènes 
seraient à l’origine de la FH. Actuellement, le seul traitement de la FH est une thérapie 
aux statines. En général les statines sont bien tolérées, cependant, une monothérapie 
ne permet pas d’atteindre des niveaux thérapeutiques acceptables et dans bien des cas, 
une thérapie combinée devient nécessaire. De plus, l’intolérance aux statines est 
présente dans environ 12% des patients. Dans les trois dernières décennies, la survie 
des patients avec la FH a augmentée de façon notoire mais on observe aussi 
l’apparition d’une calcification vasculaire sévère chez certains d’entre eux. Il est donc 
primordial de développer des nouvelles approches thérapeutiques afin de prévenir ces 
complications tardives. 
 
Dans cette thèse doctorat, nous présentons l’étude d’une famille avec un phénotype 
de FH sévère non causé par des mutations dans les gènes LDLR, APOB et PCSK9. Par 
des études biochimiques et par séquençage d’ADN utilisant les technologies de nouvelle 
génération (NextGenSeq), nous avons découvert une mutation dans le gène de l’APOE 
(Leu167del). Ceci nous permet de proposer le gène codant pour l’APOE comme le 4e 
locus responsable de la FH (FH4). Par la suite, nous avons effectué deux études de 
cohortes chez les patients atteints de FH. Premièrement, dans l’étude JUPITER, nous 
avons démontré que la rosuvastatin augmente les niveaux sanguins de la protéine 
PCSK9 et ceci limiterait l’efficacité du traitement aux statines. Nous avons aussi étudié 
l’influence du mutant naturel R46L (perte de fonction de la PCSK9) dans la réponse aux 
statines. Deuxièmement, nous avons examiné les effets de la perte de fonction de la 
PCSK9 sur le profil cardiométabolique au sein d’une population pédiatrique. Nous avons 
déterminé  que le génotype de l’APOE est déterminant dans ce profil cardiométabolique. 
Enfin, nous avons étudié la calcification vasculaire chez les patients atteints de FH. 
Cette calcification vasculaire progresse de façon indépendante des niveaux de 
cholestérol sérique et n’est pas associée aux anomalies de l’homéostasie du calcium. 
En utilisant des modèles murins, nous avons démontré que les souris Ldlr-/- et Tg(Pcsk9)  
développent des calcifications vasculaires semblables à celles observées chez l’homme. 
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De plus, nous avons confirmé  l’implication de la voie de signalisation LRP5/Wnt dans la 
pathophysiologie de la calcification artérielle. Avec une étude interventionnelle, nous 
avons trouvé que l’inhibition de l’interleukine 1β (IL-1β) diminue fortement l’apparition de 
calcifications vasculaire dans notre modèle murin. 
 
En conclusion, nos études ont permis l’identification d’un nouveau gène impliqué 
dans la FH, ont démontré aussi que les statines augmentent les niveaux sériques de 
PCSK9 et que la perte de fonction de la PCSK9 altère le profil cardiométabolique. Enfin, 
nous avons établi que la calcification vasculaire représente une complication tardive 
chez les patients atteints de FH et que, dans notre modèle murin, la calcification 
vasculaire peut être retardée par l’inhibition d’IL-1β. Ces découvertes peuvent avoir 
d’importantes répercussions cliniques chez l’humain.  
 
Mots-clés: FH, ADH, LDLR, PCSK9, APOE, IL-1β, Calcification, la prévention 
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ABSTRACT 
 
Familial Hypercholesterolemia (FH) is the most common lipoprotein disorder 
associated with premature cardiovascular disease. Mutations in the LDLR, APOB and 
PCSK9 genes cause the FH phenotype, but in a20% of FH patients, no mutations in 
these genes are identified, suggesting that mutations in other genes cause FH. 
Treatment with statins has been the cornerstone of therapy. While statins are generally 
well tolerated, statin intolerance is found in approximately a12% of patients. 
Furthermore, statin use may not allow reaching LDL-C goals and combination therapy is 
often required. Nevertheless, survival of FH patients over the past 3 decades has 
improved significantly. As FH patients live longer, severe vascular calcifications have 
been described as a late complication in these patients. Given the increased survival 
rate and late complications, novel approaches and therapies are needed.  
 
In the present thesis we examined a kindred with a severe FH phenotype, where 
sequencing of candidate genes failed to identify a causal mutation. Through biochemical 
analysis and next-generation exome sequencing we report a mutation (Leu167del) 
within the APOE gene that identifies the 4th locus causing FH (FH4). Next, we performed 
two cohort-based studies. Firstly, in the JUPITER trial we report that 20mg rosuvastatin 
treatment increases PCSK9 levels by a30%, thereby possibly limiting the efficacy of 
statin therapy. Then we show the effect of a loss-of-function (LOF) mutation of PCSK9, 
p.R46L, on the response to rosuvastatin. Secondly, we report that two PCSK9 gene 
variants, p.R46L and insLEU, were more frequent in French Canadian individuals. We 
also report that the APOE genotype determine the metabolic risk profile in these 
mutations. Finally, we studied vascular calcifications in FH individuals. These 
calcifications appear to progress independently of cholesterol levels and are not 
associated with disturbances in calcium homeostasis. Using mouse models, we show 
that Ldlr-/- and Tg(Pcsk9) mice develop aortic calcifications similar to that observed in 
humans. Furthermore, the involvement of the LRP5/Wnt pathway in the pathogenesis of 
calcification is illustrated. In a proof-of-concept experiment, inhibiting the upstream pro-
inflammatory cytokine IL-1ȕ attenuates calcification in mice. 
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
In conclusion, we have contributed to the identification of a novel locus 
responsible for FH, reported the increase in PCSK9 levels with a statins treatment and 
the associated altered cardiometabolic profile in PCSK9 LOF. Finally, we demonstrated 
that vascular calcifications represent a severe complication of FH that can be prevented 
by inhibiting IL-1ȕ in a mouse model. The latter novel approach may have an important 
translational application in human. 
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CHAPTER 1: LITERATURE REVIEW 
 
1. Prevention of Cardiovascular Disease (Introduction) 
The American cardiovascular disease (CVD) epidemic began after the Second 
World War, often affecting businessmen in their fifties. At that time, CVD was attributed 
to work-related stress in these otherwise healthy men (Keys et al. 1963). Ancel Keys, a 
biochemist from the University of Minnesota also known as “The Father of the Low Fat 
Diet”, was among the first to suggest that dietary fats might be the cause of this 
epidemic. In 1952, Keys and his colleagues conducted the pivotal Seven Countries 
Study (Circulation et al. 1970, Keys et al. 1980), which enrolled 12,000 participants and 
was the largest study at that time. From this large study, Keys and his colleagues 
reported a correlation between fat consumption and rates of heart disease. Thus, as a 
preventive measure to decrease CVD, the authors advocated the reduction of fat 
consumption to <39% of total caloric intake. This movement launched the notion of CVD 
prevention, while later the Framingham Heart Study (Kannel et al. 1961) associated 
cholesterol levels to CVD. From then on, the American Heart Association (AHA) 
advocated lower dietary fat intake for men with high total cholesterol levels.  
 
Donald S. Fredrickson was later responsible for developing a classification 
system for dyslipidemia (abnormal amount of lipids in the blood) based on 
electrophoretic lipoprotein patterns and clinical features (Fredrickson et al. 1965). This 
system was the first to differentiate type III Familial Dysbetalipoproteinemia from type IIa 
Familial Hypercholesterolemia (FH) (Levy et al. 1967). Fredrickson’s classification did 
not address the mode of inheritance, secondary sources of dyslipidemia or plasma high-
density lipoprotein cholesterol (HDL-C) levels. Nevertheless, it was adopted by the 
World Health Organization (WHO) as an international standard and thus brought global 
attention to lipoprotein and lipid disorders (Fredrickson et al. 1971). Fredrickson was 
also the leading investigator of the group that conducted the landmark Coronary Primary 
Prevention Trial (CPPT) (The Lipid Research Clinics 1984). When this study began in 
1973, epidemiological studies had not yet associated increased low-density lipoprotein 
cholesterol (LDL-C) levels and CVD. Indeed, CPPT was the first study to conclusively 
establish that lowering LDL-C levels pharmacologically results in CVD reduction (Gotto 
et al. 2002). 
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According to the World Heart Federation 17.1 million lives are now claimed 
annually by the global burden of heart disease and stroke, 82% of which are in the 
developing world (www.world-heart-federation.org). This alarming statistic is sad, as 
simple preventive measures can effectively reduce this pandemic. These include low-
cost non-pharmacologic measures such as: cessation of smoking, healthy eating, 
regular physical activity and weight loss. However, such strategies are ineffective in 
cases of premature CVD (defined as the occurrence of CVD before age 55-60 in men 
and 65 in women). Prevention of premature CVD requires initiation of pharmacological 
therapy early on, since the underlying cause is typically a combination of genetic 
predisposition and unhealthy lifestyle. The prevalence of dyslipidemia is higher in 
individuals with premature CVD compared to age-matched controls without CVD 
(Genest et al. 1992, Roncaglioni et al. 1992) (Figure. 1).  
 
 
 
Figure 1: Dyslipidemia is a major risk in CVD. As shown in the chart, dyslipidemia 
accounts for 54% of the attributable risk for developing CVD in the INTER-HEART study 
(Yusuf et al. 2004 and Ruff et al. 2010). In addition, subjects with premature CVD have a 
54% chance of having CVD if they had familial dyslipidemia (Genest  et al. 1992). Given that 
the prevalence of FH is 1:500 to 1:80 in some subpopulations, it is reasonable to assume that 
a significant proportion of  dyslipidemias will be FH and therefore represent an unmet 
opportunity in CVD prevention (adopted from both Ruff and Braunwald et al. 2010 and 
Genest et al. 1992).  
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The INTER-HEART study (a global heart study designed to assess the 
significance of CVD risk factors in different populations) reported that dyslipidemia (high 
apoB:apoA1 ratio) had the highest attributable risk (54%) for the development of 
myocardial infarction (MI) (Yusuf et al. 2004) (Table 1). 
 
 
Table 1: Risk of CVD associated with risk factors in the general populations 
Risk factor Odds Ratio  
(Yusuf et al 2004)  
Attributable risk %  
(Ruff and Braunwald 2010) 
Diabetes mellitus * 
No exercise 
No fruit and vegetable intake 
No alcohol intake 
Hypertension 
Psychosocial factors 
Abdominal obesity * 
Current smoking * 
Dyslipidemia* (high apoB:apoA1 ratio) 
8.08 
0.72 
0.70 
0.79 
2.48 
2.51 
2.24 
2.27 
3.87 
12.3 
25.5 
12.9 
13.9 
23.4 
28.8 
33.7 
36.4 
54.1 
* Risk factors for both atherosclerosis and arterial calcification, Apo: apolipoprotein (adopted from 
Yusuf et al. 2004 and Ruff and Braunwald 2010). 
 
 
 
Familial Hypercholesterolemia (FH) also referred to as Autosomal Dominant 
Hypercholesterolemia (ADH), is a prevalent type of dyslipidemia in the general 
population. FH and ADH are used interchangeably, ADH being the newer and less used 
term after the discovery of non-classical genes associated with the same phenotype. 
  
The prevalence of FH in the population is most often quoted as affecting 1:500 
individuals worldwide (Goldstein et al. 2001). Thus, FH puts an individual at risk for 
premature CVD. Since early detection and treatment can improve outcomes 
(Nordestgaard et al. 2013) it is imperative that FH be indentified early in life, yet 
presently it is under-diagnosed. Therefore the majority of national guidelines have 
recognized that FH and other high risk CVD conditions such as advanced diabetes, 
chronic kidney disease and chronic inflammation require early intervention (Anderson et 
al. 2013, Stone et al. 2013). In these guidelines, patients are stratified according to 
gender and family history as either high- or moderately high-risk. Regardless of the level 
of CVD, physician must actively treat patients with such risk factors; the initial preventive 
measure is the prescription of a cholesterol lowering medication.  
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In some cases, cholesterol lowering medications are either contraindicated (liver 
toxicity), associated with adverse effects (drug intolerance, myopathy, rhabdomyolysis), 
or do not allow the patient to reach target levels, as determined by the current guidelines 
(Anderson et al. 2013, Stone et al. 2013). Thus, new therapeutic approaches are 
required to decrease CVD and associated atherosclerosis (hardening of the arteries). 
Additionally, the development of a national FH registry would facilitate a targeted 
cascade screening of families. In targeted cascade family screening, undiagnosed family 
members of the index FH patient (proband) are screened for FH. Cascade family 
screening also provides an opportunity to implement the best medical practices, and to 
better understand the underlying basic biology of the disease.  For example, new 
mutations may be identified through index cases and confirmed by family screening 
leading to the identification of new therapeutic targets. This was how pro-protein-
convertase-subtilisin-kexin-9 (PCSK9) was linked to FH, thereby offering a new 
treatment targeting PCSK9. Furthermore, the measurement of serum levels of PCSK9 
can be used as a tool in cascade family screening to identify likely FH individuals, and as 
a criterion for placing FH patients on PCSK9 inhibitor (blocking monoclonal antibody) 
regiments. The fascinating role of PCSK9 in lipid metabolism is assisting in the evolution 
of a new category of pharmacological approaches to lower cholesterol (discussed further 
in Part 3 of this Chapter).  
 
The first chapter of this thesis is divided into 5 parts:  
x Part 1: Prevention of Cardiovascular Disease (Introduction), see above. 
x Part 2: Overview of Familial hypercholesterolemia. Including a description of the use 
of registries to discover new mutations (APOE gene, 4th loci in FH) that would assist 
in cascade family screening to prevent CVD (related to Chapter 2). 
x Part 3: Familial hypercholesterolemia and PCSK9. Including a description of PCSK9, 
the 3rd locus in FH and approaches for screening different populations using PCSK9 
levels to identify natural loss-of-function (LOF) mutations (related to Chapter 3 and 
Chapter 4).  
x Part 4: Familial Hypercholesterolemia and calcified atherosclerosis. This section 
includes the biology and molecular mechanism of aortic calcification in FH and the 
associated subendothelial inflammation (related to Chapter 5 and Chapter 6).  
x Part 5: Hypothesis and objectives.  
Finally, I will discuss and summarize the overall progress (Chapter 7). 
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2. Familial Hypercholesterolemia (FH) Overview  
 
2.1. Familial hypercholesterolemia definition, signs and symptoms 
The catalogue assignment number for FH at the Mendelian Inheritance in Man 
(MIM) system is [MIM:143890] and may also be referred to as essential 
hyperlipoproteinemia, type IIa hyperlipoproteinemia and hypercholesterolemic 
xanthomatosis. FH is a genetic disorder where an affected individual has abnormally 
elevated LDL-C levels; above the 95th percentile. Before the genes that are responsible 
for the disease were identified, the mode of FH inheritance was first described by 
Khachadurian in 1964. FH shows a Mendelian pattern of inheritance; it can be inherited 
in an autosomal dominant fashion or an autosomal recessive fashion. Autosomal 
dominant inheritance is the most prevalent form of FH. In FH, the abnormal elevation of 
LDL-C is primarily attributable to mutations in the low-density lipoprotein receptor gene 
(LDLR) (Goldstein et al. 1974, Brown et al. 1974). High levels of LDL-C increase the risk 
of atherosclerosis that results in narrowing and hardening of the arteries at an early age 
seen in many patients with FH. Given the genetic background, FH disease begins at 
birth leading to lifelong LDL-C elevation and can cause premature CVD, myocardial 
infarction (MI) or even death.  
 
Many attempts have been made to develop a unified definition and diagnostic 
criteria of FH. There are at least three sets of genetically and statistically trusted criteria 
that are most commonly used: the Dutch (Civeira et al. 2004), the UK (Simon Broome et 
al. 1991) and the MedPed criteria (Williams et al. 1993). Below is an illustration of the 
Dutch Lipid Network criteria (Nordestgaard et al. 2013) (Table 2). 
 
Table 2: Dutch Lipid Clinic Network criteria for diagnosis of FH in adults 
Group 1:  
Family history  
Group 2:  
Clinical history 
Group 3:  
Physical exam 
Group 4: 
Biochemical 
Group 5: 
Molecular test 
1: 1st degree relative with 
known premature coronary 
heart disease (CHD) OR 
2: Subject has 
premature CHD 
6: Tendon 
xanthoma 
8: >8.5 mmol/L 
(325 mg/dL)  
8: mutation in 
LDLR, APOB, or 
PCSK9 genes 
1: 1st degree relative with 
known LDL-C >95th % 
1: premature 
cerebral or PVD* 
4: Corneal arcus in 
a person >45 Y 
5: >6.5–8.4 (251–
325) 
 
2: 1st degree with xanthoma  
+/- corneal arcus OR 
Add the pints in each group to obtain a score: 
- Definite FH if the subject scores 8. 
- Probable FH if the subject scores 6 to 8. 
- Possible FH if the subject scores 3 to 5. 
- Unlikely FH if the subject scores 0 to 2. 
3: >5.0–6.4 (191–
250) 
 
2: Child(ren) ,18 years with 
LDL-C >95th % 
1: >4.0–4.9 (155–
190) 
 
* PVD: peripheral vascular disease (adopted from Nordestgaard et al. 2013). 
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FH diagnosis requires plasma LDL-C levels to be elevated by 2-fold (likely 
heterozygous FH) or 3- to 5-fold (likely homozygous FH) above the reference levels of a 
control population adjusted for age and sex. In FH patients, serum triglyceride (TG) 
concentrations remain within a normal range (Rader et al. 2003). Limited workup should 
be performed to rule out secondary hypercholesterolemia that can mimic the FH 
phenotype. Essential tests to rule out diabetes, hypothyroidism, hepatic disease and 
renal disease are usually adequate (Awan et al. 2009). Other tests that are done to 
confirm an FH diagnosis include: (i) genetic screening for mutations known to be 
associated with FH and (ii) use of fibroblast cultures to determine LDLR levels and/or 
activity. 
 
Signs of FH may include: fatty skin deposits called xanthomas over the hands, 
elbows, knees, ankles; xanthelasmas or fatty deposits near the eyelid (Figure. 2). In 
some cases, the systolic murmur (loud sound heard during a heartbeat) of aortic 
stenosis and carotid artery stenosis reflects valve calcification and severe 
atherosclerosis, respectively. Angina (pain in the chest) or other signs of coronary artery 
disease may be present at a young age.  
 
 
Figure 2: Signs and symptoms of FH. The panel on the left shows the skin manifestations 
of FH including xanthelasmas around eyes, tendinous xanthomas in hands and Achilles 
tendon xanthoma in a man in his 40’s. The lesions are demarcated with a dash line (photos 
are related to the patient in chapter 2). The panel on the right shows a computed tomographic 
(CT) scan of a woman in her 40’s with homozygous FH. In the center is the CT scan 
reconstruction (3D) of her aorta showing calcified lesions and on the sides are horizontal CT 
scan cuts corresponding to the same lesions indicated by dash arrows (adopted from Awan 
et al. 2008 and 2013). 
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2.2. Molecular genetics of familial hypercholesterolemia  
FH is a genetic disease with a Mendelian pattern of inheritance, where affected 
individuals have elevated total cholesterol predominantly due to elevation in LDL-C 
levels. The genetic basis of FH is primarily a result of mutations in the LDLR gene 
(Goldstein et al. 1974, Brown et al. 1974, Asselbergs et al. 2012); however, new genes 
are still being shown to be associated in the broad-spectrum of FH (i.e., Autosomal 
Dominant Hypercholesterolemia, ADH). The LDLR is located on chromosome 19 (FH1, 
19p13.1-13.3) (Lindgren et al. 1985) and many mutations have been identified in this 
gene (Heath et al. 2000, Villeger et al. 2002). More than 1000 mutations in the LDLR 
gene (Guardamagna et al. 2009) with the associated endocytosis pathway have been 
identified to date. They are classified into the following groups (Goldstein et al. 1987, 
Hobbs et al. 1990) (Table 3):  
Table 3: Broad classes of mutations in the LDL receptor (LDLR) 
1) A null mutation: LDLR is either not synthesized in Endoplasmic Reticulum (ER) or fails to mature in 
Golgi Body. For example, the 15kb or larger deletion in the promoter and first exon yield no protein. This 
null mutation is a common mutation in French-Canadians (Awan et al. 2008).  
2) Defective binding: LDLR is made and reaches the cell surface but cannot bind its apoB ligand, 
resulting in LDL not being internalized nor cleared from the blood. This type of defect can also be 
mimicked by mutations in the APOB gene encoding apoB. Interestingly, apoE also binds LDLR and thus 
the LDLR is often called apoB/E receptor (discussed further in Chapter 2) 
3) Defective recycling: LDLR reaches the cell surface (newly synthesised each time) and cannot recycle 
back once internalized. This type of defect can also be mimicked by gain-of-function mutations in the 
PCSK9 gene which targets intra-cellular LDLR for degradation and prevents its recycling (Seidah et al. 
2003). 
4) Defective internalization: LDLR can bind the ligand but does not cluster in the coated pits, thereby 
minimizing LDL internalization. Mutations in autosomal recessive hypercholesterolemia gene (LDLRAP1 
or ARH) can cause defective internalization (Anderson et al. 1977, Zuliani et al. 1999, Garcia et al. 2001, 
Arca et al. 2002). 
Sources are indicated in each class 
 
Similarly, mutations in 2 other genes are responsible for causing FH. One of 
these is the apolipoprotein B-100 gene (APOB), located on chromosome 2 (FH2, 2p23-
24) (Knott et al. 1985, Law et al. 1985). APOB encodes for the protein ligand of the LDL 
particles (Innerarity et al. 1990). In contrast to LDLR, only a small number of loss-of-
function (LOF) mutations have been identified in APOB. The third gene found to be 
associated with FH, is the PCSK9 gene identified on chromosome 1 (FH3, 1p32) 
(Seidah et al. 2003, Abifadel et al. 2003). In one FH cohort, it was estimated that 64% of 
mutations were associated with the LDLR, 16% with APOB and 2% with PCSK9 
(Abifadel et al. 2003, Seidah 2009). There are still 17% unknown mutations that cannot 
be accounted for. Thus, identifying new mutations and novel genes associated with FH 
will bring important insights to the field.  
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The carrier frequency of mutations leading to FH in the general population is 
1:500 (Brown et al. 1983); however, this frequency increases in certain French-Canadian 
subpopulations who may suffer from the “founder effect” of the first French settlers. This 
founder effect may be explained by many years of geographical isolation and a small 
genetic pool. The carrier frequency in some of the rural sites in Quebec can reach 1:80 
(Scriver et al. 2001). This phenomenon may be observed not only in the French-
Canadian population but in similar culturally isolated environments in South-Africa, as 
well as in some regions of Italy, Scandinavia and Lebanon (Khachadurian 1964).  
 
Homozygous FH occurs when a child inherits the same mutation from both 
parents. When this rare form of FH occurs (1 in a million), the increase in cholesterol 
levels is much greater than in the heterozygous form (Awan et al. 2008). The 
homozygous form of undiagnosed and untreated FH can lead to heart attack and death 
within the first decade of life.  
 
From a clinical perspective, human mutations in FH are of two categories 
depending on residual LDLR activity (Rader et al. 2003), either less than 2% activity 
(receptor-negative, poor response to statin) or 2-25% activity (receptor-defective, good 
response to statin). The latter category is the one that would respond to PCSK9 
inhibition (Stein 2013) since PCSK9 function is mediated through LDLR. Mutations in 
PCSK9 causing FH are usually on the background of an active LDLR and will be 
discussed further in Part 3 
 
Familial hypercholesterolemia molecular diagnosis - Individuals with clinical signs 
and symptoms of FH are referred to specialized lipid centres where they can be offered 
a sensitive lipoprotein testing that includes lipoprotein fractionation by Fast Protein 
Liquid Chromatography (FPLC) and molecular testing. A pedigree is constructed around 
the proband (with a premature CVD; for example) and detailed lipid profiles and histories 
of CVD from close family members are carried out to identify affected subjects. A 
candidate gene approach usually is used to sequence exons of the LDLR, APOB and 
PCSK9 genes, as well as genes involved in Autosomal Recessive Hypercholesterolemia 
(ARH; also called LDLRAP1), and recently the LIPA gene that regulates cholesterol 
ester accumulation (Stitziel et al. 2013). In many clinical cases, FH patients fail to show 
a mutation in these genes.  
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In addition, candidate genes are reported to be negative in many clinically 
diagnosed FH cohorts who are screened for mutations. Thus, a search for common copy 
number variants (CNV) at the 5’ end of LDLR is usually performed if the individual is of 
French-Canadian heritage. One study showed that exon-by-exon sequencing analysis 
diagnosed only two thirds (67%) of the FH patients (Wang et al. 2005). However, using 
the Multiplex Ligation-Dependent Probe Amplification (MLPA) technique to detect CNV, 
additional 9% mutations were detected in the negative patients (Wang et al. 2005). This 
suggests that heterozygous LDLR CNV's are associated with more severe phenotypes 
and they are usually missed by exon-by-exon sequencing (Hegele et al. 2006). This 
suggests that mutations in LDLR represent ~76% of those associated with FH. With the 
estimated 14% mutations in APOB contributing to FH (Seidah 2009), this leaves ~10% 
contributions to FH by mutations in other genes. Thus, more mapping studies to look for 
novel genes (discussed further in Chapter 2) are needed to complete the list of genes in 
the FH spectrum. 
 
Whole exome sequencing with next-generation sequencing technology is a 
powerful approach (Marduel et al. 2013, Reddy et al. 2012). This involves a large-scale 
automated genome analyser that screens the entire coding genome region for 
mutations. However, this method identifies a very large number of variants (typically 
>105) that are non-deleterious. These include common variants (i.e., genetic variants 
with a minor allele frequency of > 5%), intronic variants and variants that do not fit a 
Mendelian pattern of inheritance. Therefore, genetic filters are used to remove variants 
that are unlikely to be causal. This includes identified SNPs in non-coding regions and 
genetic variants that are not expected to impart functional defects through in silico 
analysis using genetic software; PolyPhen-2 (http://genetics.bwh.harvard.edu/pph2) and 
SIFT (http://www.jcvi.org). Once a novel candidate is identified, we evaluate the mutation 
in vivo or in silico to understand its impact. The latter involves computer prediction, using 
modeling software and algorithms to identify and illustrate the impact of a mutation on a 
protein function, thus the name in silico experiments. For example; the Protein Variation 
Effect Analyzer (PROVEAN) server is an in silico tool that is reserved for variants with 
more than one SNP change. This tool is able to reliably predict if a given genetic variant 
is deleterious to the protein structure and assign a probability score 
(http://provean.jcvi.org/index.php) (PROVEAN 2013).  
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Afterwards, using the template-based protein structure modeling I-TASSER 
server (http://zhanglab.ccmb.med.umich.edu/I-TASSER), or similar software available 
online, we can predict in silico the effect of the variant on the 3-dimensional structure of 
the protein. This important step allows the visualization of the protein structure and the 
mutations site with programs like PyMol (http://www.pymol.org). PyMol is a computer 
program that allows the 3-dimensional viewing of both a mutated protein generated as 
mentioned above and a crystallized wild-type protein side by side and thus permits 
comparative studies. These tools globally assist in predicting the effect of a given 
genetic variant on the protein structure. However, the ultimate functional test is the LDLR 
binding assay. Once a new mutation is identified from genetic screening and is 
suspected to be causal, this candidate gene must be sequenced in affected and 
unaffected family members (Sanger et al. 1977) to confirm association of the mutation 
with disease. Sanger sequencing is the gold standard for detecting genetic variants; 
even variants identified by next generation sequencing technologies must be confirmed 
by Sanger sequencing. The new mutation is finally sequenced independently in a series 
of individuals with a clinical diagnosis of FH but without (negative) a known mutation in 
LDLR, APOB or PCSK9 to determine the prevalence of this mutation. If analyses from 
sequencing results show that this new mutation segregates very well with FH, the gene, 
in which this new mutation is located, can be classified as a new causal gene for FH, in 
addition to the three known FH-causing genes. 
 
Familial hypercholesterolemia and GWAS studies - The Global Lipid Genetic 
Consortium is an international, collaborative, meta-analytical study that used the 
Genome Wide Association Study (GWAS) approach to identify common loci that are 
associated with lipid levels in the human population. The GWAS study by the Global 
Lipid Genetic Consortium (GLGC) identified 95 loci that affect lipid levels in the human 
population. The GLGC has shown that 37 of the 95 SNPs affect LDL cholesterol levels in 
the general population (Teslovich et al. 2010). This is of significant value since a 
percentage of FH patients who do not have mutations in any of the known FH-causing 
genes, thus referred to as mutation negative FH, and may actually be associated with 
these SNPs.  
Recent work by Talmud et al to identify an alternate molecular basis for FH, 
studied mutation negative FH patients and found that FH could be polygenic and not of 
conventional Mendelian inheritance. In this work, they tested for significantly greater 
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association of 12 LDL-C SNPs in mutation negative FH patients relative to FH patients 
with known FH causing mutations (i.e. Mutation positive FH patients) (Talmud et al. 
2013).  The work of Talmud et al showed that FH can also have an alternate genetic 
origin such as a polygenic etiology because the accumulation of those 12 SNPs was 
significantly greater in mutation negative FH patients than in mutation positive FH 
patients. These SNPs include two mutations in apoE and many apoE isoforms. GWAS 
studies have shown that apoE is strongly linked to LDL-C levels (Asselbergs et al. 2012). 
Furthermore, the first to report a strong genetic link between an APOE mutation and FH 
in a large family was Marduel et al.   
 
2.3. Familial hypercholesterolemia, lipid metabolism and atherosclerosis  
Prognosis of FH depends largely on the severity of the mutation, the impact of 
the mutation on LDLR function, how early a diagnosis of the disease is made and the 
start and intensity of treatment. Treatment may significantly delay atherosclerosis and 
heart attack, but does not eliminate the underlining condition. Risk of death generally 
varies among FH, but individuals who inherit two copies of a defective gene 
(homozygotes) have a poorer outcome. Homozygous FH causes early heart attacks, is 
resistant to treatment and may cause development of aortic calcification (Awan et al. 
2008). Late complications include aortic valve stenosis that may require urgent 
replacement.  
Herein, I will present the biochemical pathways where excess circulating 
cholesterol leads to complications. I will illustrate how cholesterol is transported in the 
blood and the essential role of different biological players, namely, the low-density 
lipoprotein receptor (LDLR), Proprotein convertase subtilisin/kexin type 9 (PCSK9) and 
the widely expressed ligand apoE. 
Lipoproteins are macromolecular structures via which hydrophobic lipids can be 
transported through the aqueous environment of the blood. A lipoprotein is defined as a 
complex of lipid and protein (apolipoprotein), wherein hydrophobic lipids are surrounded 
by a monolayer of phospholipid and peripherally located apolipoproteins. The 
amphipathic apolipoprotein interacts with the aqueous environment of the blood via its 
hydrophilic face while the hydrophobic face is buried in the ‘hydrophobic lipid core’. 
Lipoproteins can be classified by size and density, and the following are lipoproteins 
found in the body in the order of decreasing size: chylomicrons, very-low density 
lipoprotein (VLDL), intermediate density lipoprotein (IDL), low-density lipoprotein (LDL), 
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and high-density lipoprotein (HDL). Lipoprotein particles constantly exchange, transfer 
and accept free cholesterol, triglycerides (TG) and proteins from other lipoprotein 
particles and tissues. Lipoproteins are also classified according to their densities and 
diameters, which reflect their load of cholesterol, TG and apolipoproteins as illustrated in 
(Figure. 3): 
 
 
 
Figure 3: Lipoprotein class and subclass. Lipoprotein are measured by density-gradient 
ultracentrifugation. A lipoprotein particle is composed of apolipoproteins, phospholipids, 
triglycerides, cholesterol and cholesteryl ester (adopted from Grundy et al. 1990).  
 
A single lipoprotein particle is usually composed of specific combinations  of 
apolipoproteins, free cholesterol, triglyceride (TG), phospholipids and cholesteryl esters. 
When traveling in the blood, lipoproteins are susceptible to plasma and tissue enzyme 
actions, thus lipoprotein metabolism/catabolism can be described in three conventional 
pathways namely; the endogenous pathway, the exogenous pathway and the reverse 
cholesterol transport pathway (Brown et al. 1983, Von Eckardstein et al. 2001) (Figure. 
4).  
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Figure 4: Lipid metabolism and cholesterol transport pathways. VLDL, CM and HDL 
initiate and mediate the (1) exogenous, (2) endogenous and (3) reverse cholesterol transport 
processes; respectively. Abbreviation – LDL: low density lipoprotein, VLDL: very low density 
lipoprotein, HDL: high-density lipoprotein, IDL: intermediate-density lipoprotein, ABCA1: ATP-
binding cassette 1, CETP: Cholesteryl ester transfer protein, CM: chylomicron, FFA: free fatty 
acid, LCAT: lecithin: cholesterol acyl transferase, LPL: lipoprotein lipase, PLTP: phospholipid 
transfer protein (adopted from Genest and Libby 2011). 
 
The exogenous pathway - In the intestinal epithelium; dietary cholesterol, TG, 
apolipoproteins (apo) A-I and A-II, A-IV, A-V, apo B-48 and phospholipids are assembled 
into chylomicron (CM) particles. Postprandially, CM facilitates the transport of these 
dietary lipids through the aqueous plasma and distributes them to different tissues. 
Shortly after their secretion into the circulation, an exchange of lipid components and 
apolipoproteins takes place between CM and HDL. In circulating blood, free cholesterol, 
apoE, apoC-II, apoC-III and phospholipids are transferred from HDL to CM while apoA’s 
are transferred from CM to HDL. ApoC-II in the chylomicrons activates lipoprotein 
lipases (LPL) found on the epithelium of muscle and adipose tissues (Saxena et al. 
1991) and associated with heparan sulfate proteoglycans (HSPG). Thus when a VLDL 
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particle docks onto a VLDL receptor (VLDLR), the LPL starts to hydrolyze TG in the core 
of the particle. Newly liberated free fatty acids (FFA) can then enter either adipocytes for 
storage as TG or enter myocytes for energy utilization (Jensen et al. 2003). As a result, 
CM shrink in size and free cholesterol, apoC-II, apoC-III, and phospholipids are taken 
back to HDL particles. CM-remnants containing apoB-48, apoE and cholesteryl esters 
are internalized and catabolized after binding the hepatic apoE receptor (Brown et al. 
1983, Gregory et al. 2001). In brief, exogenous source of lipids (i.e. from diet) are 
transported as CM which circulate and transfer lipids to tissues. 
 
The endogenous pathway - The metabolism of lipids from an endogenous source 
is referred to as the endogenous pathway or de novo pathway. This pathway is the 
fundamental cause of FH. De novo lipids synthesised by the liver are incorporated in 
nascent VLDL particles for export. These VLDL contains more TG relative to cholesterol 
in addition to apoB-100, apoE and phospholipids.  ApoB-100 and TG are assembled by 
microsomal TG transfer protein (MTP) enzyme and secreted by hepatocytes into the 
circulation when the body is fasting. In circulation; apoE, apoC-II and apoC-III are 
transferred to the VLDL particle from HDL. ApoC-II activates LPL to hydrolyze TG from 
VLDL and yield denser and smaller intermediate-density lipoprotein (IDL) particles. The 
liver removes some IDL particles through the apoE receptor (Brown et al. 1983). 
Formation of LDL from IDL is only accomplished after most CE is transferred from HDL 
to IDL, while apolipoproteins and TG (except apo B-100) are removed from IDL. The 
LDL particle is now capable of taking cholesterol to hepatocytes and metabolically active 
tissues like adrenals that are also capable of LDL receptor (LDLR)-mediated 
endocytosis. The LDLR is mostly expressed at the hepatic cell surface (Brown et al. 
1983) that recognizes the ligand apoB-100, but also recognizes the apoE carried on 
VLDL remnants, IDL and some classes of HDL (Innerarity et al. 1990, Kane et al. 2001). 
Thus, the LDLR is frequently called apoB/E receptor (Olsson et al. 1997). Receptor-
mediated endocytosis of the LDL particles by LDLR occurs in most, but not all, cells in 
clathrin-coated vesicles. This step involves the LDLR adapter protein 1 (LDLRAP1; 
ARH), hence its absence causes an autosomal recessive form of the disease (Garcia et 
al. 2001, Arca et al. 2002). Upon internalization, the low pH in endosomes facilitates the 
dissociation of the LDLR from its ligand LDL, composed of apoB and lipid (Figure. 9, 
Part 3).  
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The LDLR then recycles back to the surface to clear more LDL particles from 
circulation (Goldstein et al. 1985). The liver then utilizes this cholesterol and TG to 
synthesize VLDL particles, which are then exported once again into circulation and/or 
excreted in the intestine as bile acid salts. Shortly after the LDLR discovery in 1979, 
Brown and Goldstein won the Nobel Prize for their decisive discovery of the endogenous 
cholesterol pathway (Brown et al. 1983). The transcribed LDLR is a transmembrane 
glycoprotein (839-amino acids) (Brown et al. 1987) (Figure. 5). Its C-terminal 
cytoplasmic domain (50-amino acids) serves to direct the receptor to the coated pits 
where it meets the LDLR adaptor protein, ARH. Binding ARH helps LDLR cluster in the 
coated pits and assists endocytosis (Anderson et al. 1977, Zuliani et al. 1999). In 
addition to the membrane-spanning region (22-amino acid),  the extracellular portion of 
the receptor contains a  region of 13-18 O-linked carbohydrate chains (58-amino acid) 
and a domain (400-amino acid) that is homologous to the precursor for epidermal growth 
factor (EGF) (Brown et al. 1997). Its N-terminal ligand-binding domain (292-amino acids) 
is composed of a cysteine-rich sequence where apoB-100 binds the LDLR. The EGF 
precursor homology domains contain EGF repeats and YWTD spacer regions which are 
involved in the pH-dependent release of the LDL from LDLR. PCSK9 binds to the EGF-A 
like domain, thereby negatively regulating the recycling of the LDLR (discussed further in 
Part 3). LDLR shares structural similarity with members of the LDL receptor superfamily. 
Sequence alignment revealed that the closest members to the LDLR in structure were 
the VLDLR (59% identity) and the apolipoprotein E receptor 2 (apoER2) (46% identity) 
followed by the LDL receptor-related protein 1 (LRP1) (Poirier et al. 2009). Mutation in 
LDLR and/or associated proteins causes FH and depending on the residual LDLR 
activity, severity of FH may vary. The apoER2, VLDLR and LRP1 proteins all bind apoE 
carried on many particles (Herz et al. 2006).  
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Figure 5: The LDL receptor superfamily and the apoE ligand. The structure of some 
members of the LDL receptor family is illustrated on the left side. The closest member to the 
LDLR is the VLDLR and the apoE receptor followed by the LRP. The apoE structure (on the 
right top corner) is a component of most lipoproteins and binds most of the LDL receptor 
superfamily members.  The right lower corner, shows the structure of the LDLR that is 
common for all the LDLR family members  (adopted from Brown et al. 1997 and Protein Data 
Bank, NMR structure, full length apoE3: 2l7b). 
 
 
ApoE is a multi-functional glycosylated protein (34 kDa) with two structural 
domains; the N- and the C-terminal domain. The N-terminal domain contains the 
receptor-binding region (Figure. 5). ApoE is secreted from a variety of tissues, including 
the liver, adrenals, adipocytes, kidney, brain and macrophages. It is a key component of 
all lipoproteins, especially TG-rich lipoproteins such as CM, CM-remnants, VLDL and 
IDL. ApoE participates in their catabolism through interactions with LDLR superfamily 
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members. Three common polymorphisms in the APOE gene, apoE3, E4 and E2 have 
been recognized, with apoE2 having the least affinity to the LDLR. Homozygosity for the 
E2 allele occurs in approximately 0.5% of the population and a small percentage of 
these subjects will develop type III dyslipidemia, characterized by accumulation of 
remnant lipoprotein particles in plasma and premature vascular disease. A “second hit” 
is postulated to contribute to the expression of the apoE2/E2 genotype leading to an 
obvious clinical dyslipidemia (Johansen et al. 2011), characterised by tuberous 
xanthoma and palmar creases, which sometimes can mimic a FH phenotype.  
Interestingly, rare mutations in APOE can lead to a form of lipid glomerulopathy 
(Tsimihodimos et al. 2011).  
 
Reverse cholesterol transport - HDL particles facilitate the return of cholesterol 
from peripheral cells to the liver and thus are believed to protect the vessels from the 
harmful effect of excess lipids, hence the name “good cholesterol”. Nascent HDL 
particles containing apoA1 and apoE are assembled and secreted by both the intestine 
and liver. Free cholesterol from other lipoproteins or peripheral cells is transferred to 
HDL and esterified by lecithin cholesterol acyltransferase (LCAT). The cholesteryl esters 
can be transferred to other lipoproteins such as LDL and IDL to be transported back to 
the liver or transported by HDL directly to the liver via scavenger receptor class B type I 
(SR-BI) (Von Eckardstein et al. 2001). Scavenger cells (e.g. macrophages) in vessels 
may pick up oxidized LDL (ox-LDL) particles, in case of hypercholesterolemia, leading to 
atherosclerotic plaque formation (Brown et al. 1983, Gregory et al. 2001) as we will 
discuss below. 
 
Pathogenesis of atherosclerosis - The pathogenesis of atherosclerosis is far too 
complex to be summarized in a thesis introduction; however I will allude to key 
processes (Figure. 6).  The remote description of atherogenesis includes foam cell 
accumulation and plaque formation that may potentially erupt to cause thrombosis. 
When excess LDL-C stays in the blood too long (as is the case of FH), the LDL is likely 
to be oxidized. The oxidized LDL (ox-LDL) accumulates between the endothelium and 
tunica intima layer of the arterial wall. As ox-LDL becomes an immunogen, it triggers an 
immune response; so in essence, atherosclerosis can be considered as an antigenic 
immunological response. Furthermore, these ox-LDL particles are then engulfed by 
macrophages that become activated (Figure. 6).   
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Figure 6: The stages of atherosclerosis development. Stage I: vascular injury leads to 
endothelial cell (EC) activation, monocyte recruitment into the intima and macrophage 
activation. Stage II: the earliest atherosclerotic lesion, the fatty streak, is an almost purely 
inflammatory lesion consisting of monocyte-derived, lipid-laden macrophages (foam cells) 
and T-lymphocytes. Stage III–IV: the progressive accumulation of lipids (intracellular and then 
extracellular) forms the lipid core. Stage V: a fibrous cap develops around the lipid core 
forming an atherosclerotic plaque. Stage VI: activated macrophages secrete enzymes that 
weaken the fibrous cap leading to plaque rupture, hemorrhage or thrombosis and CVD 
(adopted from www.r3i.org). 
Macrophages engulfing ox-LDL enlarge and are then referred to as foam cells. 
These foam cells subsequently may undergo apoptosis and become part of fatty streaks 
and plaques. The plaque formation process stimulates the cells of the vascular bed to 
differentiate and produce substances that accumulate in the subendothelium (i.e. tunica 
intima). Notably, calcium deposition and calcified connective tissue start to accumulate. 
The inner layer of the arterial wall thickens, the artery diameter shrinks and the blood 
flow starts to be compromised. This plaque formation may lead to decreased blood flow 
to vital organs like the heart or the brain. Cholesterol-lowering drugs such as statins 
might regress the atherosclerotic plaques; however calcified plaques (as seen in FH 
homozygotes) may be more resistant to regression upon  statin treatment (Chan KL et 
al. 2009), underscoring a hidden process beyond lipid lowering. Current data implicates 
cholesterol micro-crystals as being an initiating factor in liberating cytokines (discussed 
further in Part 4).  In Part 4, we go in-depth into the inflammatory component of 
atherosclerosis and the earlier trials to modulate the immune system to prevent CVD 
and in Chapter 6 we investigated whether inhibition of the inflammatory response 
prevents vascular calcification in an animal model.  
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2.4. Familial hypercholesterolemia disease prevention  
Pharmacological intervention in familial hypercholesterolemia - The goal of 
treatment is to reduce the risk of atherosclerotic plaque formation and consequently 
heart attacks. These include appropriate physical activity and early reduction of 
saturated fatty acid intake to less than 7% of daily calories and a cholesterol intake of 
less than 200 mg/day (Guardamagna et al. 2009). Usually diet represents a first line of 
treatment but it takes several years to see an effect. Counselling is often recommended 
to help people make changes to their dietary habits. Those who inherit only one copy of 
a defective FH gene may respond well to dietary changes combined with use of drugs 
such as statins. However, these environmental changes are not expected to drastically 
reduce hypercholesterolemia in homozygous FH individuals. Therefore, the first line of 
therapeutic action for molecularly confirmed homozygous FH is the implementation of a 
lipid lowering medication. There are several types of drugs available to help lower blood 
cholesterol levels, and they work in different ways. Some are better at lowering LDL-C; 
some are good at lowering triglycerides, while others help raise HDL cholesterol. The 
most commonly used and most effective drugs for treating high LDL-C are the statins: 
inhibitors of hydroxylmethylglutaryl coenzyme A (HMG-CoA) reductase, a rate limiting 
step in cholesterol biosynthesis. Statins also induce the cellular production of LDLR; 
therefore statins are effective mostly when LDLR activity is still preserved in FH subjects. 
Conventional statin drugs include; pravastatin (Pravachol), lovastatin (Mevacor), 
fluvastatin (Lescol), simvastatin (Zocor), atorvastatin (Lipitor), pitivastatin (Livalo), and 
rosuvastatin (Crestor) being the most recent and potent. Other cholesterol-lowering 
medicines include: Bile acid-sequestering resins (not frequently used due to gastric 
symptoms, useful in pregnancy), Ezetimibe (inhibits cholesterol absorption from gut, 
usually in combination with statin or in FH with complete LDLR loss of activity), Fibrates 
(less effective on LDL-C, but better on TG) and Nicotinic acid (mostly used to raise HDL-
C, with subtle effect on LDL-C).  
 
Before the statin era, cholestyramine (bile acid binder) and niacin (vitamin B3 
analog) (Grundy et al. 1981, Goldstein et al. 1987) were among the prescribed options to 
lower lipids, but intolerability limited wide spread usage. Statins on the other hand 
represent a class of medication that inhibits HMG-CoA reductase (Goldstein et al. 1987), 
limiting de novo cholesterol synthesis. Thus, statins reduce LDL-C by reducing 
endogenous cholesterol production from the liver; statins also increase the uptake of 
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circulating LDL particles by increasing the expression of LDLR and PCSK9 regulator as 
we are going to discuss below (Goldstein et al. 1987, Dubuc et al. 2004). Statins also 
have lower side effects which lead to higher patient compliance. Statins not only 
increase LDLR and decrease cholesterol levels, but they also have been correlated with 
a reduction in CVD in over 26 randomized clinical trials (Baigent et al. 2010). The 
additional protective role on CVD beyond cholesterol lowering can be explained by the 
pleiotropic effects of statins (Davignon et al. 2004). These pleiotropic properties 
influence various aspects of cell function, coagulation, vasomotor activity and even 
inflammation to a certain degree (De Lorenzo et al. 2006). However, in patients lacking 
LDLR or having significantly lower LDLR activity, the statins are not efficient in lowering 
cholesterol on their own, and ezetimibe (Rader et al. 2003), a class of specific inhibitors 
of intestinal cholesterol absorption, are usually added. If all pharmacological attempts to 
lower cholesterol fail, a drastic invasive technique, LDL-apheresis (similar to renal 
dialysis), is then required (Rader et al. 2003). In apheresis, blood or plasma is removed 
from the body and travels through special filters, where apoB binding beads then remove 
the extra LDL, and the blood plasma is then returned back into the body. LDL apheresis 
has allowed homozygous FH individuals with no LDLR activity to live beyond their short 
life expectancy; however they are not free of disease, as they experience premature 
arterial calcification as a late complication of the underlying disease (Awan et al. 2008).  
New to the lipid field are sequence-specific antisense oligonucleotide against apoB 
mRNA (Mipomersen) and the synthetic inhibitor of Microsomal TG transfer protein MTP 
(Lomitapide). The MTP antisense drug down regulates the MTP enzyme in a post 
translational fashion leading to less TG and apoB assembly and thus lowers hepatocyte 
output of VLDL into the plasma. Mipomersen and Lomitapide have been tested in phase 
III clinical trials in patients with FH, but discouraging results in the form of liver toxicity 
are reported (Cuchel et al. 2007), underscoring the importance of cardiometabolic 
screening. The latest and highly anticipated drugs, PCSK9 inhibitors, are designed to 
block PCSK9 from binding to LDLR, thus allowing LDLR to lower cholesterol and will be 
discussed further in Part (3) of this Chapter.  
 
Cardiometabolic disease prevention in familial hypercholesterolemia - A diet low 
in cholesterol and saturated fat would not prevent disease in FH without a statin based 
therapy. In statin-resistant individuals with a lack of LDLR activity, a combination therapy 
that includes a potent statin and ezetimibe is required; for some severe homozygotes 
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LDL-apheresis may be the only remedy. However, cardiometabolic burden associated 
with homozygotes that receive apheresis on chronic bases include calcification and 
anemia (Stefanutti et al. 1995). Genetic counselling is an option for those who have a 
family history of this condition, particularly if both future parents carry the defective gene; 
genetic counselling is also an option for individuals who have signs of xanthoma and 
xanthelasma. In essence, prevention of a cardiometabolic disease refers to the optimal 
care that takes into account all metabolic conditions that are associated with the 
underlying disease as well as diseases that may result from treatment with drugs. For 
instance, atherosclerosis and arterial calcification may lead to high blood pressure as the 
aortic wall loses compliance; chronic kidney disease may result from renal artery 
stenosis (Fantus et al. 2013). Interestingly, FH patients do not suffer from bone 
metabolic dysregulation even though the aorta might calcify completely on lipid 
treatment as one study suggested (Awan et al. 2010). As alluded to earlier, there are 
cardiometabolic diseases that are treatment-associated, like statin-induced muscle 
toxicity (myositis, rhabdomyolysis), renal toxicity (elevated creatinine), liver toxicity 
(elevated alanine aminotransferase or ALT), glucose intolerance or even remote 
diabetes (Ridker et al. 2008). Thus complete assessment and follow-up is required. 
 
Familial hypercholesterolemia screening - Screening individuals for a mutation 
known to be common in a family or common in an isolated sub-population like French-
Canadians has proven to be both life saving and cost-effective (Wonderling et al. 2004, 
Nherera et al. 2011). This usually is triggered when an index case is brought to medical 
attention or when surveying high risk populations. After identifying the DNA mutation in 
FH individuals, the hope is to stop CVD events (primary prevention) in that family or sub-
population. For index cases identified after a CVD event, the goal is to prevent a 
subsequent event (secondary prevention) with aggressive treatment and close follow-up. 
Various mutation screening methods are used in different countries, including direct 
sequencing (Defesche et al. 2010), diagnostic criteria (Civeira et al. 2008) or PCR 
melting analysis (Laurie et al. 2009) and Denaturing High Performance Liquid 
Chromatography (DHPLC). Today most screening strategies cover the candidate genes; 
LDLR, APOB and PCSK9. A more novel screening strategy has been implemented in 
Iceland, whereby ancestors of FH probands were traced and the oldest in every 
pedigree was screened for the Icelandic common LDLR mutations (Thorsson et al. 
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2003). This genealogical tracing might be superior to the conventional first-degree 
relative approach in founder populations.  
 
Familial hypercholesterolemia registry - FH is commonly referred to as the 
missed opportunity in preventive medicine (Watts et al. 2007). With an incidence of 
1:500 or even more in some areas, the benefit of early diagnosis and treatment will 
translate into decreased mortality and morbidity in a short time. Many campaigns from 
the National Lipid Association (Goldberg et al. 2011) is calling for a “FH Awareness Day” 
so that medical practitioners recognize that they are missing one of the more common 
genetic diseases while concentrating on very rare ones, including Cystic Fibrosis and 
Phenylketonuria. A national registry is being called for in Canada (Saraf et al. 2013). A 
registry can be defined as an official national record keeping of individuals with FH 
across the borders.  Building a national FH registry would require cascade family 
screening of each FH proband or index case (as we will discuss in Chapter 2), which 
will, as a result, reduce national mortality rates and have a better economic outcome. An 
article by Al-Saraf et al recently pointed out the importance of an FH registry in Canada 
and the need to devise a system where FH can be systematically detected in the 
population. Lack of a national registry led to FH being diagnosed in only 15% of 
Canadians who have FH; in other words 85% of Canadians do not know that they have 
the life-threatening disease (Al-Sarraf et al. 2013). Countries that have a national FH 
registry, with Netherlands having the best national FH registry in the world, identifies 8 
new FH cases per family using cascade screening (Al-Sarraf et al. 2013). Thus, these 
real examples should fuel the Canadian government to quickly make a national FH 
registry an imperative. To simplify this further, entry to FH registries should include the 
first and at least one of the following: 
 
x Lipid Profile (isolated increase in LDL-C/apoB) and at least one of: 
o Family history of premature coronary artery disease 
o Clinical stigmata (Xanthoma/Xanthelasma) 
o Molecular diagnosis/mode of inheritance 
o Functional analysis of LDLR (skin fibroblast) 
Simplified suggested criteria for FH registry 
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In Chapter 2, we present a case directly related to FH registry at the McGill 
University Health Centre that was referred to a specialized lipid clinic, where advanced 
molecular testing and cascade family screening were preformed. As a result, we 
identified a novel mutation in the APOE gene responsible for FH. The latter mutation 
was used to screen family members and successfully could identify asymptomatic 
carriers for FH that might benefit from early diagnosis and follow-up. In summary, 
lipoproteins and lipoprotein disorders play an important role in the onset and progression 
of FH disease. Unrecognised FH and cardiometabolic related risks will prolong the 
period of elevated cholesterol exposure in the individuals, thus leading to atherosclerosis 
and an acute CVD event. Suboptimal treatment in FH will lead to advanced 
subendothelial inflammation, atherosclerotic calcification, hypertension, renal failure and 
stroke. Mistreated FH without close follow-up and specialized care may result in 
insufficient LDL-C reduction, statin-related muscle, liver and renal toxicity.  In addition, 
available treatments to date, including statins and LDL- apheresis, are not sufficient to 
eliminate cardiovascular risk and so the search for newer and safer cholesterol-lowering 
agents continues. Therefore, classes of drugs, such as the PCSK9 inhibitors are viable 
candidates if proven safe and thus we will discuss the PCSK9 biology below. 
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3. Familial Hypercholesterolemia and PCSK9 
 
In the 1970’s, it was established that bioactive proteins, including hormones and 
enzymes, were secreted as inactive precursors and processed to a bioactive form, as 
illustrated by the activation mechanism associated with pro-insulin being converted to 
the bioactive insulin (Bailyes et al. 1991). Conversion from an inactive precursor is 
catalyzed by a special group of enzymes known as proprotein convertases. Proprotein 
convertases (PCs) intracellularly cleave precursors in both the constitutive and secretory 
pathway to produce a mature protein. In the 1990’s, eight of these mammalian 
proprotein convertases were discovered and shown to be responsible for the tissue-
specific processing of secretory precursors (Seidah 1999, Fugère et al. 2002) (Figure. 
7). 
 
 
Figure 7: Primary structures of the human proprotein convertases. The kexin-like basic 
amino acid specific proprotein convertases (PC 1-7), pyrolysin-like subtilisin kexin isozyme 1 
(SKI-1) and proteinase K-like proprotein convertase subtilisin kexin 9 (PCSK9) are grouped to 
emphasize their distinct subclasses. The various domains are emphasized, along with the 
primary (depicted using arrows) processing sites. PCSK9 has a Cys-His-rich domain 
(indicated by a lavender color) that is required for the trafficking of the PCSK9–LDLR 
complex to endosomes and lysosomes (adopted from Seidah and Prat 2012).  
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 Substrates of these proprotein convertases include: hormones, growth factors, 
receptors, transcription factors and surface glycoproteins. Proprotein convertases are 
known calcium-dependent serine endoproteases. The family of these proprotein 
convertases comprises 9 members coded by genes assigned by the letters ‘PCSK’ (Pro-
protein Convertase Subtilisin Kexin) and numbered from 1 to 9 (Seidah et al. 2008). 
PCSKs are critical to several physiological processes depending on their site of action, 
and their protease activities result in activation/inactivation events, some of which 
indirectly impact cardiovascular health (Seidah et al. 2007). All PCSKs contain an N-
terminal signal peptide (SP), a prosegment domain, a P domain and a catalytic domain 
that is highly conserved across species. The ~80-90 amino acids prosegment domain is 
cleaved first by an autocatalytic event in the endoplasmic reticulum (ER). The 
prosegment domain acts both as an intracellular chaperone to ensure proper folding and 
as a competitive inhibitor of PCSKs’ action. The competitive inhibitory effect seems to 
prevent PCSKs from being inadvertently activated during synthesis. The second round 
of cleavage occurs in the prosegment domain and results in its release from the catalytic 
domain and activation (Bergeron et al. 2000, Seidah et al. 2008). 
 
 
The eighth member of the PCSK family, PCSK8, is known to cleave membrane-
bound transcription factors including sterol regulatory element binding proteins (SREBP), 
in the luminal domain of the Golgi apparatus (Horton et al. 2002). In the absence of 
sterols, the SREBP are further cleaved by site-2 protease (S2P) that results in the 
release of their DNA-binding domain which becomes soluble and translocates to the 
nucleus (Horton et al. 2002). The activated SREBP then binds to specific sterol 
regulatory element sequences to upregulate the synthesis of enzymes involved in 
sterol/lipid biosynthesis. Sterols inhibit the additional cleavage of SREBP through a 
negative-feedback-loop and cholesterol synthesis is tapered down. Thus, SREBPs are 
named master regulators of lipid homeostasis (Eberlé et al. 2004).   
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The last member of the PC family is PCSK9. To date, the only confirmed 
biological property of PCSK9 is the protein-protein interaction (PPI) with LDLR, and 
possibly apoB, leading to its degradation (Seidah et al. 2003, Lambert et al. 2006). 
Disrupting this PPI between PCSK9 and LDLR prevents LDLR degradation, lowers 
cholesterol and is thought to protect from atherosclerosis. A third of the adult population 
in the United States suffers from elevated LDL-C and as a consequence is at risk for 
CVD [CDC. MMWR. 2011;60(4):109–14]. Furthermore, cholesterol lowering treatment 
based solely on statins has proven futile in a significant number of patients. Developing 
PCSK9 inhibitors as a new class of cholesterol lowering drugs has emerged recently. 
Within less than a decade, inhibitors of PCSK9 have been translated into a potential 
clinical application. After this discovery, there are at least a dozen potential drugs at 
different stages of clinical trial. All these potential drugs are awaiting endpoint data that 
fully describes their safety and utility.  
 
 
 
3.1. PCSK9 history 
The discovery of PCSK9 came about when a search for novel members in the 
proprotein convertase (PC) family was conducted; around the era of the human genome 
project. Degenerate oligonucleotides and the polymerase chain reaction (PCR) were 
used to amplify the catalytic subunit of various PCs, including the 8th member SKI-1/S1P. 
This led to the identification and biochemical characterization of the 9th member of the 
PC family, previously called Neural Apoptosis-Regulated Convertase 1 (NARC-1) 
(Seidah et al. 2003). NARC-1 shows sequence similarity across many species 
(http://www.ncbi.nlm.nih.gov/), and since it shares many structural features of subtilases 
it qualifies as a member of the PC group. NARC-1, now renamed PCSK9 (Abifadel 
2003), was proposed to be involved in a wide spectrum of biological processes, 
including neurogenesis, hepatogenesis, enterogenesis and nephrogenesis (Seidah et al. 
2003). The expression of Pcsk9 in the liver was the most robust, signifying a role therein 
yet to be established for this protein.  The history of PCSK9, from discovery to 
application, is shown in (Figure. 8): 
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Figure 8: PCSK9 history at a glance (Reference on the top right corner). 
 
 
Before the discovery of PCSK9, FH had only two loci linked to it: Chr19 p13.1-
13.3 (LDLR) and Chr2 p23-24 (APOB). A fruitful collaboration between Canadian 
scientists and a French group studying a cohort of non-LDLR/non-apoB 
hypercholesterolemic families confirmed that the newly discovered PCSK9 gene was 
indeed the culprit of the disease that they were looking for around Chr1p34.1-p32 (Varret 
et al. 1999). Thus, it was designated as the third locus implicated in FH (Abifadel et al. 
2003). This sparked a worldwide race to identify gain-of-function (GOF) mutations 
causing hypercholesterolemia as well as loss-of-function (LOF) mutations compatible 
with hypocholesterolemia (low cholesterol in the blood) (Cohen et al. 2005). The 
Caucasian PCSK9 p.R46L variant was not only associated with hypocholesterolemia but 
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also showed a remarkable 47% reduction in CVD (Cohen et al. 2006). The African 
nonsense mutation had an even more remarkable 88% reduction in CVD risk compared 
to non-carriers.  Additionally, two complete loss-of-function mutations causing severe 
hypocholesterolemia were found in apparently healthy individuals. The loss-of-function 
(LOF) mutations were (i) a compound heterozygous LOF mutation and (ii) a 
homozygous LOF mutation that leads to almost undetectable levels of PCSK9 (Zhao et 
al. 2006, Hooper et al. 2007). The discovery of PCSK9 LOF mutations leading to 
hypocholesterolemia in healthy individuals represented a potentially novel therapeutic 
target for the pharmaceutical industry.  Being healthy and hypocholesterolemic due to a 
LOF mutation in PCSK9 was thus demonstrated for the very first time in humans.  
 
Interestingly, the enzymatic activity of PCSK9 is solely used to cleave itself, 
which in turn prevents it from its own proteolytic activity after the prosegment occupies 
the catalytic pocket (Figure. 9).  The evidence suggests that PCSK9 expression 
enhances LDLR degradation through a pathway that involves endosomal/lysosomal 
shuttling. However, its mechanism remains to be fully elucidated (Canuel et al. 2013). 
Nevertheless, the downstream effects of a GOF mutation in PCSK9 are mediated by 
increased LDLR removal, adversely leading to hypercholesterolemia. The downstream 
effects of PCSK9 LOF mutations lead to considerably increased accumulation of LDLR 
at the cell surface, leading to more LDL-C clearance and consequent 
hypocholesterolemia. 
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Figure 9: PCSK9 domains, biology and crystal structure. PCSK9 is a protease that is 
synthesized as an enzyme precursor. Following synthesis in ER, PCSK9 undergoes 
autocatalytic cleavage, which is required before exiting the ER. The various domains and 
N-glycosylation positions are emphasized, along with the primary (VFAQ 153 ↓, black arrows) 
as well as the secondary autocatalytic processing sites (at position 218, black arrows). 
Although cleaved, the pro-segment and catalytic domains of PCSK9 remain together. PCSK9 
binds to the LDL receptor, near the EGF-A-like domain, as shown by the crystal structure of 
both (Source candidate private collection and Protein Data Bank, structure of PCSK9 binding 
LDLR: 2W2M).  
 
 
 
3.2. PCSK9 Cellular Biology  
PCSK9 biosynthesis - The 25-kilobase PCSK9 is located on the small arm of 
chromosome 1, region p32 in humans and contains 12 exons and 11 introns (Seidah et 
al. 2007, Davignon et al. 2010) (Figure. 9). This novel proprotein convertase showed 
atypical biology that made it a non-classical convertase. PCSK9 is a typical PCSK in that 
it has a serine protease-like structure of the bacterial subtilase family, but it is different in 
that it also shares structural similarity with the fungal proteinase K-like enzymes. Full 
length PCSK9 is characterized by 9 leucine residues within the signal peptide domain 
that guides the synthesized protein to the ER. As a PC, it has all the domains, namely 
                                                                                                                                                                  30  
the signal peptide (SP), prosegment (PRO) and a catalytic domain (CAT), but not a P-
domain. Instead, it contains a C-terminal region characterized by a Cysteine/Histidine-
Rich Domain (CHRD) (Figure. 9). A hinge region (H) also is present between the 
catalytic pocket and the CHRD; the function of the hinge region is poorly understood. 
Once in the ER, the SP domain of PCSK9 is cleaved and shortly after the 692 amino 
acid pro-protein undergoes autocatalytic processing at position VFAQ 152 –SIP. This 
autocatalytic event deprives mature PCSK9 of its proteolytic activity since the 
prosegment occupies the catalytic site. This step is necessary for exiting the ER (Seidah 
et al. 2008). Mature PCSK9 together with the prosegment (62 kDa + 15kDa) bind non-
enzymatically (PPI) LDLR. The crystal structure of PCSK9 was determined in 2007 
(Cunningham et al. 2007, Piper et al. 2007) (Figure. 9).  Sequence analysis of the 
catalytic domain shows that 3 conserved residues; Asp186, His226 and Ser386 are 
involved in the active site and mutations at these sites makes the protein inactive  (Piper 
et al. 2007).The PCSK9 S1 pocket that recognizes the P1 cleavage site of its 
prosegment is shallower in comparison with other PCs (Figure. 9). This is due to a 
glycine residue in the S1 pocket of PCSK9, versus alanine in other PCs, thereby raising 
the floor of the catalytic pocket (Piper et al. 2007). Mature PCSK9 interacts with the 
EGF-A domain of the LDLR through a region near the PCSK9 catalytic domain (Kwon et 
al. 2008). This interaction of PCSK9 with LDLR targets LDLR for degradation by an 
unknown mechanism: one hypothesis is that a third protein escorts the entire complex to 
the degradation pathway. Substituting certain domains in the CHRD or removing them 
from this region has shown that the M2 module (one of 3 distinct subdomains) of the 
CHRD is essential for the extracellular activity of PCSK9 on cell surface LDLR 
(Saavedra et al. 2012) (Figure. 9).  Finally, the mature protein is post-translationally 
modified by Asn-glycosylation, Ser-phosphorylation and Tyr-sulfation (Seidah 2009).  
PCSK9 cellular activity - Recent studies showed that PCSK9 is secreted mostly 
by the liver (Roubtsova et al. 2011). Unlike other PCs, no substrate has been identified 
for PCSK9 other than itself (Zaid et al. 2008). In blood, a significant percentage of 
circulating PCSK9 (40%) is carried on the LDL-C particle and is postulated to bind apoB 
(Kosenko et al. 2013, Tavori et al. 2013). The PCSK9-prosegment complex binds in a 
non-enzymatic fashion to the EGF-A like surface of the LDLR (Zhang et al. 2007) 
(Figures. 9 and10): 
 
                                                                                                                                                                  31  
 
Figure10: LDLR recycling and PCSK9 pathways. Proprotein convertase subtilisin/kexin 9 
(PCSK9) undergoes autocatalytic cleavage to exit the ER. Upon reaching the trans-Golgi 
network (TGN), PCSK9–prosegment complex can either be sorted directly to lysosomes as a 
complex with the low-density lipoprotein receptor (LDLR) (intracellular pathway), or it is 
secreted and then internalized with the LDLR into clathrin-coated endosomes for lysosomal 
targeting and degradation, which requires the binding of the cytosolic adaptor protein 
autosomal recessive hypercholesterolemia protein (ARH) (extracellular pathway). Therefore, 
in the absence of PCSK9, the endocytosed APOB–LDLR complex dissociates and the LDLR 
is recycled back to the cell surface. In the presence of PCSK9, the LDLR is not recycled, and 
(by a currently undefined mechanism) the PCSK9–LDLR tight-binding complex is sent to 
lysosomes for degradation (Source candidate private collection, adopted from Seidah and 
Prat 2012). 
 
Once PCSK9 interacts with LDLR, the whole complex is directed to the 
endosomal/lysosomal pathway (Figure. 10) for degradation as shown by using a DiI-
LDL tracing experiment (Qian et al. 2007).  
Deletion analysis revealed that an N-terminal region of the PCSK9 prosegment 
domain (31–52 aa) inhibits LDLR binding (Benjannet et al. 2010, Kosenko et al. 2013). 
The CHRD domain of PCSK9 is not ordered in most crystal structures, likely due to its 
high mobility; nevertheless module M2 of the CHRD, as previously mentioned, is 
essential for extracellular activity of PCSK9 on cell surface LDLR (Saavedra et al. 2012), 
but not required for secretion or autoactivation (Zhang et al. 2008). PCSK9’s journey 
through the secretory pathway is also conditional (Figure. 10), hence a low pH in 
endosomal compartments facilitates PCSK9 binding to the LDLR (Benjannet 2004, 
Fisher et al. 2007). A pH change to a more acidic pH ~5.5-6.0 leads to a ~2.5-fold 
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increase in PCSK9 activity on total and cell surface LDLR; thus pH-dependent activation 
of PCSK9 is optimal in the acidic endosomes (Zhang et al. 2007, Benjannet et al. 2010).   
Evidence exists for an intracellular pathway that targets LDLR directly to 
endosomes/lysosomes without it being secreted (Poirier et al. 2009). Thus, there are two 
proposed sites where PCSK9 can interact with LDLR: on the cell surface of hepatocytes 
(extracellular route, major) (Lagace et al. 2006) and in the TGN (intracellular route, 
minor) (Nassoury et al. 2007, Poirier et al. 2009) (Figure. 10). This may explain why 
circulating levels of PCSK9 do not correlate well with LDL-C levels in population studies 
(Awan et al. 2012).  
Other members of the LDLR superfamily sharing homology in the EGF-A like 
domain have also been reported to be targeted by PCSK9. VLDLR, apoER2, LRP-1, 
intestinal cell surface receptors like NPC1L1, CD36 and other receptors used by viruses, 
like CD81, are shown to be PCSK9 targets. A similar degradation pathway thus is 
expected to down regulate expression of these receptors (Table 4):  
Table 4: Evidence of PCSK9 targeting receptors and proteins   
PCSK9 Targets Evidence Consequences  Reference 
LDLR in vivo LDL-C regulation Maxwell et al. 2004 
VLDLR and apoER2 in vitro TRL regulation  Poirier et al.2008  
Shan  et al. 2008 
CD81 in vitro Hepatitis C virus receptor.  
RSV, Rhino virus & VSV receptor. 
Labonté et al. 2009 
VLDLR in vivo TRL regulation Roubstova   et al. 2011 
LRP-1 in vitro Numerous regulation Canuel   et al. 2013 
NPC1L1 and CD36 in vitro Intestinal lipid transport regulation Levy   et al. 2013  
CD36 in vivo Intestinal lipid transport regulation (unpublished data) 
apoB in vivo Raises ApoB production Ouguerram et al. 2004 
Lp(a) Observational Lower levels with mAb PCSK9 Desai et al. 2013 
Source indicated in each. mAb: monoclonal antibody. RSV: respiratory syncytial virus. VSV: 
vesicular stomatitis virus. TRL: TG-rich lipoproteins. 
 
One study has linked the GOF PCSK9 phenotype to an increase in ApoB 
production. ApoB overproduction would drive hepatic VLDL production, as seen in fasted 
mice (Lambert et al. 2006). However, this is secondary to intracellular depletion of lipids 
and activation of SREBP (Ouguerram et al. 2004, Park et al. 2004, and Lanlanne et al. 
2005). Consistent with this, LOF in PCSK9 was associated with low LDL-C and lowered 
production of apoB in primary hepatocytes after PCSK9 silencing (Rashid et al. 2005).  
 
PCSK9 is upregulated by SREBP in response to a low intracellular lipid pool and 
also by statin treatments and downregulated by PPARα agonists (e.g., fenofibrate) 
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(Lambert et al. 2006). Additional regulation of PCSK9 is believed to be mediated by the 
hepatocyte nuclear factor 1α (HNF1α). PCSK9 has been documented to undergo a Furin 
(or PC5/6A) cleavage inactivation at position 218 (human nomenclature) of the catalytic 
domain (Benjannet et al. 2006, Essalmani et al. 2011) (Figure. 9). One study had 
indicated that circulating furin-cleaved PCSK9 is capable of regulating LDLR but less 
efficiently than the intact PCSK9 (Lipari et al. 2012). However, the complete role of the 
furin-cleaved PCSK9 form is not known.  
 
3.3. PCSK9 animal models  
Hypercholesterolemia and atherosclerosis (Transgenic models) - The PCSK9 
gene sequence is conserved in many species including; chimpanzee, rhesus monkey, 
mouse, rat, chicken and zebrafish (http://www.ncbi.nlm.nih.gov/). However, adenoviral-
mediated expression of PCSK9 was first demonstrated in mice models and these 
models resembled an intermediate LDLR knockout phenotype (Maxwell et al. 2004). The 
effects of PCSK9 are mostly exerted in a paracrine fashion as shown by earlier 
parabiosis experiments (Lagace et al. 2006). As expected, transgenic mice expressing 
PCSK9 are viable, fertile and develop severe hypercholesterolemia. Pcsk9(Tg) mice on 
an Apoe(KO) background display an increase in plaque size as well as accelerated 
atherosclerosis when maintained on a regular diet. However, a protective effect was 
found when crossing Apoe(KO) mice with Pcsk9(KO) mice (Denis et al. 2012). Advance 
calcified atherosclerotic plaque takes place in Pcsk9(Tg) mice to a lesser degree (and 
takes longer to occur) in comparison to Ldlr(KO) mice (Awan et al. 2011) (Figure 11. A, 
B and C):  
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Figure 11: PCSK9 animal models. (A) and (B) are representative wild type (WT) and Pcsk9 
transgenic (Tg) mice; respectively. Aortas are seen after fine dissection (top panel), and a 
corresponding 3D reconstructed image by micro-CT (bottom panel); Atherosclerosis and 
aortic calcification are seen in Pcsk9(Tg) but not WT after 12 months on a Western diet 
(Arrows indicate site of calcification). (C) Aortic calcium score (AoCS) histogram of WT mice 
compared to Pcsk9(Tg) mice. (D) and (F) are representative WT and Pcsk9(KO) mice; 
respectively. Abdominal incision is made to expose the perigonadal fat. Visceral adiposity is 
seen in Pcsk9(KO) but not in WT at 6 months. Arrows indicate site of perigonadal fat. (C) 
Diagram showing the site of abdominal incision (adapted from Awan et al 2011, Roubtsova et 
al. 2011 and candidate private collection). 
Finally, hypercholesterolemia and atherosclerosis were recapitulated in a pig 
model of a PCSK9 gain-of-function (GOF) mutant. Following liver-specific expression of 
human GOF p.D374Y, pigs displayed reduced levels of hepatic LDLR, impaired LDL 
clearance, severe hypercholesterolemia and eventually developed spontaneous 
progressive atherosclerotic lesions that could be visualized by non-invasive imaging. 
Based on these observations several conclusions were made: first, an inhibitor of 
PCSK9 would be a potential therapeutic modality; second, the use of these models will 
advance the translational research aspect of treating atherosclerosis from animals to 
human (Al-Mashhadi et al. 2013).  
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Hypocholesterolemia and fat metabolism (Knockout models) - One of the 
standard experiments to understand the function of a given gene is to delete the gene in 
question from the genome and observe the consequences of such deletion. Knocking 
down PCSK9 in zebrafish resulted in loss of hindbrain-midbrain boundaries and 
embryonic death in less than 4 days (Poirier et al. 2006) hence the earlier name NARC1. 
This result signified that PCSK9 is essential in some lower vertebrates, but not in mice or 
humans. To further investigate the effect of PCSK9 inhibition, conditional knockout (KO) 
of the Pcsk9 gene have been generated in mice on a C57BL/6 background, as 
previously described (Zaid et al. 2008). Total inactivation of Pcsk9 by disrupting the 
proximal promoter and exon 1 led to a viable and fertile mouse with severe 
hypocholesterolemia (Zaid et al. 2008). A mouse with a total Pcsk9 gene (KO) is 
apparently normal with a 40% drop in total cholesterol and 80% drop in LDL-C. Total and 
liver specific (KO) mice exhibit a ~42% and ~27% decrease in circulating cholesterol, 
respectively. This observation confirmed that PCSK9 produced in the liver was 
responsible for more than two thirds of the phenotype (Zaid et al. 2008). By examining 
the outcome of crossing multiple mouse models, it is now believed that most circulating 
PCSK9 comes from the liver as seen from total KO expressing PCSK9 in the liver which 
recovers 80-90% of wild type mice PCSK9 levels (Roubtsova et al. 2011). Some data 
suggested that local and not circulating PCSK9 regulates cholesterol levels, because 
mice did not reach the total cholesterol levels observed in Ldlr(KO) mice. In Pcsk9(KO) 
mice, LDLR accumulates at the hepatocyte surface as determined by 
immunohistochemistry (IHC) (Roubtsova et al. 2011), leading to more LDL clearance 
from the blood and lower cholesterol levels. However, with lipidomic analysis of lipid 
subspecies, Pcsk9 inactivation or (KO) changes the composition of lipid classes in 
comparison to wild type (WT) mice. KO mice express a higher level of plasma 
sphingomyelin and ceramide, known risk factors for coronary artery disease (Jänis et al. 
2013).   
As mentioned above, PCSK9 may target other receptors. VLDLR is up-regulated 
in perigonadal depots of Pcsk9(KO) mice, specifically females. As a consequence, 
adipocyte tissue becomes hypertrophied after the excessive free fatty acid (FFA) 
internalization due to the accumulation of VLDLR in the adipocytes of these Pcsk9(KO) 
mice (Roubtsova et al. 2011) (Figure 11. D, E and F). Conversely, plasma triglycerides 
were slightly increased in Pcsk9(KO) males (+35%; not significant) and females (+46%; 
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P=0.03).  Furthermore, in vivo studies had shown that PCSK9 deficiency was associated 
with a 2-fold decrease in postprandial triglyceride levels, suggesting improved TG 
clearance and a role for PCSK9 in TG metabolism (Le May et al. 2009). PCSK9 is thus 
essential in fat metabolism as it maintains high circulating cholesterol levels via hepatic 
LDLR degradation, but at the same time restricts visceral adipogenesis possibly via 
adipose VLDLR degradation (Roubtsova et al. 2011). 
 
3.4. PCSK9 in extrahepatic tissue 
Adipocytes and muscles - PCSK9 is expressed in many tissues, but abundantly 
in liver, small intestine, and kidneys (Seidah et al. 2003, Zaid et al. 2008). However, the 
majority of PCSK9 effects on cholesterol are exerted by circulating levels produced by 
the liver. Since human PCSK9 targets human VLDLR ex vivo (Poirier et al. 2008) and 
binds mouse VLDLR in vitro (Shan et al. 2008), PCSK9 has the capacity to target human 
VLDLR in vivo. Indeed, visceral fat accumulates in Pcsk9(KO) mice (Figure 11. D, E 
and F) due to the high uptake of chylomicrons and VLDL-C in tissues that predominately 
express VLDLR (such as adipose tissue, heart and muscles). Lack of PCSK9 increases 
the surface expression of VLDLR and this facilitates triglyceride hydrolysis and free fatty 
acid uptake in the visceral adipose. In theory, skeletal muscles and striated muscles of 
the heart should be affected too, but muscles burn fat continuously while adipose tend to 
store energy in the form of fat droplets for later usage. Thus, LOF PCSK9 variants in 
humans are suggested to affect postprandial lipemia, which further establishes the 
association between serum PCSK9 and lipids (Mayne et al. 2013). However, the 
capacity of LOF subjects to clear fat in their adipose could be different from individual to 
individual, such that visceral fat may be metabolically harmful to some. At least in mice, 
Pcsk9(KO) was not associated with cytokine induction due to visceral adiposity 
(unpublished data).  
 
Adrenals and kidney - The adrenals are metabolically active organs like the liver 
and thus require synthesis and uptake of cholesterol for proper function. It was found 
that by blocking Annexin A2, a natural inhibitor of PCSK9 (discussed below), plasma 
PCSK9 levels double and LDLR levels decrease by a 50% in extrahepatic tissues such 
as adrenals and the colon.  
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This translates to higher LDL-C and suggests a potential cholesterol regulatory 
role yet to be identified in the adrenals (Mayer et al. 2008). In addition, transgenic mice 
expressing human PCSK9(Tg) in the kidney showed degraded LDLR in the liver. 
However, adrenal LDLR levels were not affected, and the authors attributed this to poor 
PCSK9 retention in adrenals. Nevertheless, human PCSK9 expression in these mice 
increased the hepatic secretion of apoB-containing lipoproteins in an LDLR-independent 
fashion and thus a mutual regulation of PCSK9 by the liver and the kidney is thought to 
exist (Tavori et al. 2013). Interestingly, silencing PCSK9 using locked nucleic acid (LNA) 
led to an adverse kidney toxicity (van Poelgeest et al. 2013), thought to be technically 
related. However, given the accelerated renal disease, one would not rule out an 
alternative hypothesis by which LNA may have mediated an acute cholesterol influx in 
the proximal convoluted tubules of the kidney. This is especially relevant given that a 
phase I clinical trial did not report kidney complications (Fitzgerald et al. 2013).  
 
Small and large intestine - Findings from examination of cellular and tissue 
expression in rat, mouse and human showed that not only are the liver and cerebellum 
rich in PCSK9, but so are the intestines, especially the ileum (Seidah et al. 2003). The 
relationship between the small intestine and PCSK9 was recently discussed, as well as 
its implication in trans-intestinal reverse cholesterol excretion (TICE). It is possible that 
PCSK9 regulates LDLR at the intestinal surface the same way it does in hepatocytes. 
However, Ldlr(KO) mice exhibited an increase in intestinal LDL uptake, contrary to what 
is observed in the liver, and tended to have higher TICE independent of the LDLR. The 
authors suggested that there might be at least 2 mechanisms contributing to TICE, one 
involving LDL receptor and a second unknown mechanism. More experiments are 
needed to explain some of the missing links in the TICE model (Le May et al. 2013). 
Interestingly, the phenotype of the AnxA2(KO) mouse suggests that AnxA2 acts as a 
natural regulator of LDLR degradation, primarily in extrahepatic tissues and especially in 
the intestine (Seidah et al. 2012).   
 
Pancreas - It was reported that PCSK9 was expressed in pancreatic delta-cells 
and that PCSK9 co-localized with somatostatin in human pancreatic islets. In one study, 
changes in insulin secretion were not seen in young Pcsk9(KO) mice under glucose 
challenge (Langhi et al. 2009). Later studies have showed that compared to controls, 
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older male Pcsk9(KO) mice express more LDLR in insulin-producing β-cells, secreted 
less insulin and were hyperglycemic as well as glucose-intolerant.  
In addition, Pcsk9(KO) mice islets exhibited signs of malformation, apoptosis and 
inflammation (Mbikay et al. 2010). In view of these discordant reports, it is thought that 
circulating PCSK9 may be necessary to protect the pancreatic islets by limiting the role 
of LDLR in internalizing excessive LDL-C. Therefore, a concern is that by losing this 
protective mechanism, lipotoxicity-induced diabetes may occur when PCSK9 inhibitors 
are given (discussed below) (Cnop et al. 2002, Roehrich et al. 2003, Ishikawa et al. 
2008). Thus, more experiments are needed to address this issue. 
 
3.5. PCSK9 in other pathological conditions  
Liver regeneration - Due to the wide expression of PCSK9, investigators are 
currently examining the role of PCSK9 in many organs and in different pathological 
conditions. Given that PCSK9 is mainly produced by the liver, any liver condition is 
expected to influence the production of PCSK9. Studies in mice have shown that 
conditional knockout in livers have led to delay in liver regeneration and formation of liver 
lesions (Zaid et al. 2008). The regenerating liver in Pcsk9(KO) mice exhibited necrotic 
lesions but when a high-cholesterol diet was supplemented after partial hepatectomy, 
the lesions where absent indicating an indirect role of PCSK9 in hepatic regeneration 
(Zaid et al. 2008). This data indicate that upon hepatic damage, patients lacking PCSK9 
could be at risk. However, under normal circumstance lipid accumulation in hepatocytes 
of these mice was markedly reduced under both regular and high-cholesterol diets. This 
indicates that PCSK9 deficiency confers resistance to liver steatosis (fatty liver disease) 
(Zaid et al. 2008). So, PCSK9 inhibition protects against steatosis, but puts one at risk if 
the liver receives an insult (liver surgery). 
 
Insulin resistance - Adult mice deficient in PCSK9 exhibit impaired glucose 
tolerance and may be at risk for diabetes mellitus as stated above (Mbikay et al. 2012). 
However, the mechanism is largely unknown. In one population study, it was shown that 
PCSK9 LOF p.R46L variants have a significant increase in markers of insulin resistance: 
namely, insulin and HOMA-IR (homeostasis model assessment of insulin resistance) in 
individuals carrying apoE2 isoforms in comparison to other apoE isoforms (Awan et al. 
2013). This indicates that there is an APOE and PCSK9 gene interaction that regulates 
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insulin resistance. There is additional evidence that another PCSK9 LOF p.Q152H 
induces insulin tissue resistance (Unpublished data).  
On the contrary, when rats were made diabetic by streptozotocin (STZ) injection, 
qPCR and Western blot analyses showed that there was an 81% reduction in hepatic 
LDLR mRNA but no change in LDLR protein (Niesen et al. 2007). Interestingly, PCSK9 
protein levels were decreased to almost undetectable levels and there was a 72% 
reduction in PCSK9 mRNA levels. This indicates that the rate of LDL receptor recycling 
is impaired in diabetic rats and thus the diabetic induced dyslipidemia.  
 
Cancer metastasis - PCs are known to play a significant role in tumor 
progression, notably furin (PCSK3) and PACE4 (PCSK6) (Bassi et al. 2000). 
Furthermore, growing cancer cells need a constant source of nutrition to survive and 
lipids in particular to meet the need to form new cell membranes. A tissue PCSK9 
expression analysis in tumor vs. normal tissue was conducted to select candidate 
malignancies associated with PCSK9 activity. It was found that PCSK9 is upregulated in 
human primary renal cell carcinoma, various head and neck cancers, germ cell tumors, 
esophageal adenocarcinoma and cervical cancer, but not elevated in breast carcinoma 
or in prostate carcinoma (unpublished data). Intrasplenic injection of B16 melanoma 
cells to recipient Pcsk9(WT) and Pcsk9(KO) mice revealed more than a 50% decrease 
in cellular invasion of cancer in the absence of PCSK9, a protection that was lost upon 
feeding the mice with a high fat diet, which enhanced cancer spread (Sun et al. 2000).   
Thus, the absence of PCSK9 can be protective against melanoma invasion at least in 
animal models and could open the door to novel applications of PCSK9 
inhibitors/silencers in cancer/metastasis. Of note, it was reported in a thesis report that 
PCSK9 expression was significantly downregulated in hepatocellular carcinoma (HCC) 
and associated with poorer survival after transplantation (Bhat et al. 2010).  This may 
imply that more aggressive HCC tumors alter their local microenvironment by modulating 
PCSK9 expression, thus enabling energy supply to fuel tumor growth. These findings, if 
confirmed with mRNA studies, could have interesting therapeutic implications.   
 
Viral infections - Most infectious hepatitis C virus (HCV) particles interact with a 
number of putative HCV receptors, including CD81, scavenger receptor class B type I 
(SR-BI) and claudin-1 (Andre et al. 2005, Meredith et al. 2012). Circulating HCV particles 
are associated with VLDL and LDL of infected patients, suggesting that LDLR is critical 
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for hepatic viral infection. Recently, it was shown that liver expression of CD81 is 
markedly increased in Pcsk9(KO) mice and that the HCV receptor CD81 protein is 
downregulated independently of LDLR (Labonte et al. 2009). Therefore, it was proposed 
that the plasma level and/or activity of PCSK9 could modulate HCV infectivity in 
humans. In summary, LDLR and CD81, two HCV entry receptors are dose-dependently 
down-regulated by PCSK9, resulting in the reduction of the cellular infectivity of HCV in 
mice. Although never shown in human, PCSK9 has the potential to protect humans 
against HCV. Thus, caution must be exercised when administering PCSK9 inhibitors to 
subjects that could be potentially infected with HCV or other viruses that use one or 
more of the LDLR superfamily members as entry receptors (Finkelshtein et al. 2013). 
 
Inflammation - Pcsk9 gene expression was upregulated in a concentration-
dependent manner in vitro after incubation with oxidized LDL (ox-LDL) (Wu et al. 2012). 
In addition, ox-LDL upregulated the expression of inflammatory cytokines; interleukin-1α 
(IL-1α), interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNFα) in macrophage 
precursor cells that also exhibited an ox-LDL dose-dependent upregulation in PCSK9 
expression (Tang et al. 2012). In mice, lipopolysaccharide (LPS)-induced inflammation, 
stimulates Pcsk9 expression (Feingold et al. 2008). High levels of PCSK9 accelerate 
atherosclerosis by promoting inflammation, endothelial dysfunction, and hypertension by 
mechanisms independent of the LDLR pathway (Urban et al. 2011). Furthermore, 
Pcsk9(Tg) mice develop advanced atherosclerosis (Denis et al. 2012) and aortic 
calcification (Awan et al. 2011). However, under stimulation, Pcsk9(Tg) mice induce half 
the expression of interleukin-1β (IL-1β) seen in total Ldlr(KO) mice, possibly contributing 
to the intermediate atherosclerosis phenotype seen in Pcsk9(Tg) compare to Ldlr(KO) 
mice (Chapter 6). Whether such inflammation is related to the amount of accumulated 
ox-LDL or PCSK9 levels in these models is not clear. In contrast, conflicting data exists 
in Pcsk9(KO) mice. Liver specific Pcsk9(KO) that are resistant to melanoma invasion 
exhibit higher levels of the inflammatory cytokine TNFα (Sun et al. 2012), while total 
Pcsk9(KO) mice accumulate visceral fat without a change in TNFα (unpublished data). It 
must be emphasized that mice and human do not always exhibit similar inflammatory 
responses, as evidenced in a recent human study. In the latter, both PCSK9 LOF and 
APOE LOF significantly elevates insulin and leptin levels, underscoring chronic 
inflammation of adipose tissue (Awan et al. 2013). Thus, further research is needed to 
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better understand the tissue- and species-specific association of PCSK9 with 
inflammation (Urban et al. 2011). 
 
3.6. PCSK9 physiological variations 
Variation in PCSK9 measurements - Before discussing the physiological 
variations in PCSK9 levels, it is important to note that PCSK9 exhibits a wide 
interindividual variation (Dubuc et al. 2010). Therefore, levels vary considerably among 
human subjects and exhibit a skewed distribution toward higher values in both men and 
women (Dubuc et al. 2010). However, the absolute values are mainly dependant on 
variations in the detection methods and the type of antibody used (Cariou et al. 2011) 
(Table 5). 
Source are indicated in each 
 
Variation with age, gender and pregnancy - In a cross-sectional pediatric study of 
~1700 subjects, plasma PCSK9 decreased with age in boys, whereas the inverse was 
true for girls. In girls of the same age, mean TC levels are higher in 9- and 16-year olds 
than in 13-year olds and there is an inverse effect on mean plasma PCSK9 
concentrations. It is believed that this follows a growth hormone pattern (Baass et al. 
2009). In the multi-ethnic Dallas Heart Study carried out in 3138 patients between 2000 
and 2002, plasma PCSK9 levels were significantly higher in women (n=1863) than in 
men (n=1489). This difference persisted after adjusting for most variables (Lakoski et al. 
2009). In the same study (n=3138), premenopausal women had considerably higher 
levels of plasma PCSK9 than postmenopausal women. Estrogen treatment did not 
significantly affect fasting PCSK9 levels in postmenopausal women. In comparison, 
Table 5: Physiological condition associated with PCSK9 levels 
Exhibits a diurnal rhythm (parallels cholesterol biosynthesis) (Persson et al. 2012) 
Exhibits a pubertal rhythm (growth hormone secretion) (Baass  et al. 2009) 
Exhibits stability over time as a biomarker (during hormonal stability) (Awan  et al. 2012) 
Exhibits a right-word skewed distribution (Lakoski  et al. 2009, Awan  et al. 2012) 
Higher in familial hypercholesterolemia (LDLR dependent mechanism) (Huijgen  et al. 2012) 
Higher with certain drugs: statin, fibrate (SREBP, PPARa) (Dubuc et al. 2004, Kourimate et al. 2008) 
Higher in females than males (suggesting sex hormonal regulation) (Awan  et al. 2012) 
Higher in  premenopausal than postmenopausal women (central regulation)  (Lakoski et al. 2009) 
Higher in pregnancy and lower in cord blood (parallels cholesterol demand)  (Peticca et al. 2013) 
Higher postprandial (suggesting insulin regulation) (Costet et al. 2006) 
Higher with inflammation (LPS stimulation) (Feingold et al. 2008). 
Lowered by estrogens induction therapy (Persson  et al. 2012) 
Lowered by fasting over 16 hours  (Costet et al. 2006) 
Lowered in response to acute stress (suggesting inflammation mechanism) (unpublished data) 
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there was no difference in plasma PCSK9 levels in men over 50 years old in comparison 
to men under 50 years old. Similar findings were obtained in postmenopausal women 
and older men with a 9-14 % higher level observed in female (Awan et al. 2012). Finally, 
serum PCSK9 levels were increased in pregnancy at term. However, recent data also 
showed that the human fetus has a ~2-fold lower PCSK9 level than the mother, which 
may be necessary to provide LDL-C to the growing fetus (Peticca et al. 2013). 
 
Variation with cardiometabolic markers - In the paediatric population mentioned 
above, PCSK9 was associated with fasting insulinemia, which suggests that PCSK9 
could play a role in the development of dyslipidemia associated with the metabolic 
syndrome (Baass et al. 2009). There were statistically significant positive associations 
between PCSK9 and fasting glucose and HOMA-IR (homeostasis model assessment of 
insulin resistance). PCSK9 levels correlated with multiple demographics, lipid and 
carbohydrate metabolic variables. The highest constant correlation is with total 
cholesterol and LDL-C. However, PCSK9 has a positive correlation between TC, LDL-C, 
apoB, and infrequently TG, and a weak correlation with HDL-C in most population 
studies. The next highest correlation after cholesterol and LDL-C is with triglycerides, 
suggesting a link to the metabolism of triglyceride-rich lipoproteins. The correlation with 
serum glucose, insulin and HOMA raises the possibility of a causative role of PCSK9 in 
the metabolic syndrome (Baass et al. 2009). In a randomized trial, variations among 
those taking statins was wide, nevertheless a significant relationship was observed 
between the magnitude of LDL-C reduction and the increase in PCSK9 concentrations. 
This relationship was seen in both an analysis of quintiles of LDL-C reduction and when 
the LDL-C change was treated as a continuous variable (Chapter 4). 
 
Variation with diet and medication - It was found that a 5-week Mediterranean 
diet in normal subjects can lower plasma LDL-C and PCSK9 by as much as ~10% and 
~15%, respectively (Richard et al. 2011). Moreover it was shown that PCSK9 
transcription could be suppressed by fasting and induced by insulin, likely by activating 
liver X receptor and SREBP (Costet et al. 2006). Like the LDLR gene, PCSK9 is also 
regulated by intracellular sterol depletion and with statins. Thus, statins, including 
atorvastatin, upregulated LDLR and PCSK9 mRNA expression in hepatic cell lines 
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(Dubuc et al. 2004). This suggested that statins would have a higher capacity to 
decrease LDL-C if not for the associated rise in PCSK9 level following statin treatment.  
Indeed, statin treatment of Pcsk9(KO) mice results in a greater reduction in LDL-
C than WT mice, signifying a hypersensitive state (Rashid et al. 2005). This was 
confirmed in individuals with FH harboring the common R46L LOF variant that seems to 
be more responsive to statins (Berge et al. 2006). While statins directly increase PCSK9 
mRNA expression, PPARα agonists, such as fibrates, indirectly affect PCSK9 
expression through modulation of cholesterol levels (Mayne et al. 2008). In a 
randomized trial, while statins were shown to increase the levels of circulating PCSK9, 
the cholesterol absorption inhibitor ezetimibe had no effect on PCSK9 (Berthold et al. 
2013). Finally, in a study where women underwent in vitro fertilization, high estrogens 
resulted in a reduction in VLDL, LDL and PCSK9 levels (Persson et al. 2012). However 
this might have been an effect of the 3-fold increase in growth hormone (GH) as a 
response to induction of ovulation. Thus, GH my negatively impact PCSK9 to favour 
increased uptake of circulating cholesterol by growing cells. 
 
 
 
3.7. PCSK9 genetic variations 
Family studies of coronary heart disease patients led to the mapping of PCSK9 
gene to FH (Abifadel et al. 2003). This was supported by GOF mutations exhibiting high 
serum levels of LDL-C. In addition, the LOF mutations were found to lower LDL-C and 
protect against coronary heart disease (Cohen et al. 2005). Until now, one compound 
heterozygote LOF mutation and one homozygote mutation have been reported (Zhao et 
al. 2006, Hooper et al. 2007). One of the individuals harbouring these mutations, a 32-
year-old fertile apparently healthy female, had been described with undetectable 
circulating PCSK9 resulting in an eighty percent reduction in LDL-C (Zhao et al. 2006). 
She is now 40 and all eyes are on her hoping that she will provide human confirmation 
that lowering lipids is better and PCSK9 inhibition is a safe modality. The function of 
PCSK9 is to enhance the elimination of LDLR, thus PCSK9 genes that increase the 
expression or affinity toward LDLR lead to cholesterol accumulation and vise versa. Gain 
or loss of function mutations have been reported in all domains of PCSK9.  
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A continuously updated list of all natural mutations of PCSK9 is found at 
(http://www.ucl.ac.uk/ldlr/LOVDv.1.1.0/index.php?select_db=PCSK9).  
 
Variations in determining PCSK9 levels - By screening the PCSK9 gene in 
individuals with the FH phenotype, but negative for LDLR/APOB mutations, FH causes 
attributed to PCSK9 GOF mutations are estimated to be 2% of all FH patients (Abifadel 
et al. 2003, Seidah et al. 2009). However, since the LDLR is the major route for PCSK9 
uptake, its circulating levels are also higher in FH patients with a defective LDLR 
mutations, which may contribute to the wide spectrum of FH and the variation seen in 
PCSK9 levels (Huijgen et al. 2012). Plasma PCSK9 levels are increased not only in FH 
but also in Familial Combined Hypercholesterolemia (FCHL) patients (Brouwers et al. 
2013). PCSK9 GOF mutations were associated with increased severity of coronary 
atherosclerosis in patients with polygenic hypercholesterolemia (Chen et al. 2005). 
These findings suggest that variations in the PCSK9 gene may alter the lipid clinical 
phenotype of patients having FH.  
 
After the first report of PCSK9 gene implementation in FH in 2003, several 
additional mutations were reported. Residents in Japan, US and Finland were among 
the first to confirm mutations associated with FH and higher levels of PCSK9 (Figure. 
12). However, not all PCSK9 mutations were associated with LDL-C changes in large 
cohorts (Kotowski et al. 2006). One of the first mutations identified was p.D35Y and later 
p.L108R with moderate changes in PCSK9 levels. Both mutations occur in the PCSK9 
prosegment and thus it is thought to enhance the interaction of the prosegment of 
PCSK9 with the beta-barrel domain of the LDLR (Benjannet et al. 2012). However, as a 
general rule, the higher the PCSK9 levels the more it is indicative of a GOF and FH 
(e.g., p.L108R, p.S127R, p.F206L, p.R218S, p.D374Y, p.R469W, p.L474V, p.R496W, 
p.H553R) and lower PCSK9 levels are more indicative of a LOF and 
hypocholesterolemia (e.g., insLeu 10L, p.R46L, p.G106R, p.Y142X, p.Q152H, p.Q219E, 
p.C679X) especially when the mutation is a nonsense mutation that leads to a truncated 
protein. The p.C679X mutation introduces a stop codon and this leads to a misfolded 
protein that fails to exit the ER (Peterson et al. 2008). The p.R46L is a common LOF 
mutation most likely due to an alteration in phosphorylation of an adjacent serine 
(Dewpura et al. 2008). LOF mutations are more frequent than GOF mutations; the 
carrier rate of p.R46L in French-Canadians is higher (4.8%) than the general population 
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(2.4%), perhaps to counter the founder effect of FH gene enriched in this genetic pool 
(Chapter 3).  p.R46L is the second most common variant in the French-Canadian 
population. However, the most common PCSK9 LOF mutation in the French-Canadian 
population is the insertion of an extra leucine (L10) in the SP region with a carrier rate of 
24%. Many PCSK9 mutations were recently summarized (Davignon et al. 2010) and 
presented in Figure 12: 
 
 
Figure 12: The PCSK9 protein and mutations impacting plasma LDL-C level. The 
primary structure and domains of PCSK9 (SP: signal peptide, pro: pro-segment domain, 
catalytic: catalytic domain, H: hinge region and CHRD: Cysteine-Histidine rich domain). Key 
residues, aspartic acid (D), histidine (H), asparagine (N) and serine (S) are depicted. The 
position and the amino acid substitutions of the mutations that are associated with high LDL-
C levels are shown above the protein. Those that are associated with a reduced plasma LDL-
C are shown below (adopted from Davignon et al. 2010). 
 
Finally, PCSK9 GOF and LOF mutations are synergistic and additive in their final 
impact on the cholesterol phenotype (Zhao et al. 2006). Furthermore, PCSK9 and LDLR 
gene mutations exert an additive effect on the FH phenotype. Interestingly PCSK9 and 
APOB genes were sequenced in the pedigree of 2 subjects with homozygous FH who 
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were heterozygous for LDLR gene mutations. LDL-C levels were ~50% higher in double 
heterozygotes than those found in simple heterozygotes for two LDLR mutations 
(Pisciotta et al. 2006). Therefore, rare missense mutations in PCSK9 may worsen the 
clinical phenotype of patients carrying LDLR mutations. On the other hand, APOE 
genotype will influence the lipid phenotype of PCSK9 mutations as suggested in Chapter 
3, underscoring the importance of gene-gene interaction in PCSK9. 
 
 
Variations with exceptional mechanism - Some mutations allowed a better 
understanding of the biosynthesis and secretion of PCSK9 biology and are worthy of 
highlighting (Figure. 12). (i) The French-Canadian LOF p.Q152H mutation prevents the 
autocatalytic processing of proPCSK9, resulting in a dominant negative form of the 
protein that in a heterozygote state reduces the circulating levels of PCSK9 and LDL-C 
by as much as ~80% and ~50%, respectively (Mayne et al. 2011). This mechanism was 
later confirmed following an exhaustive analysis of all possible Gln152 mutations 
(Benjannet et al. 2011). (ii) Intriguingly, the GOF p.R218S mutation significantly 
decreases PCSK9 catabolism allowing it to circulate longer and negatively impact LDLR 
to promote high cholesterol (Allard et al. 2005). This is likely due to the resistance of this 
mutant for furin inactivation (Benjannet et al. 2006). Conversely, the LOF p.A443T 
(Kotowski et al. 2006) mutation likely results in a novel PCSK9 O-glycosylation site that 
favours furin-induced degradation of the protein (Benjannet et al. 2006). (iii) The most 
severe Anglo-Saxon GOF mutation p.D374Y (Timms et al. 2006), which despite lower 
circulating levels results in a 10-25 fold higher binding affinity of PCSK9 to the LDLR 
(Cunningham et al. 2007). (iv) A few variations in the PCSK9 have also been reported in 
the hinge region (Figure. 12), for example the LOF p.R434W mutation results in lower 
secretion levels of PCSK9 and reduced circulating LDL-C levels, likely due to a negative 
effect on the folding of the protein in the ER (Dubuc et al. 2010). (v) On the opposite 
side, the LDLR GOF p.H306Y mutation in the EGF-A domain associated with PCSK9 
binding, results in an enhanced PCSK9-mediated cellular degradation (McNutt et al. 
2009). 
 
 
 
 
                                                                                                                                                                  47  
3.8. PCSK9 therapeutic approaches 
Berberine (BAR) is an alkaloid compound that decreases PCSK9 gene 
expression by reducing HNF1α mRNA levels (Cameron et al. 2008, Li et al. 2009). In 
addition, berberine also increases LDLR mRNA stability (Abidi et al. 2005) and based on 
these properties it has been proposed that it could be used as a monotherapy or in 
combination with statins to treat hypercholesterolemic patients (Kong et al. 2004, 
Cameron et al. 2008). In an animal model of LPS-induce inflammation, BAR treatment 
reduced the expression of hepatic PCSK9 and decreased the plasma levels of TC, TG, 
LDL-C, IFNγ, TNFα and IL-1α while increasing HDL-C level and LDLR expression (Xiao 
et al. 2012). Thus, both lipid and inflammatory lowering effect are demonstrated by 
Berberine therapy. 
Oncostatin M (OM) is a pleiotropic cytokine that induces LDLR gene transcription 
resulting in an enhanced LDL uptake in liver cells and a reduction of plasma LDL-C as 
seen in hypercholesterolemic hamsters (Cao et al. 2011). With OM, a rapid increase in 
LDLR mRNA levels occurs while PCSK9 mRNA steadily decreases in treated cells. 
Using siRNA, it was possible to identify a cytokine-triggered regulatory network for 
PCSK9 expression implementing JAKs signaling pathway. Therefore, OM is a 
proinflammatory cytokine (IL-6 family) that activates LDLR transcription through binding 
to transcription factors on a sterol-independent regulatory element of the LDLR 
promoter. However, lowering PCSK9 and inducing inflammation is not a suitable 
therapeutic approach in the context of CVD protection. 
Annexin-A2 (AnxA2) binds the C-terminus of PCSK9 protein identified by our 
group (Mayer et al. 2008). AnxA2 was strongly expressed in lungs, aorta, heart, adrenals 
and small intestine. Immunofluorescence staining demonstrates a partial co-localization 
of PCSK9 with AnxA2 at the plasma membrane of cells in vitro. AnxA2 inhibits PCSK9-
induced LDLR degradation and peptides from the R1 domain of AnxA2 act as PCSK9 
inhibitors.  Expression analysis showed that surface LDLR doubles in AnxA2(KO) mice 
while decreasing by 50% in extrahepatic tissues such as adrenals and colon that 
translated to higher LDL-C. This effect occurs without significant changes in VLDLs or 
HDLs, thus AnxA2 peptides block the PCSK9≡LDLR interaction and may represent a 
promising therapeutic approach (Mayer et al. 2008). One possible mechanism is through 
binding the CHRD domain of PCSK9 and inducing a conformational change in PCSK9 
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such that the interaction with the LDLR is compromised. This suggested allosteric model 
is supported by the observation that blocking CHRD, using a monoclonal antibody 
(mAb), can also inhibit ~50% of PCSK9-induced LDLR degradation. Indeed, a human 
AnxA2 V98L variant was associated with reduction in PCSK9 both in healthy and 
hypercholesterolemic subjects treated with statins (Seidah et al. 2012).  
 On a separate note, companies are trying to develop drugs using the 
knowledge gained from PCSK9 LOF mutations. Monoclonal antibodies, antisense 
approaches and small molecules are among the approaches to modulate PCSK9. As 
previously mentioned, PCSK9 favors the post-translational degradation of the LDLR, 
therefore decreasing its capacity to lower LDL-C. This makes PCSK9 a promising 
therapeutic target (Seidah et al. 2007) and several approaches to inhibit PCSK9 are in 
active clinical or preclinical trials (Figure. 13): 
 
Figure 13: Novel pharmacological approaches to treat hypercholesterolemia.  After the 
cholesterol particle binds LDLR, the PCSK9 can also bind the LDL receptor thus redirecting 
the complex to lysosomal degradation compartment and prevented the recycling of the LDLR. 
If an internalized LDL receptor is not bound to PCSK9, the receptor is recycled back to the 
cell surface, where it continues to remove LDL-C from the blood. A number of companies are 
developing compounds that suppress PCSK9 activity, the numbers in black circles represent 
the following approaches: (1) Inhibit PCSK9 expression (Antisense drugs: LNA-ASOs and 
LNP or siRNAs). (2) Inhibit PCSK9 self autocleavage and secretion (Small molecules 
inhibitors). (3) Neutralizing circulating plasma PCSK9 activity (mAbs or enhance inactivation 
of furin). (4) Disrupt PPIs and inhibit PCSK9 binding to the LDLR surface (small domain or 
EGF-A mimetic), (Source candidate private collection, adopted from Seidah and Prat 2012). 
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The best approach to date has been monoclonal and polyclonal antibodies. 
Monoclonal antibodies (mAb) targeted against PCSK9 showed remarkable cholesterol 
lowering in monkeys as well as an amazing 80% reduction in LDL-C levels for more than 
a week (Chan et al. 2009). Furthermore, there is a synergistic effect of mAb and statins 
on the reduction of LDL-C levels.  This suggests that a PCSK9 mAb in combination with 
a statin would lead to a greater reduction of hypercholesterolemia (Chan et al. 2009). 
 Indeed, phase I and II clinical trials in humans have been conducted by many 
pharmaceutical companies including Sanofi/Regeneron and Amgen. In phase I trials, 
safety and efficacy were confirmed. In phase II trials, both companies report LDL-C 
reductions varying between 60-70% upon subcutaneous injection of ~140-150 mg of the 
mAb every 2 weeks, with no significant elevation in liver enzymes (Seidah 2013, Stein 
2013). However, the reduction is dependent on the frequency and dose. Table 6 
summarizes some of the clinical trials outcomes: 
Table 6: Selected PCSK9-targets in development 
Approach Company Stage Comments 
mAb-REGN727 
(SAR236553)  
SA-Regeneron  Ph 3 
Odyssey  
~22,000 subjects injected 
(by 2018)  
mAb-REGN727 
(SAR236553)  
SA-Regeneron  Ph 2  40-72% LDL-C↓ vs  
17% Atorvastatin alone  
mAb-AMG145  Amgen  Ph 2/3  Subcut. injections/4 wks; 
43-55% LDL-C↓ at wk 12  
mAb-RN316  
(PF-04950615 )  
Pfizer-Rinat  Ph 2  Completed  
LGT209  Novartis  Ph 2  Completion: 2015  
RG7652  Roche/Genentech  Ph 2  Completion: 2015  
mAb  Merck  In develop.  WO-patent appl. 2010  
Ad. BMS-962476  BMS-Adnexus  Ph 1  Completion: 2013  
siRNA  Alnylam  Ph 1  Cationic lipidoid formula  
Small molecule  Shifa Biomedical Corp  Pre-Clinical  In preparation for Ph 1  
Serometrix  In develop.   
Neurochem/Amorchem  In develop.   
LDL-C, low-density lipoprotein cholesterol; LNA, locked nucleic acid; mAb, monoclonal antibody; 
PCSK9, proprotein convertase subtilisin/kexin 9; siRNA, small interfering RNA (adopted from 
Seidah and Prat 2012).  
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Conversely, the antisense small interfering RNA (siRNA) (Frank-Kamenetsky et 
al. 2008) and locked nucleic acid (LNA) approaches had less successful starts (Gupta et 
al. 2010). Phase I clinical trials with siRNA targeting PCSK9 have been recently 
published with encouraging efficiency in healthy volunteers (Fitzgerald et al. 2013). On 
the other hand, locked nucleic acid antisense oligonucleotides (LNA ASO) that target 
both human and mouse PCSK9, though efficient in reducing PCSK9 (Gupta et al. 2010), 
cause kidney toxicity and this has resulted in LNA-targeted PCSK9 treatment to be 
terminated from further clinical trials (van Poelgeest et al. 2013).  
Finally, the development of conventional small-molecules to inhibit PCSK9 
continues to present challenges (Hedrick et al. 2009). None of the published therapeutic 
anti-PCSK9 approaches used a small-molecule inhibitor, possibly due to the relative 
flatness of the PCSK9≡LDLR interface (Seidah et al. 2012).  
The approach that will move to routine clinical application will depend on long-
term safety data (phases III clinical trials), ease of administration and price (Davignon et 
al. 2010). While injections are not particularly attractive for long-term treatment, such 
treatments would likely be embraced by patients suffering from side effects with current 
lipid lowering agents or in high risk subjects striving to achieve lower LDL-C (Anderson 
et al. 2013, Stone et al. 2013). For example, homozygous FH patients, generally have 
initial LDL-C levels around 3-4 times higher than those of the general population. Thus, 
they are usually unable to achieve a 50% reduction using available oral agents and thus 
require LDL apheresis, a form of dialysis eliminates LDL-C from the blood (Sachais et al. 
2005). 
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In summary, with the discovery of PCSK9 in 2003 the lipid field took a sharp turn, 
with PCSK9 inhibitors becoming an unquestionable therapeutic reality. The molecular 
basis for PCSK9 action supports a model in which PCSK9 is self-cleaved, secreted, and 
tightly bound to the EGF-A like domain of LDLR. This reduces LDLR recycling, and 
down-regulates LDLR activity, thereby increasing the levels of LDL-C in the blood. Thus, 
PCSK9 plays a key role in cholesterol homeostasis. Humans with PCSK9 GOF 
mutations leading to high levels of PCSK9 and increased levels of plasma LDL-C are at 
significantly increase risk of CVD. Humans with LOF mutations have reduced levels of 
plasma PCSK9 and LDL-C and are at a significantly lower risk of developing a CVD 
during their lifetime.  
In addition, PCSK9 exhibits pleiotropic metabolic effects that need to be further 
explored. Statin therapy results in increased plasma PCSK9 levels but lower overall 
LDL-C levels. This suggests that lowering PCSK9 levels may enhance the efficacy of 
statins to reduce LDL-C. Animal models have proven invaluable to screen a new drug 
modality, as atherosclerosis and vascular calcification are enhanced in Pcsk9(Tg) mice 
and reduced in Pcsk9(KO) mice. In humans, loss of one copy of PCSK9 prevented 88% 
of cardiovascular events in the ARIC trial that followed more than 3000 individuals over 
15 years. Thus, PCSK9 is a clear target for the development of new lipid lowering 
therapies. Long-term studies will establish whether the beneficial effects of PCSK9 
inhibition on LDL-C levels directly translates into safe and effective CVD risk reduction.  
Despite its apparent safety, there are concerns about the inhibition of PCSK9, 
since we still know little about its global physiological functions.  Nevertheless, it has 
been such a long time since the discovery of statins; that a new avenue should come 
about to substantially reduce cholesterol levels. The realization that a complete LOF 
PCSK9 mutation and/or inhibition of plasma PCSK9 results in very low cholesterol 
levels, suggests that PCSK9 inhibitors could be the next blockbuster drug to combat 
hypercholesterolemia, which would be a harbinger of things to come (Hall 2013). The 
outcomes of the multiple ongoing phase III clinical trials using PCSK9 mAbs are 
expected to be made public in 2016-2018, and are surely going to be revealing in terms 
of the wider use and safety of plasma PCSK9 inhibition (Sheridan et al. 2013). 
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4. Familial Hypercholesterolemia and Calcified Atherosclerosis 
 
Given national guidelines mandating strict targets for LDL-C, the treatment of 
lipoprotein disorders has been one of the most successful therapeutic measures in the 
prevention and treatment of CVD (Anderson et al. 2013, Stone et al. 2013). The 
analysis of large-scale clinical trials using statins has led to an impressive decrease in 
cardiovascular events, cardiovascular mortality and total mortality, with no substantial 
side effects. The decrease in CVD appears to be related to dose and duration of 
treatment (Baigent et al. 2005). However in FH subjects this reduction in mortality has 
not necessarily translated into disease-free life expectancy. Indeed, even with combined 
lipid regimens and drastic LDL-C reduction using extracorporeal LDL removal (LDL-
apheresis), patients develop premature and severe aortic valve and aortic wall 
calcification (Awan et al. 2008) (Figure. 2).  
Generally, there are inhibitory and stimulatory factors that influence calcification 
in vessels and these are summarized in Chapter 5. These factors are not directly 
targeted by lipid lowering drugs, and thus they need to be addressed separately. In 
brief, vascular calcification is the net result of loss of inhibitory factors and the addition 
of stimulatory ones. The co-morbidities and mechanisms associated with this condition 
are further discussed in Chapter 5.  
Currently there is no effective therapy targeting vascular calcification that does 
not also negatively impact the skeletal system (Fantus et al. 2013). Raising HDL-C has 
long been associated with CVD protection. However, using Mendelian randomization, 
the causal relationship between HDL-C and CVD has recently been called into question 
(Frikke et al. 2010; Voight et al. 2012). Thus, HDL-C may be considered more as a 
marker of cardiovascular health despite its strong epidemiological association with MI 
(Di Angelantonio 2009), and the biological plausibility linking HDL-C to cardiovascular 
health. Furthermore, there is little evidence that raising HDL-C pharmacologically with 
fibrates (Jun et al. 2010), niacin (Boden 2011, HPS2-THRIVE 2013) or the two inhibitors 
of cholesteryl ester transfer protein (CETP), torcetrapib and dalcetrapib, leads to an 
improvement in cardiovascular health and vascular calcification.  
As previously discussed, a new class of lipid lowering agents, the PCSK9 
inhibitors, has the potential to further lower LDL-C. A significant reduction in LDL-C 
levels has been reported with mAbs in phase 1 and 2 studies in healthy volunteers and 
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in subjects with FH or non-FH (Stein et al. 2012). Large scale phase 3 clinical trials are 
also underway to test the hypothesis that further LDL-C lowering with PCSK9 inhibitors 
will improve cardiovascular health. The agents being studied include evolocumab 
(FOURIER trial), alirocumab (ODYSSEY trial) and bevacizumab. However, their effect 
on vascular calcification is still unknown. 
In spite of the impressive lowering of MI events attained with lipid lowering 
agents, there remains significant “residual risk” in the prevention and treatment of 
cardiometabolic disease. Meta-analysis of statin trials showed a 21% reduction in risk of 
CVD per mmol of LDL-C (Baigent et al. 2010). Furthermore, a search for other 
modifiable factors has led to novel targets in the atherosclerosis process. Indeed, a 
systematic review of available evidence determined that chronic inflammatory diseases 
result in a greater risk of developing CVD. However, further research of prospective 
cohort studies are needed to better quantify this risk (Roifman et al. 2011).  
Nevertheless, inflammation is critical to the development of atherosclerosis. 
While conventional cardiovascular risk factors, such as elevated cholesterol, are causal 
in atherosclerosis, the mechanism by which cholesterol induces calcification is mediated 
to a great degree by the immune system. Elegant work by Duwell et al. has shown that 
excess cholesterol is taken up by macrophages that then elicits an inflammatory 
reaction, mediated by the release of interleukin-1 (IL-1β) (Duewell et al. 2010), and 
leading to an amplification of the immune response cascade (Maritnon et al. 2002). IL-1β 
and IL-6, together with other systemic inflammatory mediators, such as tumor necrosis-
alpha (TNFα), are released into circulation, leading to hepatic production of C-reactive 
protein (CRP), a marker of systemic inflammation (Harris et al. 1999). Furthermore, work 
by our group has shown that the osteogenic Wnt pathway is implicated in calcified 
lesions in Ldlr(KO) mice (Awan et al. 2011); ox-LDL and inflammatory cytokines are 
hypothesized to be upstream to this pathway. 
The strong association between CRP as a marker of systemic inflammation and 
CVD has been tested in multiple epidemiological studies and meta-analysis. These 
studies show that high sensitivity CRP is a graded and independent biomarker of 
cardiovascular risk. However, the causal link between CRP and atherosclerosis has 
been called into question by animal studies failing to support a pro-atherosclerotic role 
for CRP. Likewise, Mendelian randomization experiments have cast doubt on the causal 
role of CRP in atherosclerosis. Thus, the potential role of CRP in CVD is still a matter of 
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debate (Koening et al.  2013). Nevertheless, the use of CRP to identify patients at 
increased cardiovascular risk of recurrent cardiovascular events is the basis in launching 
the Justification for the Use of Statins in Primary Prevention: An Intervention Trial 
Evaluating Rosuvastatin (JUPITER trial) (Ridker et al. 2008). 
In JUPITER, 17,800 men (over 50 years of age) and women (over 60 years of 
age), with elevated CRP levels, but levels of LDL-C that did not warrant lipid-lowering 
therapy according to the standard of care at the time, were given either 20 mg of 
rosuvastatin (a potent statin) or a placebo. Two years after trial commencement, the 
Data and Safety Monitoring Board recommended that the study be halted due to the 
overwhelming benefit of rosuvastatin in patients. Patients in the 20 mg rosuvastatin 
treatment group had a 50% decrease in LDL-C and a 37% reduction in CRP, leading to 
a 44% reduction in CVD primary end-point, with no heterogeneity of treatment benefit in 
any sub-group analyzed (Ridker et al. 2008). This overwhelmingly positive result was 
reflected in updates of several national guidelines recommending more aggressive lipid 
lowering regimens (Anderson et al. 2013, Stone et al. 2013). However, the results of 
JUPITER questioned whether the benefits of rosuvastatin were due solely to the 
reduction in LDL-C or due the reduction in CRP. The trial was not designed to answer 
this apparently simple question, but offered a novel hypothesis that could be tested in 
large-scale, appropriate clinical trial (discussed later). In Chapter 4, we study blood 
samples and DNA from a subset of this population to draw associations between LDL-C, 
PCSK9 and many cardiometabolic markers including the inflammatory marker CRP. 
 
 
4.1. Atherosclerosis and inflammation  
The pathogenesis of atherosclerosis and inflammation is complex and many 
excellent reviews have been published on this subject (Libby et al. 2013). Furthermore, 
chronic inflammation and many of the cytokine mediators are considered inducers of 
vascular calcification (Chapter 5).  This is why atherosclerotic soft plaques may stabilize, 
shrink and become less susceptible to rupture in response to statins, yet calcified 
plaques do not regress and the course of calcification is intimately linked to inflammation 
(Sia et al. 2009) (Figure. 14). 
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Figure 14: The immune cells populating the atherosclerotic plaque. The atheroma has a 
core of lipids, including cholesterol-crystals, apoptotic and living cells and a fibrous cap with 
collagen and smooth muscle cells. Excess lipoproteins accumulate in the subendothelial 
space. Several types of cells of the immune response are present throughout the atheroma 
including (1) T cells, (2) monocyte/macrophages, (4) APC and DCs and (3) mast cells. The 
plaque builds up in the intima, while cells of the immune system also accumulate outside 
advanced atheroma and may develop into tertiary lymphoid tissue with germinal centers. 
APC: antigen-presenting cell, DC: dendritic cells (adopted from Hansson and Klareskog 
2011). 
Arterial inflammation in response to stressors (cholesterol-crystals, cigarette-
derived vascular toxins, protein modification by diabetes, and shear stress due to 
elevated blood pressure) leads to endothelial dysfunction. The hallmark of endothelial 
dysfunction is the expression of vascular cell adhesion molecules (VCAM) and monocyte 
chemotactic protein-1 (MCP-1). These proteins will attract antigen-presenting cells 
(APC), monocytes and dendritic cells (DC) to the arterial intima. In turn, these cells will 
differentiate into macrophages under the influence of macrophage colony stimulating 
factors and lead to the formation of foam cells together with more inflammation, cytokine 
release and T-cell recruitment. Unstable vulnerable plaques may rupture and cause 
platelet activation and thrombosis, leading to vessel obstruction in vital organs, such as 
the heart (MI), peripheral blood vessels (limb gangrene) and the brain (strokes). 
Interestingly, even in healthy aortas of children, the intima is continuously under 
surveillance by T cells and macrophages that have the capacity to express IL-1, IL-6 and 
TNF when they are induced (Kishikawa et al. 1993). Some studies have documented 
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endothelial activation, inflammation and premature atherosclerosis in children with FH 
phenotype (Guardamagna et al. 2009) (Figure. 15). 
 
Figure 15: The functions of cells participating in atherosclerosis. The figure outlines the 
functions attributed to various cellular components in atherosclerosis. Mononuclear 
phagocytes represent the first line of the innate immune defenses. They give rise to 
macrophages which form foam cells, the hallmark of the arterial fatty streak. Inflammatory 
cells express high levels of Toll-like receptors (TLR), and release high levels of the cytokines 
TNF and IL-1. Dendritic cells present antigens to T cells, linking innate to adaptive immunity. 
Mast cells release many mediators as shown. Recent data support a causal role for mast 
cells in mouse atherosclerosis (adopted from Libby et al. 2009). 
 
The oxidized LDL particles that intrude into the subendothelial space as a result 
of endothelial dysfunction are sensed and engulfed by macrophages and may trigger the 
expression of immune mediators. Under control of innate immunity, mononuclear 
phagocytes, mast cells, platelets, granulocytes, and the complement cascade contribute 
to amplifying the immune response and promoting the growth of atherosclerotic plaques 
(Libby et al. 2013) (Figure. 15). In the adaptive cellular immune response, T- and B-
cells, antigen-presenting DCs, along with humoral immunity, exert modulatory effects on 
atherosclerosis. The interplay between human genetic susceptibility and response to 
environmental stressors additionally modulates adaptive and innate immunity. One of 
the best studied stressors is cholesterol elevation. 
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Current data implicates cholesterol crystals as being an initiating factor in the 
release of IL-1β through the activation of the NOD-Like Receptor family Pyrin domain 
containing 3 (or NLRP3) inflammasome (Duewell et al. 2010; Rajamäki et al. 2010). In 
innate immunity, NLRP3 inflammasomes are large, cytosolic multimeric protein 
complexes that connect metabolic stress sensors with the downstream proteolytic 
cleavage of prointerleukin-1β into bioactive IL-1β. Inflammasomes are thus responsible 
for the activation of inflammatory processes, and have been shown to induce cell 
pyroptosis (Church et al. 2008) (Figure. 16): 
 
Figure 16: Innate immune response to cholesterol crystals. Cholesterol crystals 
represent an endogenous danger signal, are engulfed by macrophages in the subendothelial 
layer of the arterial wall and activate the NLRP3 inflammasome pathway, leading to the 
cleavage-activation of pro-IL-1β and its release in plasma. IL-1β acts as a proximal 
amplification to evoke more inflammation, atherosclerosis progression and promote arterial 
calcification. Subsequent steps leading to dysregulation of local mineralization are postulated, 
which includes activation of the Wnt/LRP5/β-catenin pathway of osteoblast differentiation. 
This establishes a link between inflammation, atherosclerosis initiation and progression of 
vascular calcification. Anti-IL-1β mAb selectively targets this critical step (adopted from Rader 
2012). 
 
The identification of individuals with autosomal dominant gain-of-function (GOF) 
mutations in the NLRP3 gene associated with autoinflammatory process has supported 
the effort to develop orphan drugs inhibiting IL-1β (Walsh et al. 2009). The targeted 
inactivation of IL-1β decreases atherosclerosis in a mouse model of atherosclerosis; a 
double Apoe(KO) / IL-1β(KO) fed a high cholesterol diet (Kirii et al. 2003). In addition, 
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lack of IL-1β diminishes the burden of atherosclerosis in Apoe(KO) mice while prolonged 
treatment with IL-1β promotes arterial intimal thickening in the porcine coronary arteries 
(Shimokawa et al. 1996).  
Furthermore, IL-1 has been implicated in atherothrombosis and plaque rupture in 
several pre-clinical and clinical studies (Alexander et al. 2012). Interleukin-1β in 
particular plays an essential role in triggering an inflammatory reaction to injury and 
mediating smooth muscle differentiation via the actions of TNFα on the Wnt canonical 
pathway (Church et al. 2008). In addition, genetic strategies may help identify unknown 
key players in inflammation in humans. GWAS studies and newer deep sequencing data 
have led to the identification of genetic variants in immune mediators and inflammatory 
responses that help to determine the severity of the atherosclerosis. The most recent 
CARDIoGRAMplusC4D Consortium GWAS offered a network analysis that implicated 
inflammation as one of the pathways most strongly associated with human CVD 
(Deloukas et al. 2013). Furthermore, recent genetic studies provide robust data linking 
the IL-6 receptor to coronary heart disease (Sarwar et al. 2012). These data provide a 
strong rational for targeting inflammatory pathways to narrow the gap in the residual risk 
associated with CVD beyond lipid lowering. 
 
4.2. Atherosclerosis prevention using immunomodulation  
Herein, I will discuss the advantages and disadvantages associated with the use 
of inflammation modulation (anti-inflammation) from the literature as well as ongoing 
major clinical trials that will likely change the nature of atherosclerosis prevention. From 
many immunomodulation methods, I will rationalize the selection of one that I will test in 
a drug-placebo animal experiment to test the hypothesis that immunomodulation can 
lower the degree of calcification seen in FH (more details in Chapter 6). 
Evidence for Corticosteroids - In asthmatic patients, corticosteroids (CS) inhibit 
VCAM-1 induced by TNFα during the exacerbation of their disease. This suppression 
may contribute to their anti-inflammatory effect in bronchial epithelial cells in humans; 
however, this effect could not be extended to the vascular endothelium (Atsuta et al. 
1999). Moreover, the long term beneficial effect of inhaled CS was only validated in 
asthmatic patients and not in cardiovascular patients (Camargo et al. 2008). However, in 
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mice high-dose CS for post MI use was found to exert cardiovascular protection through 
a novel mechanism involving the rapid, non-transcriptional activation of endothelial nitric 
oxide synthase (eNOS). Binding of CS to the glucocorticoid receptor, induces nitric oxide 
dependent vasorelaxation via eNOS activation and decreases vascular inflammation and 
myocardial infarct size (Hafezi-Moghadam et al. 2002). 
  
Despite these interesting results, earlier reports suggested that CS may in fact 
promote atherosclerosis. In the early 1970s, Kalbak predicted the long-term outcome of 
CS on vascular calcification of the tibial artery as seen on X-ray films (Kalbak et al. 
1972). Furthermore, the incidence of arteriosclerosis in patients with rheumatoid arthritis 
(RA) receiving long-term CS was elevated and arterial calcification was common and 
resembles Mönckeberg's sclerosis with little intimal occlusion. Many years later, long 
term treatment of coronary artery disease with high doses of CS was clearly associated 
with adverse effects on the cardiovascular system in the form of delayed myocardial scar 
formation post MI (Sholter et al. 2000). Moreover, in a systemic inflammatory disease 
like Systemic Lupus Erythematosus (SLE), aortic valve calcification was associated with 
CS use (P = 0.049) and the use of methotrexate (P = 0.0174) (Kiani et al. 2006). 
Furthermore, it was found that rheumatoid factor (RF)-positive but not RF-negative 
patients are at increased risk of CVD events following exposure to CS. These findings 
suggest that CS interacts with RF status to modulate the occurrence of an event in 
patients with RA (Davis et al. 2007). In a nested case-control analysis of MI in a cohort 
of 17,700 patients with RA and 3,001 patients with noninflammatory rheumatic showed 
that CS increased the risk of diabetes and hypertension as well as increasing the overall 
risk of MI (Wolfe et al. 2008). Finally, a study showing a dose-dependent increase in 
CVD risk with the chronic use of CS in RA patients, confirmed the futility of CS in 
cardiovascular protection (Greenberg et al. 2011). Therefore, there are no active clinical 
trials examining the role of CS in CVD. 
 
Evidence for Methotrexate - Methotrexate (MTX) competitively and reversibly 
binds to dihydrofolate reductase preventing the conversion of tetrahydrofolate precursor 
to the co-factor necessary for DNA and RNA synthesis, arresting the cell cycle in S 
phase. MTX has been used for decades as an anti-cancer agent, as an 
immunomodulator in rheumatological and autoimmune skin diseases and as an agent to 
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terminate ectopic pregnancies.  A narrow therapeutic index makes MTX notorious for its 
side effects. A systematic review of the effects of MTX on CVD in patients with RA 
concluded that its use was associated with a reduced CVD, suggesting that MTX not 
only improves disease-specific outcomes but concomitant atherosclerosis (Westlake et 
al. 2010). Importantly, in a large study of 10,156 RA patients treated with a variety of 
TNF antagonists, MTX and Disease-Modifying Antirheumatic Drug (DMARD), only TNF 
inhibitors were associated with a reduction in cardiovascular risk events. Interestingly, 
MTX was not associated with a reduced risk and CS use was associated with a dose-
dependent increased risk as mentioned above (Greenberg et al. 2011). However, a 
systematic review and meta-analysis of evidence of relations of MTX with CVD 
occurrence were performed in patients with chronic inflammation (Micha et al. 2011). 
MTX was correlated with a 21% lower risk for CVD and the authors suggested that a 
direct treatment of inflammation may reduce CVD risk. Given its profound effect as a 
broad immunosuppressant, the National Heart, Lung, and Blood Institute (NHLBI) 
launched the cardiovascular inflammation reduction trial (CIRT) (http://clinicaltrials.gov - 
NCT01594333). This is a randomized clinical trial investigating whether taking low-dose 
MTX reduces heart attacks, strokes, or death in people with either type 2 diabetes or 
metabolic syndrome (known to be associated with vascular calcification) that have had a 
heart attack. The estimated study completion date is December 2018 (Table 7). 
Table 7: Immunomodulation approaches to prevent residual CVD risk . 
Approach Trials name  
(Agent used) 
Patients type 
 (Ph; trial phase) 
Effect on lipids and heart 
(Possible side effect) 
Inhibit 
DNA 
synthesis  
CIRT/NIH 
(Methotrexate)  
2nd prevention 
(Ph 3 ends in 2018) 
↔ LDL-C 
(Bone marrow suppression, Neutropenia, 
Infections) 
Receptor 
antagonist 
Kineret 
(IL-1R antagonist) 
2nd prevention  
(Ph 3) 
↑ LDL-C, Heart failure 
Injection site reactions, Infections, Malignancy 
mAb 
antibody   
Escape/Amgen 
(mAb TNFα) 
1ry prevention  
(Ph 3 ends in 2015) 
↑ LDL-C, Heart failure 
(Injection site reactions, Infusion reactions, 
Heart failure, Neutropenia, Infections, 
Demyelinating disease, Cutaneous reactions 
and Malignancy) 
Roche 
(mAb IL-6) 
Post MI 
(Ph 3 ends in 2013) 
↑ LDL-C 
(Injection site reactions, Infusion reactions, 
Infections, Liver function, Neutropenia and 
Diarrhea) 
CANTOS/Novartis
* (mAb IL-1β) 
previous MI   
(Ph 3 ends in 2016) 
↔ LDL-C  
(Injection site reactions, Infections) 
* CANTOS uses canakinumab, an FDA approved drug for the treatment of cryopyrin-associated 
periodic syndromes (source FDA reports and http://www.ehealthme.com accessed December 
2013). 
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Evidence for Tumor necrosis factor alpha - TNFα or cachectin is a cytokine that 
induces cytolysis of certain tumors and acts as a potent pyrogen causing fever directly or 
via IL-1β stimulation. TNFα is synthesised as a pro-TNFα with a long and atypical signal 
peptide, which is absent from the mature and active cytokine (Sherry et al. 1990). Both 
the mature protein and a partially cleaved one are secreted into the circulation (Cseh et 
al. 1989). Many animal models, as well as some initial clinical trials, have suggested that 
downregulation of TNFα may improve cardiac performance. Soluble TNF receptor 
lessens myocardial inflammation, but myocardial thickening was not reversed in this 
model (Kubota et al. 2000). Subsequent to coronary artery ligation, etanercept (mAb 
TNFα) or intravenous immunoglobulin attenuate expression of genes involved in post MI 
remodeling in rats. This suggests that early immunomodulation post MI may prevent 
later development of heart failure (Gurantz et al. 2005). In addition, the previous study 
with 10,156 RA patients treated with a variety of TNF inhibitors, CS and MTX; 
demonstrated that only TNF antagonist were associated with a reduction in CVD 
(Greenberg et al. 2011). 
On the other hand, preliminary results from a placebo-controlled study using 
TNFα inhibitors suggest no effect, or even an adverse effect of TNFα inhibitor therapy on 
mortality and hospitalization. In a three group study of RA patients that were treated with 
TNFα inhibitor, MTX and placebo, TNFα inhibition failed to completely restrain the 
inflammatory process and may promote atherogenesis (Cuchacovich et al. 2009). In a 
cross-sectional study of 23 patients with RA taking TNFα inhibitor therapy, inflammatory 
markers were non-better than classical risk markers, suggesting TNFα inhibitors could 
not be used alone in CVD prevention (Sandoo et al. 2012). Post MI, etanercept was 
shown to reduces systemic inflammation, but to increase platelet activation. This 
suggests that a TNFα inhibitor is unlikely to be a beneficial therapeutic strategy in 
patients with acute MI (Padfield et al. 2013).  
Though a bit disappointing, these adverse effects do not necessarily dismiss the 
immunomodulation hypothesis. These results only underline the difficulties in selecting 
approaches that can modulate the cytokine network in beneficial ways to combat CVD. 
The route of TNF inhibition may be indicative of successfulness depending on how fast 
they reach the vascular bed. A significant decreased risk in MI in psoriasis subjects 
using etanercept subcutaneously compared to treatment with topical agents (Wu et al. 
2013).  
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Currently, there is a model K/BxA (g7) mouse that recapitulates the human 
phenotype seen in RA, namely inflammatory arthritis followed by atherosclerosis. This 
new animal model may help identify the inflammatory component that is involved in the 
development of atherosclerosis without hindering the immune system (Rose et al. 2013).  
Importantly, targeted use of TNFα inhibitors may be associated with the 
development or exacerbation of heart failure (HF). TNFα inhibitors that were tested in 
patients with moderate to severe heart failure did not demonstrate any clinical benefits 
and suggested that etanercept may adversely affect the course of the disease (Anker et 
al. 2004, Mann et al. 2011). Concern about this possible adverse effect stems from 
randomized clinical trials testing TNFα inhibitors as a potential therapy for HF and from 
postmarketing surveillance data gathered by the FDA (Ding et al. 2010). Given the 
evidence to date, patients with symptomatic HF should be treated with strategies other 
than TNFα inhibitors. In a patient who develops HF while on a TNFα inhibitor, a drug-
induced cause should be suspected, and the use of the medication should be 
suspended (Table 7). Importantly, TNFα inhibitors have been associated with either the 
development or the exacerbation of neurologic disorders associated with demyelination, 
such as multiple sclerosis. However the true nature of this association has not been 
established (Pasumarthy et al. 2009). TNFα inhibitors should be discontinued 
immediately in patients suspected to have demyelination. At present, a study is being 
conducted in psoriasis patients using etanercept to determine whether less 
cardiovascular inflammation is attributed with the use of the drug (http://clinicaltrials.gov - 
NCT01522742). 
 
Evidence for Interleukin 6 – IL-6 is a multifunction cytokine responsible for 
stimulating acute phase protein synthesis, as well as the production of neutrophils in the 
bone marrow. It is antagonistic to regulatory T-cells while it supports the growth of B-
cells. Counter intuitively, IL-6 can also attenuate inflammation through its inhibitory 
effects on TNFα and IL-1, as well as activation of the IL-1 receptor antagonist (IL-1Ra) 
and IL-10 (Steensberg et al. 2003).  IL-6 is secreted by macrophages involved in the 
atherosclerotic plaque in response to specific antigens, referred to as pathogen-
associated molecular patterns (PAMPs) such as sodium monourate crystals and 
cholesterol crystals. PAMPs binds to a group of receptors in the innate immune system 
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named pattern recognition receptors or Toll-like receptors (TLRs).  TLRs are present on 
the cell surface and induce cytokine production. In addition, smooth muscle cells in the 
tunica media of many blood vessels also produce IL-6 as well as adipocytes, and this 
may explain the reason why obese individuals have higher circulating CRP induced by 
IL-6 (Bastard et al. 1999).  
 
In a carotid atherosclerotic model, IL-6 was found to destabilize plaques by 
downregulating a key intracellular enzyme required for synthesis of collagen (Zhang et 
al. 2012).  Tocilizumab is a humanized anti-human IL-6 receptor antibody that competes 
for both the membrane-bound and the soluble forms of the human IL-6 receptor, thereby 
inhibiting the binding of the native cytokine to its receptor and interfering with its effects. 
Tocilizumab was shown to be effective in improving endothelial dysfunction and reducing 
arterial stiffness in RA patients (Protogerou et al. 2011, Kume et al.  2011). It is 
therapeutically effective in patients with RA, but adverse events, such as liver function 
disorders, neutropenia, diarrhea, infection and hyperlipidemia, were observed in clinical 
trials (Table 7) (Kawashiri et al. 2011). Drug-induced hyperlipidemia is generally 
tolerated, however as clinical trials are being conducted in CVD prevention, the current 
TNFα and IL-6 inhibitors increase LDL-C, and thus the issue of cardiovascular safety 
needs to be addressed. Recently, it was reported that tocilizumab is being considered in 
the prevention of CVD (Hingorani et al. 2012) and may be useful for the treatment of 
acute MI (http://clinicaltrials.gov - NCT01491074). The effect of tocilizumab in post MI 
will be evaluated by CRP, the myocardial necrosis marker troponin T and pro-BNP.  
 
Evidence for Interleukin 1 - Stimulation of the IL-1 receptor type I (IL-1R1) on 
vascular endothelial cells leads to upregulation of iNOS, endothelin-1, 
chemokines/cytokines, and adhesion molecules, endothelial and smooth muscle 
proliferation and macrophage activation. These processes all contribute to endothelial 
dysfunction and progression of atherosclerosis (Fearon et al. 2008). Both IL-1α and IL-
1β activate IL-1R1 to evoke a proinflammatory response, whereas IL-1Ra naturally 
inhibits their binding. IL-1α remains associated with the plasma membrane, whereas IL-
1β is fully secreted and can act on IL-1R1 in cells distant from the cell of origin. Thus IL-
1β has been thought to be of greater relevance to the human inflammation system.  
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IL-1Ra: is a naturally occurring glycoprotein inhibitor that can neutralize the IL-1 
mediated inflammatory effects. A synthetic IL-1 receptor antagonist (Anakinra) can be 
used as a biologic DMARD. However, it is administered daily due to its short half life via 
a subcutaneous (SC) injection and acts through competitive binding with IL-1 for its 
receptor, but with no receptor signaling activation. It exhibits modest clinical efficacy and 
a dose-dependent increase in the risk of serious infection in patients with RA compared 
with placebo. The IL-1Ra:IL-1 ratio is critical in vascular inflammation. In obese patients, 
IL-1Ra levels are increased (Meier et al. 2002), partly secreted by adipose tissue. In this 
population, IL-1Ra promotes leptin and insulin resistance and weight gain (Meier et al. 
2002). It was reported that anakinra may improve vascular and left ventricular function in 
patients with RA, but without coronary disease (Ikonomidis et al. 2008). This 
improvement was related to a concomitant reduction in nitrooxidative stress and 
endothelin-1 levels. A current study is evaluating whether or not anakinra also improves 
vascular and left ventricular function in patients with coronary diseases and RA 
(http://clinicaltrials.gov – NCT 01566201). 
 
IL-1β: is a potent pyrogen that plays a role in the regulation of immune and 
inflammatory responses to infections or sterile insults. It is synthesised as a pro-IL-1β 
that needs Caspase-1 for its cleavage/activation. In clinical studies, IL-1β concentrations 
were found in high levels in atherosclerotic human coronary arteries (Galea et al. 1996). 
More significantly, IL-1β inhibition modulates a proinflammatory mediator that is neither 
essential for host defense nor critical to innate immunity. Thus, targeted inactivation of 
IL-1β decreased atherosclerosis in a mouse model of atherosclerosis fed a high 
cholesterol diet (Kirii et al. 2003). As alluded to earlier, a relationship between the 
earliest deposition of cholesterol crystals and the initiation of inflammation, is likely 
through the NLRP3 inflammasome. Even though the biological effects of IL-1β are 
mediated through its own receptor (i.e., IL-1R1), its activation leads to proinflammatory 
gene expressions similar to that of TNFα activation (Kida et al. 2005). In fact, some 
reports have shown that IL-1β also regulates the TNF receptor (Winzen et al. 1993, 
Hultner et al.  2000). In addition, IL-1β may play a role in the expression and shedding of 
the TNF receptor. One study demonstrated that IL-1β modified TNFα signaling through 
alterations in TNF receptor mRNA expression (Holtmann et al. 1987). 
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The development of an IL-1β inhibitor was promoted as an orphan drug (Walsh 
et al. 2009) by the European Medicines Agency (Doc. Ref.: EMEA/503722/2009) and 
thus granted the use of canakinumab (mAb IL-1β) in Cryopyrin-Associated Periodic 
Syndromes (CAPS), which is a genetic variance of NLRP3 gene causing 
autoinflammatory disorders. An extensive program of toxicology studies was performed 
in marmoset monkeys and conducted with the murine form mAb IL-1β in mice. Using this 
murine mAb, it was further shown that neutralization of IL-1β does not inhibit the 
development of a T cell-dependent antibody response induced by immunization in the 
presence of aluminium hydroxide. Concerning the immune system, there were no 
differences in counts of lymphocytes and red blood cells, spleen and thymus in mice 
treated with a mAb IL-1β. Treatment of littermates with mAb IL-1β once a week for 2 
month resulted in minimal inflammatory reactions at the sites of injection. These were 
reversible over a 4 week recovery period. In addition, the pharmacokinetics of mAb IL-1β 
was determined in mice after single and repeated injections. A dose-dependent increase 
was observed with a peak approximately 24 h after dosing and the elimination half-life 
ranged between 1 and 17 days. Male and female fertility was not affected by treatment. 
This initial safety profile led the way to launch the CANTOS trial (http://clinicaltrials.gov – 
NCT NCT01327846).  
The primary outcome in CANTOS is the first occurrence of a major adverse 
cardiovascular event (a composite of CV death, non-fatal MI, and stroke). Changes from 
baseline in carotid plaque burden in the bifurcation region of the carotid artery and 
changes in insulin secretion rate (ISR) across the yearly visits will be evaluated. This will 
allow for the detection of new onset type 2 diabetes among patients with pre-diabetes 
within the 5 year follow-up period (Estimated primary completion date: July 2016). Given 
the above and the potential beneficial effect of IL-1β inhibition on atherosclerosis, we 
selected a mAb against IL-1β to test the hypothesis that immunomodulation may prevent 
aortic calcification.  The choice of a mAb against IL-1β was based on the lack of 
evidence that it induces cardiovascular necrosis and its neutral effect on lipids levels. 
This we believe will be a direct answer to the question if inflammation is a residual risk in 
CVD. In Chapter 6, we test the hypothesis that inhibiting the inflammatory process 
induced by IL-1β will lead to a measurable reduction in vascular calcifications in mice.  
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4.3. Atherosclerosis immunization: 
The future of treatment in atherosclerosis will be based on lipid lowering drugs in 
combination with anti-inflammatory therapies, as large expensive clinical trials are trying 
to prove. A more cost-effective alternative approach is training the immune system to 
self-recognise culprit proteins in the pathogenesis of early inflammation that is involved 
directly in the atherosclerosis formation (De Jager et al. 2011). Historically, the concept 
of active immunization against atherosclerosis was proposed by Gero et al more that 50 
years ago using beta-lipoproteins (Gero et al. 1959), yet only in the last 10 years has it 
received attention in the field. Assisting in this interest is the enhanced understanding of 
the underlying role of immune responses in atherosclerosis. Additionally, a few labs 
have reported promising results with active immunization using antigenic epitopes found 
within the apoB-100 sequence to reduce atherosclerosis in an Apoe(KO) mouse model 
(Chyu et al. 2005). These proof-of-concept studies have raised the possibility that such 
an approach might be possible in humans. However, unlike the immunization against a 
definite pathogen, immunization against ubiquitous antigens in the vascular 
inflammation process is much harder. This is in addition to the technical challenges with 
approaches used: (i) active immunization, (ii) passive immunization or (iii) acquired 
tolerance to an antigen by suppression of cellular and humoral immune response to the 
introduced antigen formation (Chyu et al. 2013). 
Additional antigens that have been tested in animal models to reduce 
atherosclerosis include; modified LDL, homogenates of plaques, functional group on 
oxidized phospholipid, heat shock protein 60 and cholesterol ester transfer protein 
(CETP) (Chyu et al. 2013). Interestingly, none of these are cytokine-derived antigens. 
However, the concept of cholesterol crystals initiating the pathogenesis of 
atherosclerosis may evoke the development of new immunization regiments that 
provides lifelong CVD protection and may possibly prevent vascular calcification.  
Regardless of the antigen of choice, the documented side effects are so far 
cardiovascular in nature, counter intuitively, driving biomedical researchers away from 
this field (De Jager et al. 2011). As disappointing as this may be, vaccination against 
atherosclerosis remains a theoretical goal.  The development of such vaccination would 
have a high impact on the future of atherosclerosis management especially as primary 
prevention. 
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In summary, the idea that inflammation is central to the development of 
atherosclerosis has been a fundamental principle of vascular biology, atherosclerosis 
and preventive medicine. However, therapeutic modulation of inflammation for the 
prevention and treatment of arteriosclerosis remains largely unproven, even more in 
vascular calcification. Indeed the use of steroids has been associated with unwanted 
side effects and the modulation of the IL-1β and IL-6 pathways has proven safe from the 
cardiovascular standpoint, but with an increased risk of infections. A sign of harm was 
noted in patients with heart failure given the TNFα blocker etanercept.  
Basic and clinical research has led to quantum leaps forward in the identification 
of the role of both innate and adaptive immune system in arteriosclerosis. The tight 
balance and interplay of inhibitory and stimulatory pathways of the immune system 
regulate their participation in atherosclerosis progression and vascular calcifications. The 
redundancy in the immune system represents an opportunity and challenge to identify 
mediators in the host-defense mechanism susceptible to inhibition in a way that could 
diminish atherosclerosis without leading to immunosuppression, hindered tumor 
surveillance and increased susceptibility to opportunistic infections. The collective 
knowledge gained by studying the role of inflammation in atherosclerosis and the 
translational application of these advances in basic science will shape future clinical 
practice.  
To date, two large-scale clinical trials of immunomodulation to prevent 
arteriosclerosis and its many complications are underway. In the Coronary Inflammation 
Reduction Trial (CIRT), low-dose MTX is being used as a broad-term upstream anti-
inflammatory and in the Canakinumab Anti-inflammatory Thrombosis Outcomes Study 
(CANTOS) the selective IL-1β mAb canakinumab will provide a much more focused 
approach to modulating the immune system. Importantly, neither approach appears to 
have much impact on the conventional cardiovascular risk factors (plasma levels of 
lipids, blood pressure and glucose) which will make them complementary to current 
treatments. 
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5. Hypothesis and Objectives of Thesis 
  
 Familial hypercholesterolemia registries will advance the genetic bases of the 
disease and thus the care of this population.  
Through record keeping, history, physical examination, biochemical analysis, genetic 
analysis, cascade screening, next-generation sequencing and Sanger sequencing, new 
candidates genes in FH will be discovered and thus open the door for interesting 
biology. My objectives thus are: 
x Improve FH diagnosis using available molecular testing 
x Identify new loci associated with FH spectrum 
x Implement a prevention strategy to identify asymptomatic yet at risk individuals 
 
New biology of PCSK9 will be uncovered when young and old populations are 
examined as well as and when PCSK9 LOF mutations and APOE LOF mutations 
are subanalyzed.  
Through measuring circulating PCSK9 levels by an ELISA assay and determining 
common physical parameters, biochemical parameters, apoE isoforms and PCSK9 LOF 
variants, association and relations can be determined. My objectives thus are: 
x Evaluate PCSK9 as a biomarker for response to treatment with statins 
x Examine relevant cardiometabolic correlates 
x Predict possible risk of PCSK9 inhibitors by studying natural LOF individuals 
 
Animal models will advance our understanding of aortic calcification and may 
validate treatments options using immunomodulation therapy.  
Using relevant animal models, atherogenic diet, method development to invoke vascular 
calcification ex vivo and pharmacological intervention, much can be learned. My 
objectives thus are: 
x Confirm the utility of Ldlr-deficient animal models in FH-induce aortic calcification 
x Validate the sensitivity of a detection method using micro-CT 
x Investigate the pathogenesis of aortic calcification and identify key players 
x Immunomodulation intervention using IL-1β inhibitor to reduce the burden of 
aortic calcification 
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CHAPTER 2: FH AND APOE 
 
ARTICLE (A):  APOE p.Leu167del mutation in familial hypercholesterolemia 
AUTHORS: Zuhier Awan, Hong Y. Choi, Nathan Stitziel, Isabelle Ruel, Mary Aderayo 
Bamimore, Regina Husa, Marie-Helene Gagnon, Rui-Hao L. Wang, Gina M. Peloso, 
Robert A. Hegele, Nabil G. Seidah, Sekar Kathiresan, Jacques Genest 
 
FIRST AUTHOR: Zuhier Awan 
CONTRIBUTION: Conception and design (50%), analysis and interpretation (60%) and 
writing and critical revising (60%) 
CURRENT STAGE: Published  
JOURNAL: Atherosclerosis, 2013 December; 231:218–222. 
PUBMED LINK: http://www.ncbi.nlm.nih.gov/pubmed/24267230 
 
2. Foreword:  
Familial Hypercholesterolemia (FH) is a monogenic disorder classically caused 
by mutations in the LDLR gene or mutation in its ligand encoded by APOB gene. Since 
the discovery of the third locus implicated in FH, the disease was renamed Autosomal 
recessive hypercholesterolemia (ADH) to capture the phenotypic diversity. Discovering 
more genes involved in ADH will increase our understanding of the disease.  
In this article we report a relatively novel mutation within the APOE gene causing 
pure FH or ADH. Through a combination of physical examination, biochemical analysis, 
candidate gene approach, next-generation exome sequencing and Sanger sequencing, 
we uncovered the genetic basis of an ADH phenotype in a proband of an Italian origin.  
The collection of patients with familial dyslipidemia as in our FH registry was 
advantageous at multiple levels.  
The first advantage was for the patient who is directed to a specialized care unit 
with experienced staff to lessen his disease burden. The second advantage was to the 
family who benefit from cascade screening and early follow up. The third advantage was 
to the scientific community who will gain significant insight in to the biology of many 
dyslipidemia diseases including FH. Initiation of nationwide registries thus will promote 
cardiovascular prevention in more than half of the FH population that are vulnerable to 
premature CVD. 
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2.1 Abstract: 
BACKGROUND: Autosomal dominant hypercholesterolemia (ADH) is caused by 
mutations in the low density lipoprotein receptor (LDLR), its ligand apoB (APOB) or 
proprotein convertase subtilisin/kexin type 9 (PCSK9) genes. Yet DNA sequencing does 
not identify mutations in these genes in a significant number of cases, suggesting that 
ADH has multiple genetic etiologies. METHODS: Through a combination of clinical 
examination, biochemical analysis, candidate gene approach and next-generation 
exome sequencing we investigated the genetic basis of an ADH phenotype in a proband 
of an Italian origin. RESULTS: The proband presented with an acute myocardial 
infarction at age 43. He had tendinous xanthomas, xanthelasmas and elevated levels of 
total and LDL cholesterol, at 11.2 and 9.69 mmol/L, respectively, with normal levels of 
HDL cholesterol and triglycerides at 1.62 and 1.13 mmol/L, respectively. HPLC 
lipoprotein profile showed selective increase in LDL-C. DNA sequencing did not identify 
any mutation in the LDLR, PCSK9, LDLRAP1and APOB gene. We then performed 
exome sequencing on three individuals from the family. The strongest evidence of 
association was found for the previously identified apolipoprotein E mutation (APOE, 
chromosome 19:45412053-55) known as APOE Leu167del, an in-frame three base-pair 
deletion. Computational biology confirmed the deleterious nature of this mutation. The 
Leu167del mutation is predicted to alter the protein structure of apoE near the α-helix 
within the receptor binding domain. CONCLUSIONS: This report confirms a previous 
report that ADH can be caused by mutations within the APOE gene and represents the 
4th loci causing ADH. Standard screening for ADH should include APOE gene. 
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2.2 Introduction: 
  Familial hypercholesterolemia (FH) is an autosomal dominant disorder 
characterized by cutaneous xanthomas and xanthelasmas, a marked increase in low 
density lipoprotein (LDL)-cholesterol (LDL-C) and premature coronary artery disease. 
The genetic basis of FH is primarily from mutations within the LDLR gene, coding for the 
LDL receptor (LDLR) [1,2]. At least two other genes other than the LDLR have been 
found to cause a phenotype clinically similar to FH. These include the APOB [3] and 
PCSK9 [4,5] genes. The term Autosomal Dominant Hypercholesterolemia (ADH) thus 
captures the genetic diversity of FH. Mutations in the LDLRAP1 [6], coding for the LDLR 
adaptor protein 1 cause the rare autosomal recessive hypercholesterolemia disorder.  In 
population-based studies, ~20% of patients with the FH phenotype do not have 
identifiable mutations in these genes [7]. Genome-wide association studies (GWAS) had 
broadened the search for genes contributing to LDL-C levels; this technique has allowed 
the identification of several genes that contribute to small variation in LDL-C levels [8]. 
Remarkably, mutations in several of the genes identified by GWAS have been previously 
identified in patients with FH. Contemporary techniques in high-throughput sequencing 
allow the sequencing of all exons expressed in the human genome. Using exome 
sequencing has allowed the identification of the genetic basis of rare diseases, usually of 
an extreme phenotype. Here, we present a mutation of the APOE gene in a kindred with 
a classical ADH phenotype.  
ApoE is a multi-functional glycosylated protein (34 KDa) secreted from a variety 
of tissues, including the liver, brain, kidney, adrenals, adipocytes, macrophages and 
immune cells. It is a key component of all lipoproteins, but especially of triglyceride-rich 
lipoproteins (chylomicrons and chylomicron remnants), VLDL (very low density 
lipoproteins) and IDL (intermediate density lipoproteins), and participates in their 
catabolism through interacting with receptors belonging to the LDLR superfamily. ApoE 
is recognized by most receptors of this class, but especially the LDLR (also known as 
the apoB/E receptor), LDL-receptor related peptide-1 (LRP1) and LRP8 (apoE receptor 
2) [9]. Three common polymorphisms at the APOE gene, apoE3, E4 and E2 have been 
recognized. ApoE2 binds with much less affinity to the LDLR. Homozygosity for the E2 
allele is seen in approximately 0.5% of the population and a small percentage of these 
subjects will develop type III dyslipidemia, characterized by accumulation of remnant 
lipoprotein particles in plasma and premature vascular disease. A “second hit” is 
76 
postulated to contribute to the expression of the apoE2/E2 genotype into a clinical 
dyslipidemia phenotype [10]. Rare mutations of APOE also lead to a rare form of lipid 
glomerulopathy [11]. Genome-wide association studies have shown that apoE is 
strongly associated with LDL-C levels [8]. Marduel et al [12] were the first to report the 
strong genetic link between APOE p.Leu167del and the ADH phenotype in a large 
family.  
 
2.3 Material and Methods  
  Patients with an FH phenotype were selected from the McGill University Health 
Centre (MUHC). In all patients, a cascade screening of first- and second-degree 
relatives is offered. Clinical FH were suspected when total cholesterol is above 7 
mmol/L, LDL-cholesterol is above 5 mmol/L and triglycerides are below 3 mmol/L. The 
protocol for blood sampling, family studies and DNA analysis has been approved by the 
Research Ethics Board of the research institute of the MUHC. Follow-up data for a 
period of 3 years was retrieved. Proper informed consent was obtained prior to clinical 
photography. A lipid profile is obtained in the fasted state, preferably without lipid-
lowering drugs. Such medications are not withheld in subjects at high cardiovascular 
risk. In all cases, medical records are sought to determine previous lipid profiles.  
Plasma samples (150 μl) from subjects were separated into lipoprotein fractions 
using high performance liquid chromatography (HPLC) with a Superose 6 10/300 GL 
column (GE Healthcare) attached to a Beckman Coulter System GoldTM apparatus. A 
150 mM NaCl mobile phase with a flow rate of 0.4 ml/min was used for the separation of 
the sample into 72x 400 μl-HPLC fractions that were collected in a 96-well plate using 
the ProteomeLabTM automated fraction collector (Beckman Coulter). Total cholesterol 
and triglyceride concentrations were subsequently analyzed on each fraction using the 
InfinityTM Cholesterol and Triglyceride Liquid Stable Reagents (Thermo Electron 
Corporation) following the manufacturer’s instructions. 
  Using a candidate gene approach, we sequenced all exons of the LDLR, PCSK9 
and LDLRAP1 genes as well as part of exon 26 of the APOB gene, associated with the 
apoB -LDLR interaction. In addition, a search for common copy number variants (CNV) 
at the 5’ region of the LDLR was performed. We then performed whole exon sequencing 
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as previously described [12,13]. All identified SNPs in non-coding regions or not 
expected to impart functional defects on PolyPhen-2 [14] and SIFT softwares [15] were 
excluded. We used the following filters: we removed variants unlikely to be causal in the 
LDL-C genome-wide association studies, variants with a minor allele frequency >5%, 
synonymous or intronic variants and variants that did not fit a dominant model of 
transmission.  
  Exome sequencing of individuals from the proband family are performed to 
confirm association. Suspected gene are then sequenced in 39 independent individuals 
with a clinical diagnosis of ADH (primarily diagnosed based on the Simon Broome 
criteria) from a tertiary lipid referral clinic in Southwestern Ontario; mutations in known 
ADH genes, namely LDLR, APOB and PCSK9 were excluded in these patients.   
Finally we used computer prediction and modeling software to identify and 
illustrate the impact of a mutation on a protein function. Protein Variation Effect Analyzer 
(PROVEAN) was used to determine if a given mutation is deleterious to the protein 
structure in multiple nucleotide involvement [16]. Template-based protein structure 
modeling using the I-TASSER server was accessed and then illustrated with the PyMol 
viewer to show structural impact of the mutation [17, 18]. 
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2.4 Results 
  Our proband is a 43 year-old man of Italian origin. He presented initially with an 
acute coronary syndrome; a coronary angiogram revealed severe three-vessel coronary 
artery disease. He underwent coronary artery bypass surgery. Because of the presence 
of tendinous xanthomas, xanthelasmas, Achilles tendons xanthomas, elevated total 
cholesterol and LDL-C levels (Fig.1 A, B and C), he was selected for further evaluation. 
The initial lipid and lipoprotein lipid profile revealed total cholesterol of 11.2 mmol/L (457 
mg/dL), LDL-C of 9.69 mmol/L (374 mg/dL), HDL-C of 1.62 mmol/L (63 mg/dL) and 
triglyceride level of 1.13 mmol/L (100 mg/dL). He did not have any cause of secondary 
hypercholesterolemia nor was there any sign of a hematological disease and his 
abdominal ultrasound was unremarkable –specifically the spleen was not enlarged.  
Compliance issues, including the development of myalgias on atorvastatin 80 
mg/day led to unsatisfactory results during the initial year of treatment. On a combination 
of rosuvastatin 10 mg/day and ezetimibe 10 mg/day, the lipoprotein profile dropped to a 
total cholesterol of 3.87 mmol/L (150 mg/dL), and LDL-C of 2.3 mmol/L (90 mg/dL), a 
respective 67% and 76% reduction from baseline (Fig. 1D). While a target level of an 
LDL-C < 2.0 mmol/L (~80 mg/dL) was not achieved, these results are well within the 
current recommended Canadian Cholesterol guidelines [19].  
  We then conducted a family study and performed DNA sequencing for the LDLR, 
PCSK9, LDLRAP1 and exon 26 of the APOB genes; in addition, to common CNV in 
LDLR in the proband. No known mutation was identified and the several polymorphisms 
found were either in non-coding regions or were not expected to impart functional 
defects on PolyPhen [14] and SIFT software [15]. Multiplex ligation-dependent probe 
amplification was not performed for the LDLR gene.  The APOE gene was not 
considered as a candidate for the initial screening strategy. Until the report by Marduel et 
al [12], there was little biological plausibility to include APOE as causal in the ADH 
phenotype.   
We then proceeded with exome sequencing on three individuals from the same 
family (proband #301 and both sisters #303 and #304). Approximately 54,000 variants 
now were identified. We used the previously mentioned filters in the method section and 
ended with 49 missense mutations, 1 frameshift and 2 in-frame deletions in 52 genes. 
The APOE gene Leu167del mutation was the most likely candidate gene since it was 
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recently discovered in a large family with FH [12]. The proband was found to be 
heterozygous for Leu167del as well as his sister (# 303). The other sister (#304) was 
found not to carry the APOE mutation (Fig. 1E). The APOE gene was then Sanger 
sequenced to confirm results obtained from the next-generation sequencing strategy. 
APOE genotyping showed that the proband and both sisters (Fig. 1D) were homozygous 
for the apoE3 allele.  
HPLC profile on the subject’s affected sister (#303) was performed who was not 
on lipid-lowering medication at the time. Because the apoE2/E2 phenotype is not 
associated with an isolated LDL elevation but rather a “broad beta” fraction, we sought to 
contrast the lipoprotein profile –as determined by HPLC separation- between a normal 
relative (#304), an APOE mutation subject (#303) and a subject with known type III 
hyperlipoproteinemia (apoE2/E2). Therefore the major particle abnormality in the 
affected subject (#303) resides in the LDL fraction and hence the selective increase in 
LDL-sized lipoproteins in the proband’s sister is compatible with FH (type IIa 
hyperlipoproteinemia) (Fig. 1F). 
The APOE gene mutation consists of a TCC deletion (c.500_502delTCC; 
p.Leu167del) coding for a leucine at position 167 in exon 4 of the APOE gene 
(chromosome 19:45412053-55) (Fig. 2A and B). The APOE p.Leu167del mutation was 
absent from 39 individuals with a clinical diagnosis of ADH ascertained in Ontario, 
Canada who had no mutation in any of the known ADH genes; indeed no rare mutations 
in APOE were found in this cohort.  Using the protein structure algorithm online 
PROVEAN software to predict the effect of an amino acid loss on the protein 
functionality, APOE Leu167del scored -7.41 (default threshold -2.5) marking it 
deleterious to the protein structure [16]. Using established template-based protein 
structure modeling (I-TASSER server) [17] followed by 3-D structure alignment of both 
reference and Leu167del protein using PyMol viewer we could identify a leucine zipper 
disruption (Fig. 2C).   
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2.5 Discussion 
Recently APOE p.Leu167del was reported in a kindred from France with ADH 
[12]. The APOE mutation was shown to segregate in a large family with elevated LDL-C. 
Based on kinetic studies, it was postulated that this mutation may cause a decrease in 
LDL clearance [12]. Furthermore, apoE is not only a ligand for the LDLR but also for 
many other LRPs in the LDLR family that may assist in LDL clearance and may be more 
affected by the mutation seen in our patient [9]. Interestingly recent data have shown 
that LDLR-mediated LDL uptake is regulated by LRP6 (another LDLR family member) 
that can potentially bind apoE and thus the Leu167del mutation may interfere with LDL 
internalisation [20]. This mutation has also been previously reported in a patient with 
sea-blue histiocytosis [21] and was known as APOE Leu149del, due to different 
numbering based on exclusion of the pro-peptide sequence. Thus, APOE p.Leu167del is 
associated with a range of clinical phenotypes, including classical ADH, 
hypertriglyceridemia with splenomegaly and sea-blue histiocytosis and familial combined 
hyperlipidemia [12, 21-24]. The reasons behind expression of such a diverse range of 
phenotypes in carriers of this mutation, but not seen in our proband is unclear, but 
mechanism may be related to differences in genetic background of different carriers, 
gene-gene interactions, gene-environment interactions, or perhaps epigenetic and other 
non-mendelian interacting effects [22-24]. Thus our report confirms the observation of 
Marduel et al [12], and confirms that APOE is the 4th locus identified in ADH. 
The structure of apoE has been extensively studied. The amino terminal portion 
has 4 α-helical structures that contain the receptor-binding region. The major lipid 
binding region is located near the carboxyl terminus [25]. The deletion of Leu167 is part 
of this highly conserved motif within the forth helix of the apoE protein. This region 
besides containing the receptor binding site (residues 136-150), it contain 112 and 158 
residues, sites of common polymorphisms leading to apo E2, E3 and E4 isoforms and 
different binding affinity. We used computer prediction and modeling softwares to predict 
and illustrate the impact of this deletion on the 3D-structure of apoE [16-18]. It is 
apparent that APOE p.Leu167del destabilizes a leucine zipper motif in a critical region of 
the protein that, in turn, would weaken the lipoprotein particle binding to the LDLR (Fig. 
2C). However the proband was heterozygous therefore it was feasible to overcome this 
phenotype by statin therapy that is known to induce LDLR in the liver, therefore the 
pharmacological approach was remarkable. From a clinical point of view it would be 
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interesting to examine the effect of upcoming class of PCSK9 inhibitors that enhances 
LDLR availability on the liver surface and thus lowers LDL-C, with fewer myalgic effects 
than those experienced by our proband while on statin [5]. 
In conclusion the p.Leu167del mutation was associated with ADH in a kindred of 
an Italian ancestry and was identified by next-generation exome sequencing; the 
candidate gene approach did not identify mutations in genes known to be associated 
with ADH or autosomal recessive hypercholesterolemia. ADH individuals with a 
confirmed molecular diagnosis [26] are known to have premature atherosclerotic 
vascular disease, especially coronary artery disease, which if left untreated will lead to 
clinical symptoms in the third to fourth decade of life in men, and approximately ten 
years later in women [27-29]. Accordingly, the proband was 43 years of age at the time 
of presentation and had classical and biochemical features of FH, but not recognized for 
an acute coronary syndrome prior to his hospitalization. This report may have an impact 
on large registries of FH patients and access to specialized medical care. With the 
unravelling of additional genes associated with FH, future generations will benefit from 
cascade gene screening in high risk families to prevent vascular disease. 
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2.8 Legends and Figures: 
Figure 1. 
 
 
Figure 1.  A. Tendinous xanthomas in the proband, at the time of initial diagnosis. B. 
Xanthelasmas around both eyes in the proband. C. Achilles tendon xanthomas in the proband are 
demarcated with the dash line. D. Lipid and lipoprotein lipids over a three-year period in response 
to change of medication. The proband developed myalgias to high-dose atorvastatin and  finally 
tolerated rosuvastatin (Medication history indicated by numbers: 1-Atorvastatin 80mg and 
Ezetimibe 10mg, 2-No medication, 3-Atorvastatin 20mg, 4-Atorvastatin 20mg and  Ezetimibe 
10mg, 5-Rosuvastatin 10mg and Ezetimibe 10mg). E. Family tree of the kindred with APOE 
Leu167del. The proband (#301) is indicated by an arrow. The heterozygotes were subjects in red 
(#301 and #303) while the sister in blue (#304) was normal. F. HPLC profiles of the proband’s 
affected sister subjects #303, unaffected sister r#304 and a type III hyperlipidemias associated 
with apoE2/E2. 
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Figure 2. 
 
Figure 2.  A. Shows chromosome 19 sequence data of the affected subject using 
next-generation sequencing. B. Part of APOE coding gene. The deleted leucine residue is 
shown in red creating an in-frame deletion (codon TCC). C. The predicted crystal structure of 
apoE protein with Leu167 deletion in compare to the wild type. Notice proximity of Leu167 
residue (red) from LDL receptor binding site spanning between 136 to150 residues. The N-
terminal portion (gray ribbon) contains the 4th α-helical region in which the leucine zipper 
motif is destabilized (dash line) by the Leu167del. The C-terminal portion of the protein is 
indicated by a yellow ribbon. 
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CHAPTER 3: APOE AND PCSK9 
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3. Foreword:  
APOE isoforms are one of the most frequent variants that determine the 
cholesterol levels in human due to its different affinity to the LDLR, and PCSK9 is a 
natural negative regulator of the LDLR. Therefore, studying the interaction of both genes 
may lead to better insight into the outcome of using PCSK9 inhibitors in future. 
In the following paper, gene sequencing and screening of a large cohort of a 
pediatric population for loss-of-function (LOF) mutations in PCSK9 were undertaken and 
the gene-gene interactions with APOE isoforms were studied. Multiple parameters were 
captured from the study and were tested for association. The advantage of testing a 
young population is that the disease complexity should be relatively less advanced than 
adults and thus an association should be more accurate.  In PCSK9 p.R46L carriers, 
contribution of the apoE genotype better explains the cholesterol phenotype than the 
PCSK9 variants alone. Patients, with a combination of p.R46L and apoE2 genotype 
showed a tendency toward insulin resistance as indicated by a two-fold increase in 
insulin, a homeostasis model assessment of insulin resistance and leptin concentrations, 
compared to other apoE isoforms. 
 This data shows the prevalence of the p.R46L SNP and the common in-frame 
insertion of leucine 10 (insLEU, L10) in the signal peptide of the PCSK9 protein, within 
17 geographical regions of the province of Québec, Canada. The data show possible 
enrichment of the LOF mutations within specific regions of Québec and a possible 
protective founder effect to counter the FH genotype prevalence. 
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3.1 Abstract: 
BACKGROUND: Natural loss-of-function mutations in the proprotein convertase 
subtilisin/kexin type-9 (PCSK9) gene are associated with lower cholesterol and 
cardiovascular risk. Because a founder effect exists in French Canadians for many lipid-
related genes, we sought to investigate PCSK9 mutations and associated variables in 
this population. We also investigated the combined effect of PCSK9 mutations and apoE 
polymorphism on metabolic variables. 
METHODS: Gene sequencing and screening was carried out in 1745 healthy individuals 
ages 9, 13 and 16 years from a provincially representative population sample. In parallel, 
we measured related metabolic markers and used appropriate statistical methods. 
RESULTS: We report herein that the carrier rates of the R46L single nucleotide 
polymorphism were higher in the French Canadian population (4.8 %) than previously 
seen in Caucasians individuals (2.4 %). This is second to the most common variant 
insLEU at a carrier rate of 24%, making it the most common PCSK9 loss-of-function 
mutation in French Canadians individuals.  In R46L carriers the contribution of apoE 
genotype better explains the cholesterol phenotype than R46L mutation alone.  Patients, 
with both R46L and apoE3/E2 genotype also showed a tendency toward insulin 
resistance as indicated by a twofold increase in insulin, homeostasis model assessment 
of insulin resistance and leptin concentrations, compared  with those without apoE3/E2.  
CONCLUSIONS: R46L and insertion of leucine mutations were more frequent in French 
Canadians and showed a specific geographical distribution. This might represent a gene 
selection to overcome clustering genes harboring familial hypercholesterolemia and 
might suggest a founder effect. Subjects with apoE3/E2 genotype and R46L have 
increased plasma insulin, homeostasis model assessment of insulin resistance and 
Leptin, an intriguing finding that warrants further investigation. 
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3.2 Introduction:  
Proprotein convertase subtilisin kexin type-9 (PCSK9) is an autocatalytic enzyme 
with no known substrate other than itself, mainly excreted by the liver, intestine and 
kidney (1). PCSK9 is synthesized as a 72 kDa, 692–amino acid serine protease 
encoded by the PCSK9 gene located on the short arm of chromosome one. In human it 
is the ninth member of a family of proprotein convertases with homologous sequences 
found across many other animal species (2). PCSK9 share similar structure with other 
proprotein convertase subtilisin/kexin family members; a signal peptide, prodomain, 
catalytic domain and C-terminal domain. The signal peptide of the PCSK9 has 9 
residues of leucine arranged in short tandem repeats. PCSK9 acts as a cholesterol 
regulator that binds the low-density lipoprotein (LDL) receptor (LDLR) through its 
epidermal growth factor-like repeat-A and enhances LDLR degradation (3, 4) through an 
endosomal/lysosomal pathway (5), thereby prevent LDLR from capturing LDL particle 
from the circulation.  
 
Mutations in the PCSK9 gene are associated with either gain-of-function (leading to 
hypercholesterolemia) (6) or loss-of-function (LOF; leading to hypocholesterolemia) (7- 
9). Autosomal dominant hypercholesterolemia or familial hypercholesterolemia (FH) 
secondary to gain-of-function mutations in PCSK9 accounts for approximately 2% of 
cases of FH (2). In 1 study, carriers of PCSK9 LOF mutation R46L (3.6% of Caucasians 
individuals) and nonsense mutations Y142X and C679X (2.6% of African Americans 
individuals) were significantly protected from cardiovascular disease (10). The latter 2 
nonsense mutations translate into a reduction of cardiovascular risk reaching 90%. The 
R46L single-nucleotide polymorphism (SNP) is associated with reduce risk of myocardial 
infarction with a significant 0.40 odds ratio in Caucasians individuals across multiple 
sites with overall minor allele frequency of 2.4% in a meta-analysis (11). Other LOF 
mutations have been described and are summarized in a recent article (12).  
 
In addition to SNPs and stop codons leading to LOF in PCSK9 protein, an extra 
insertion of leucine (insLEU) in the leucine stretch of the PCSK9 signal peptide region is 
also mysteriously associated with lower populational levels of LDL cholesterol (LDL-C) 
and apolipoprotein (apo) B that can reach a carrier rate of 18% (13, 14), but with few 
clinical outcome data (13, 15, 16). Insertion of insLEU was referred to as c.43_44insCTG 
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in the literature (13) and later to c.61_63dupCTG (L10) for an additional one insertion of 
leucine residue and c.61_63triCTG (L11) for two insertions of leucine (17).The in-frame 
insertion of an extra leucine (L10) beyond the existing 9 residuals (L9) in the signal 
peptide region of PCSK9 is constantly associated with lower LDL-C (14, 18), unlike the 
controversial insertions of two extra leucine residues (L11) (17) which have been 
associated with familial combined hyperlipidemia in a single study. 
 
At present many novel pharmacological compounds have been developed to target 
PCSK9 inhibition mimicking the many normal occurring LOF mutations. A more recent 
clinical study was published and showed the usefulness of a monoclonal antibody 
targeting PCSK9 as an efficient way to lower PCSK9 and LDL-C (19).With the 
development of such new medications, it becomes important to definitely understand the 
biological effects and metabolic consequences of different PCSK9 gene variants to 
define those that require intervention.  
 
The aim of this study was to identify the PCSK9 mutations that determine the plasma 
PCSK9 concentration in a French Canadian population-based sample and to examine 
the combined impact of LOF mutations in PCSK9 and other available data that 
influences cholesterol levels. Intriguingly apoE polymorphism was examined for a 
synergic effect with PCSK9 variance on lipid and metabolic variables.  
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3.3 Methods: 
Population Studied 
A population sample of 1745 apparently healthy individuals aged 9, 13 and 16 years 
attending Québec schools who participated in the Québec Child and Adolescent Health 
and Social Survey (QCAHSS), conducted between January and May of 1999 was 
investigated. Information on the study design and methods has been published 
previously (20). In brief, the QCAHSS used a cluster sampling design to pull 3 
independent, representative samples from the province of Québec. Only French 
Canadians individuals were selected for this study, which encompass roughly 80% of the 
available cohort. None of the participants were on glucose- or lipid-lowering agents. DNA 
samples were available for 48 % of eligible candidates (1745 out of 3613). There were 
no sex or weight differences between youth for whom data were included or not included 
for analysis. Written informed agreement and consent were acquired from participants 
and their legal guardians, respectively. The Ethics Review Board of the Centre 
Hospitalier Universitaire (CHU) Sainte-Justine approved the study.  
 
Sample Collection and Measurements 
Samples were taken from 1745 French Canadian participants. Blood was collected in 
the morning into EDTA-Vacutainer™ tubes after an overnight fast and kept on ice until 
separation. Plasma and peripheral leukocytes were obtained by centrifugation at 850 x g 
for 15 min at 4°C. After separation the plasma was frozen on dry ice, and sent to the 
laboratory within 24 h and stored at -80 °C until analysis.  
Height and weight were recorded following a standardized protocol (20) and body 
mass index was computed as weight in kilograms divided by height in meters squared. 
Waist and hip circumferences were not measured (20). Furthermore, because of the 
anonymous design of the study, information concerning family history, such as history of 
cardiovascular disease or diabetes was not available. Total cholesterol, triglycerides 
(TG), high-density lipoprotein cholesterol, glucose and fasting plasma insulin 
concentrations were measured as previously described (20, 21). LDL-C was calculated 
using the Friedewald equation (22). ApoB and apoA-I concentrations were determined 
using nephelometry (Beckman Array Protein System). Plasma adiponectin was 
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measured using radioimmunoassay (Linco Research) (23), leptin was measured using a 
human leptin immunoassay kit (SPI-Bio, Montigny le Bretonneux, France) and apoE 
genotype was determined using amplification refractory mutation system (24) or 
restriction fragment length polymorphism (25). Homeostasis model assessment of 
insulin resistance (HOMA-IR) was calculated according to an earlier version described 
by Matthews et al. (26). PCSK9 measurement was performed using an in-house 
enzyme- linked immunosorbent assay (27- 29). 
 
Genetic Approach and Sequencing 
DNA was extracted from leukocytes using QIAmp Blood Maxi kit (Qiagen, 
Missisauga, ON) according to the manufacturer’s instructions. The PCSK9 gene was 
fully sequenced in study subjects in whom the plasma PCSK9 concentration was either 
under the 5th or over the 95th percentile. The primer sequences used for amplifying the 
12 exons were obtained from NCBI at http://www.ncbi.nlm.nih.gov/genome/probe/ using 
the resequencing amplicons for PCSK9. Amplicon was treated with ExoSAP-It (USB 
corp), followed by sequencing with Bigdye V3.1. The extension products were then 
separated using capillary electrophoresis on a 3130 XL Genetic analyzer from Applied 
Biosystems. Sequences were then assembled with Sequencher software (Sequencher 
5.1; Gene Codes Corp)  
We then screened the whole cohort for the in-frame insLEU and the R46L SNP 
identified in Exon 1-PCSK9. The insLEU screening was done by fragment analysis 
detection: an amplicon in the region of leucine was generated with two specific primers, 
the forward carrying a fluorescent dye label (forward primer 6FAM 
GCCAGGACAGCAACCTCTC, reverse primer TAGCACCAGCTCCTCGTAGTC), so the 
fluorescent-labeled product could be separated by size on 3130xl Genetic analyzer and 
then interpreted using the geneMapper sofware (GeneMapper 3.7). Additional insertion 
of leucine differed only by the size of fragment obtained:  from wild type (9L=159 base 
pairs [bp]), mutant (10L=162bp) or (11L=165bp). For R46L mutation, screening was 
performed using a TaqMan SNP genotyping assay, designed by lifetechnologies (assay 
ID: C_2018188_10); context sequence:  
TACGAGGAGCTGGTGCTAGCCTTGC[G/T]TTCCGAGGAGGACGGCCTGGCCGAA. 
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Statistical Analysis  
Samples were stratified according to their PCSK9 genotype. Because of small 
numbers, the homozygotes were pooled with heterozygotes for the R46L mutation. A 
trend analysis was performed using GraphPad InStat and Prism4 software (GraphPad 
Software, La Jolla, CA). Mean, standard error of the mean and a t-test (two sided) was 
used to compare lipid and metabolic parameters between different groups with various 
levels of statistical significance: P < 0.01, P < 0.001, and P < 0.0001. Fisher's exact or X2 
tests were used to analyze contingency categorical variables, as appropriate. The 
additional stratification with apoE genotype was performed on groups with ≥12 unrelated 
individuals and groups <12 individuals were excluded from the analysis.  
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3.4 Results: 
No gain-of-function mutations were identified at the 95th percentile end of the PCSK9 
distribution, and 2 LOF mutations were detected at the 5th percentile end; that is the 
insLEU polymorphisms (L9/L10, L9/L11, L10/L10) and the missense mutation R46L 
(rs11591147). A full screen of these variants was therefore carried out on the available 
DNA sample to determine the frequency distribution of insLEU and R46L in each 
administrative region of the province of Québec (Supplemental Table S1 and 
Supplemental Fig. S1). PCSK9 insLEU was the most frequent PCSK9 LOF mutation in 
French Canadians individuals at a carrier rate of 24% followed by the R46L mutation 
with a carrier rate of 4.8%. Polymorphism with insLEU was found in 458 out of 1745 
individuals (411 heterozygotes and 47 homozygote), with an allele frequency of 
505/1745 chromosomes or 0.29, higher than the frequency previously reported in other 
population-based studies reported between 0.12 – 0.18 (13- 15, 18). The R46L 
polymorphism was found in 73 out of 1745 individuals (72 heterozygotes and one 
homozygote), therefore the allele frequency was 74/1745 chromosomes or 0.04, higher 
than any previously frequency reported in white subjects (10). In addition we observed 
geographical differences in the frequency of these PCSK9 mutations in the province of 
Québec. The insLEU was somewhat homogeneously distributed with a frequency rate 
greater than 19% in all the regions, and the R46L was more frequent in certain regions 
such as the Saguenay-Lac-Saint-Jean (12.09%), Québec city (9.09%) and Outaouais 
(7.94%) (Supplementary Fig. S1). 
 
Characteristics of the 1745 screened participating in this study, stratified by PCSK9 
genotype is shown in Supplementary Table S2. PCSK9 genotyping led to the following 
distribution: wild type (n=1202), insLEU heterozygote (n= 411), insLEU homozygote 
(n=47), R46L heterozygote (n=72), R46L homozygote (n=1) and finally a compound 
homozygote for both insLEU and R46L (n=12). There were no significant differences in 
terms of age, sex, weight and body mass index in all groups.  
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We observed that PCSK9 concentrations were significantly lower by -3.7%, -8.6%, -
19.3% and -34.7% in insLEU heterozygotes, insLEU homozygotes, R46L heterozygotes 
and compound heterozygotes respectively, with P-value of 0.024, 0.043, <0.0001 and 
<0.0001; (Fig 1, A and B and Table 1). Interestingly the phenotype resulting from 
compound heterozygous exhibited a synergistic effect when both mutations were 
present.  An expected percentage drop in LDL-C was parallel with the PCSK9 drop, 
reaching significance in all genotypes group except insLEU homozygotes (Fig 1, D and 
C; Table 1). However, effects on high-density lipoprotein cholesterol, apoA-I, TGs and 
free fatty acids (FFAs) were not statistically significant and were inconsistent for fasting 
glucose and insulin, HOMA-IR, adiponectin, leptin and high-sensitivity C-reactive protein 
across the different PCSK9 mutations, except in the group of R46L heterozygotes in 
whom we observe near significant increment in fasting insulin (p=0.06) and HOMA-IR 
(p=0.05) in compared to wild type. Therefore, we tested the hypothesis that stratifying 
each PCSK9 mutation according to apoE genotype would reveal some metabolic 
relationships. As expected, subgroups of individuals with the R46L allele and apoE3/E2, 
E3/E3 or E3/E4 alleles exhibited a statistically significant (p<0.05) additional drop in 
LDL-C (18%, 21% and 22%, respectively) in comparison with wild type, thereby 
revealing an additive effect between the PCSK9 R46L mutation and apoE genotype on 
lipid variables (Fig. 2A).  Also, the subgroup of individuals with a PCSK9 insLEU 
mutation and apoE3/E3 genotype (n=269) had a significant lower TG concentration 
0.79±0.02; (p=0.01) compared with both the apoE3/E2 and apoE3/E4 carriers (Fig. 2B). 
More interestingly, the subgroup of individuals with the R46L allele and apoE3/E2 
genotype (n=12) now presented a significant increase in fasting insulin 87.9±30; 
(p=0.00003), HOMA-IR 3±1.1; (p=0. 00002) and leptin 15.8±4.6; (p=0. 006) compared 
with the E3/E3 group (Fig 2, C-E).  
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3.5 Discussions: 
The present Québec French Canadian population mainly originates from 8,000 
founder individuals that settled this region approximately 4 centuries ago and remain in 
genetic isolation for decades later (30). Genetic pools provide power to study genes 
contributing to complex conditions such as dyslipidemia and metabolic heart disease. 
Consequently a large number of individuals in the province carry LOF mutations in the 
LDLR gene leading to elevated LDL-C concentrations and thus prone to premature 
coronary heart disease. The founder effect for familial hypercholesterolemia (FH) in 
French Canadians has been extensively studied over many years given its high 
frequency that varies between 1:270 to 1:75 compared to 1:500 globally (31, 32).  Thus 
we propose that a gene selection process has led to increase frequency of the PCSK9 
LOF mutations in this population as a survival process to lessen cardiovascular 
mortality. This is in alignment with other observations by Mayne et al (33) that indicated 
a prevalence of LOF mutations in the same population. Furthermore, a recent study by 
Huijgen et al, (34) showing that FH patients with the same LDLR activity may have very 
different lipid profiles depending on their PCSK9 concentrations, which is genetically 
determined, ranging from the upper range of normal cholesterol to 8 times higher than 
the general population. We have also established that carrier rates of insLEU are 
roughly homogeneous across the province (24 %), and carrier rates of R46L increase in 
certain regions such as the Saguenay-Lac-Saint-Jean and Québec City regions reaching 
frequencies between 1:12 to 1:8. It is interesting to note that the region where the R46L 
frequency is the highest (Saguenay-Lac-Saint-Jean) corresponds to the region with the 
highest frequency of FH in the Province of Québec (32). This is highly suggestive of a 
founder effect for R46L mutation and warrants further co-segregation analysis in family 
members, however because of the nature of the study the patient identity was 
unattainable and thus family studies were not possible.  
 
Perceptive modulation of the LDLR by PCSK9 was a breakthrough in the 
understanding of the metabolism of this receptor. Natural LOF mutations in PCSK9 were 
first identified in 2006 (10, 11, 13, 35), resulting in apparently healthy lifelong lower 
cholesterol concentrations (3, 36), thus opening the door to a new class of lipid lowering 
agents. Furthermore, a recent report advocates that the carrier status of PCSK9 insLEU 
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(L10) is at an advantage of increase response to statin in FH patients (37). We have 
clearly shown that PCSK9 insLEU negatively affected LDL-C by -3.4%, -7.5% and -
28.9% in insLEU heterozygous (L9/L10), insLEU homozygous (L10/L10) and compound 
heterozygous (L9/L10 and R46L) subjects, with a P value of 0.027, 0.068 and 0.011, 
respectively (Fig.1, C and D; Table 1). This lowering effect does not stand true with the 
insertion of 2 leucine (L9/L11) (Data not shown, n=18), which behave more like wild 
type PCSK9 and is in sharp contrast in our study with previous observations by Abifadel 
et al (17). In this study, a limited number of subjects (n=3) with the insLEU (L11) had 
familial combined hyperlipidemia that was attributed to this polymorphism without 
consideration of the apoE genotype. Because the insLEU appears as a prevalent variant 
in the French Canadian population, we propose that the previously observed association 
was a random relationship.  
 
ApoE phenotype is known to influence lipid and lipoprotein profile in the general 
population. There is a well-known relation between apoE genotypes and LDL-C; apoE4 
is associated with higher cholesterol concentrations, and apoE2 is associated with lower 
cholesterol concentrations compared to apoE3 carriers (38- 41). Such a relationship is 
observed in our cohort study, which also reveals an additive effect of the PCSK9 
mutation, most noticeably in R46L group, but also with insLEU group on LDL-C levels 
(Fig. 2A). It is important to note that subjects with both the R46L and apoE3/E2 
genotype represented 0.73 % of our study population and was associated with LDL-C 
that was lower (-17.68 %) than the population average. This new association between 
the R46L and apoE3/E2 genotype might therefore be a relatively frequent cause of 
hypobetalipoproteinemia in the French Canadian population. It is noteworthy that a novel 
APOE p.Leu167del mutation can lead to FH (42) hence screening patients for single 
point mutation in APOE gene is informative. 
 
Regarding the effects of apoE genotype on other lipid parameters, there are some 
inconsistencies in the literature. A meta-analysis (43) demonstrated that TG 
concentrations were significantly higher in apoE2/E2, E3/E2, E4/E3 and E4/E2 than in 
E3/E3 subsets. Further, this trend was found in samples of normolipidemic adults and 
children, in diabetic and obese individuals, and in hyperlipidemic subjects. These 
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observations indicate ubiquitous and consistent relationship. In our study the TGs 
concentration was also higher in apoE3/E2 and apoE3/E4 subset regardless of PCSK9 
mutation, and decreased significantly in apoE3/E3 with R46L mutation subgroup (Fig. 
2B); with invariable plasma (FFA) concentrations (Data not shown). We also report for 
the first time an intriguing phenotype associated with the combination of apoE3/E2 
genotype and R46L mutation characterized by higher HOMA-IR (2.17 fold, p<0.0001), 
insulin (2.05 fold p<0.0001) and leptin (1.99 fold, p=0.006), an alarming finding that 
warrants further investigation. To explain these observations additional in vitro studies 
are necessary, however we shown that fasting glucose, insulin and HOMA-IR were 
trending upward in total R46L and compound heterozygote groups (Table 1). Recent 
data confirmed that even modest elevations in FFA and glucose could cause 
glucolipotoxicity in vivo, which may represent an important mechanism leading to failure 
of β-cell mass expansion in pre-diabetes (44). The authors of the study speculated that 
the anti-proliferative effect of FFAs might represent the connection between increased 
expression of inhibitor of INK4 (cyclin dependent kinase 4) family cell cycle inhibitors p16 
and p18 and genetic risk of diabetes. It will be interesting to investigate if this anti-
proliferative effect is observed in patients carrying the R46L mutation and apoE3/E2 
genotype.  
 
In summary, we have identified 2 frequent LOF mutations in the French Canadian 
population and shown their specific geographic frequency distribution. We have also 
shown that the insLEU and R46L mutations in French Canadians are associated with a 
lowering effect on total cholesterol, LDL-C and apoB. Interestingly, TG concentration 
was negatively associated in subjects with simultaneous apoE3/E3 genotype and 
insLEU or R46L mutation, representing a favorable lipid phenotype. The discovery that 
subjects with apoE3/E2 genotype and R46L are associated with higher insulin, HOMA-
IR and Leptin, is intriguing and warrants further investigation. Therefore it would be 
important to investigate the potential deleterious effects of the R46L mutation and 
apoE3/E2 genotype on insulin resistance in other populations. Attention should be taken 
when confirming the findings of this study in older cohorts to adjust for waist and hip 
circumferences between groups because they correlate better with central obesity. With 
further validation, the inhibition of PCSK9 might encounter some health hazard in a 
subset of patients with cardiometabolic risk tendency.  ‘ 
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3.8 Legends, figures and tables: 
 
 
Figure 1. 
 
 
Figure 1. (A) Proprotein convertase subtilisin/kexin type-9 (PCSK9) concentration distribution for 
PCSK9 wild type (WT), insertion of leucine (insLEU), and R46L. (B) Average PCSK9 
concentration of the WT, insLEU, and R46L carriers. (C) Low-density lipoprotein cholesterol 
(LDL-C) concentration distribution in PCSK9 WT allele, insLEU, and R46L. (D) Average LDL-C 
concentration of the WT, insLEU, and R46L carriers. * P < 0.01, ** P < 0.001, and *** P < 0.0001. 
hetero, heterozygotes; homo, homozygotes; NS, not significant. 
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Figure 2. 
 
 
 
Figure 2. Subgroup analysis of proprotein convertase subtilisin/kexin type-9 (PCSK9) mutations 
depending on apolipoprotein (apo) E genotype. (A) Additive effect of R46L mutation and apoE 
genotype on low-density lipoprotein cholesterol (LDL-C). (B) Effect of the insertion of leucine 
(insLEU) mutation and apoE3/E3 genotype on triglycerides (TG). Carrying the R46L PCSK9 
mutation and the apoE3/E2 genotype (n ¼ 12) encompass a significantly increased (C) 
homeostasis model assessment of insulin resistance (HOMA-IR; 3±1.1; P =0.00002); (D) fasting 
insulin (87.9±30; P =0.00003), and (E) leptin (15.8±4.6; P = 0.006). * P < 0.01, ** P < 0.001, and 
*** P < 0.0001. 
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Table 1. 
 
 
Table 1. Lipid and metabolic effect of different PCSK9 mutations on individuals in compared to 
wild type (Hetero: heterozygote, Homo: homozygote, Comp: compound)  
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4. Foreword:  
While PCSK9 and LDLR are under the regulation of SREBP, statin therapy is 
known to increase concentrations of LDLR and PCSK9. PCSK9 induction by statin will 
lead to more LDLR down regulation at the cell surface and less LDL cholesterol (LDL-C) 
cleared from blood. The magnitude of these relationships is unknown.  
This study was undertaken to examine the relationship between PCSK9 and 
LDL-C reduction. The selected population was normolipidemic elderly individuals with no 
fluctuation in sex hormones. This is to eliminate all possible confounding factors from the 
study and to get a homogeneous result. PCSK9 was never evaluated in the same 
individual after one year or in the same individual before and after taking statin 
(rosuvastatin) in a relatively large sample size. 
Our data indicate that among those taking rosuvastatin in the JUPITER trial, 
greater reductions in LDL-C were associated with greater increases in PCSK9 on both 
absolute and relative scales. However the LDL-C response to rosuvastatin could not be 
inferred by PCSK9 levels. While carriers of the p.R46L mutation (rs111591147) were 
found to have lower PCSK9 and LDL-C levels at study entry, the gene status did not 
alter the magnitude of LDL-C associated with rosuvastatin use.  Therefore, future 
PCSK9 inhibitors should lower PCSK9 level beyond that seen in this population to see a 
significant drop in LDL-C. 
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4.1 Abstract: 
BACKROUND: Although statin therapy is known to increase concentrations of (PCSK9), 
whether this effect is related to the magnitude of LDL reduction is uncertain. This study 
was undertaken to understand the extent of this effect and examine the relationship 
between PCSK9 and LDL-C reduction.  
METHODS: We measured plasma PCSK9 concentrations by ELISA at baseline and at 
one year in 500 men and 500 women participating in the Justification for Use of Statins 
in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER) trial that 
randomly allocated participant to rosuvastatin 20 mg daily or placebo was also evaluated 
rs11591147, a single nucleotide polymorphism known to have an impact on plasma 
PCSK9 concentrations.  
RESULTS: At baseline, median (interquartile range) PCSK9 concentrations were higher 
in women 73(62-90) ng/mL than in men 69(57-81) ng/mL (P<0.005). During one year, 
there was no change in PCSK9 concentrations in the placebo arm, suggesting stability in 
time. In contrast, the rosuvastatin increased PCSK9 by 35% in women 101(82-117) 
ng/mL and 28% in men 89(71-109) ng/mL (P<0.0001). Among those allocated to 
rosuvastatin, greater reductions in LDL-C were associated with greater increases in 
PCSK9 on both absolute and relative scales (r=-0.15, P<0.0005). Furthermore PCSK9 
(rs11591147) did not alter the magnitude of LDL-C reduction associated with 
rosuvastatin use.  
CONCLUSIONS: In this randomized trial, rosuvastatin increased plasma concentration 
of PCSK9 in proportion to the magnitude of LDL-C reduction; the LDL-C response to 
statin could not be inferred by PCSK9 concentrations. 
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  4.2 Introduction: 
 The major mechanism of action of statins is mediated through up-regulation of the 
LDL receptor (LDLR) found predominantly on hepatocytes (1). Recently, a critical role for 
the PCSK9 protein was found in the cellular processing of the LDLR (2,3) and it has 
subsequently been reported that mutations in the proprotein convertase subtilisin/kexin 
type 9  (PCSK9) gene associate with wide variation in LDL cholesterol (LDL-C) 
concentrations. Specifically, gain-of-function mutations in PCSK9 are associated with 
marked increases in LDL-C similar to that seen in familial hypercholesterolemia due to 
defects in the LDLR protein (4), whereas loss of function mutations are associated with 
lower PCSK9 concentrations, low life-long LDL-C concentrations, and reduced 
cardiovascular risk (5,6). Given these inter-relationships, there has been considerable 
interest in understanding the effect of statins on PCSK9 concentrations, particularly 
since agents designed to inhibit PCSK9 are likely to be used as adjuncts to statin 
therapy. To date, it has been established that several statins increase plasma PCSK9 
concentrations, but whether this effect is related to the magnitude of LDL-C reduction 
associated with statin treatment or is modified by genetic status at rs11591147 remains 
uncertain.  
We addressed these issues among 500 men and 500 women participating in the 
Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating 
Rosuvastatin (JUPITER) trial (7) these individuals underwent genotyping at rs11591147 
and had baseline and 1-year blood samples evaluated for both PCSK9 and LDL-C 
concentrations.  
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4.3 Methods: 
  The patient population was derived from participants in the JUPITER trial, a 
primary prevention trial comparing rosuvastatin 20 mg daily to placebo in 17,802 
apparently healthy men and women with LDL-C < 3.4 mmol/L (130 mg/dL) and high-
sensitivity C-reactive protein (hsCRP) > 2.0 mg/L. For the purposes of the current 
analysis, 500 men and 500 women allocated to either rosuvastatin or placebo were 
selected using a stratified randomization method from compliant trial participants whom 
provided consent for genetic and plasma biomarker studies as approved by the Review 
Ethics Board. 
Concentrations of LDL-C were measured centrally as part of the overall JUPITER 
trial protocol. Genotyping was performed using the Omni 1M Quad platform (Illumina) as 
part of an ongoing genome wide association study being conducted within the JUPITER 
trial. Using these data, genetic information on rs11591147, a previously described 
polymorphism at the PCSK9 gene locus that leads to an arginine for leucine substitution 
at position 46 (R46L), was available in 955 out of the 1000 participants. We evaluated 
plasma PCSK9 concentrations were evaluated using a sandwich ELISA as previously 
described (8).  This assay measures total PCSK9, i.e., both mature and furin-cleaved 
forms (9, 10).  
On the bases of our previous reports using PCSK9 ELISA in a healthy 
population, we assumed a mean value of 89 μg/L at baseline and a standard deviation of 
32(8). With a likely effect of 12.5%, an α value of 0.01 and a 90% power, we expected 
that a minimum of 200 participants per group would be required. The estimated cohort 
size effect is considered a minimum and is likely to be larger.  Because each subject 
serves as his or her own control, we anticipated achieving sufficient statistical 
robustness for firm conclusions. Therefore we analyzed 250 men and 250 women 
randomized to placebo and rosuvastatin and determined PCSK9 concentrations at 
baseline and at 1 year. In a sex-specific analysis, we compared baseline clinical 
characteristics between the placebo and rosuvastatin groups using t-tests for continuous 
variables and the X2 statistic for categorical variables. The difference in the change in 
PCSK9 and LDL-C over time in the all groups was tested using Spearman rank 
correlation coefficients. We uesed  ANOVA and Tukey-Kramer multiple comparison to 
determine differences in PCSK9 by quintile of LDL-C, adjusted for age, sex, body mass 
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index, blood pressure, serum glucose, serum concentrations of lipids and lipoprotein 
lipids (total cholesterol, triglycerides, LDL-C, HDL-C), apolipoproteins AI and B and 
hsCRP. Correlations between PCSK9 and these variables were analyzed by Spearman 
rank correlation coefficients.  
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4.4 Results: 
  Baseline characteristics of the 500 men and 500 women participating in this 
study, stratified by rosuvastatin or placebo use, are shown in Table 1. As would be 
anticipated in a randomized trial, there were no significant differences at study entry 
within each sex-specific group according to treatment allocation.   
  Baseline and 1-year concentrations of measured lipid parameters, hsCRP, and 
PCSK9 are shown in Table 2 and Fig. 1. Median (interquartile range) baseline 
concentrations of PCSK9 were higher in women [73(62-90) ng/mL (n=499)] than in men 
[69(57-81) ng/mL (n=500)] (P<0.005).  Participants randomized to placebo had no 
significant change in any measured variable, including PCSK9, suggesting considerable 
stability of PCSK9 concentrations over time. In contrast, participants randomized to 
rosuvastatin had significant reductions in total cholesterol, LDL-C, triglycerides, and 
hsCRP as well a modest increase in HDL-C. These effects were accompanied by a 35% 
increase in median concentrations of PCSK9 in women from 75(66-85) ng/mL to 101(82-
117) ng/mL, P<0.0001 and a 28% increase in men from 69(57-81) ng/mL to 89(71-109) 
ng/mL, P<0.0001 (Fig. 1). At baseline, there was a significant correlation (n=999, r=0.15, 
P<0.0001) between concentrations of PCSK9 and LDL-C; however this relationship was 
no longer observed on rosuvastatin treatment (n=498, r=-0.01, P=0.84) (see 
Supplemental. Fig. 1, A and B).  
  Furthermore, the individual LDL-C percent change from baseline in response to 
rosuvastatin treatment was plotted in a declining manner as shown in Fig. 2A and 
corresponding individual percent change from baseline in PCSK9 is shown in Fig. 2B. 
Although, individual variation among those allocated to rosuvastatin was wide, a 
significant relationship was observed between the magnitude of LDL-C reduction and the 
increase in PCSK9 concentrations; this was seen in both an analysis of quintiles of LDL-
C reduction (Fig. 2C) and when the LDL-C change was treated as a continuous variable 
(Fig. 2D). A similar response was observed for apo B and non-HDL-C changes and 
PCSK9 changes (data not shown).  
 Polymorphism at rs11591147 PCSK9 (R46L) was found in 46 of 955 individuals (24 
male heterozygotes, 21 female heterozygotes and 1 male homozygote). The allele 
frequency was thus 47 of 1910 chromosomes or 0.0246, close to that previously 
reported in population-based studies (6). The sole homozygous subject was excluded 
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from further analysis. Serum PCSK9 at baseline was lower in carriers of the R46L SNP 
by -19% (P<0.005) (see online Supplemental. Fig.2A). And as seen in previous 
studies (6) the baseline LDL-C concentrations in R46L carriers were lower by -9% in 
men (n=24, mean 94 mg/dL vs n=451, mean 103 mg/dL) and by -7% in women (n=21, 
mean 100 mg/dL vs n=458, mean 107 mg/dL). In the rosuvastatin arm with available 
genetic status (n=478), no significant differences in LDL-C reduction were observed as 
influenced by the genetic status and thus no increased response to statin therapy in the 
R46L carriers. (see online Supplemental. Figure 2B).  
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4.5 Discussion: 
  We examined 1,000 patients in the JUPITER trial. Half (n=500) were randomized 
to placebo and half, to rosuvastatin 20 mg/day. We established that plasma PCSK9 
concentrations are stable as a biomarker over time among those allocated to placebo, 
but increase by approximately 30% among those allocated to rosuvastatin 20 mg. 
Although, individual responses were variable, we observed a significant relationship 
between the magnitude of LDL-C reduction and the increase in PCSK9 concentrations 
on both an absolute and relative scale. Specifically, across the full study cohort, greater 
LDL-C reductions were associated with greater increases in plasma PCSK9 
concentrations, an effect present in both sexes despite higher baseline PCSK9 
concentrations in women compared to men. 
PCSK9 gain-of-function mutations were identified as 1 of 4 molecular causes of 
familial hypercholesterolemia (4). PCSK9 is the ninth member of the mammalian 
proprotein convertase family of serine endoproteases (11). PCSK9 is recognized as a 
key regulator of serum LDL-C concentrations. The gene for PCSK9 is located on 
chromosome 1p34 and encodes a 692-amino acid protein that is mostly expressed in 
the liver and intestine (11). The protein comprises a 30 amino acid signal, peptide (SP), 
a pro-domain (amino acids 31-152), a catalytic domain (amino acids 153-454) and a 
cysteine- and histidine-rich C-terminal domain (amino acids 455-692) (12,13). The only 
known substrate for PCSK9 is itself. PCSK9 catalytic domain contains the main binding 
structure for the epidermal growth factor-like repeat A (EGF-A) domain on the LDLR 
(14), whereas the C-terminal domain binds cell surface proteins, including annexin A2 
(15). The major function of PCSK9 is to mediate the degradation of the LDLR protein 
and evidence exists for both an intracellular and extracellular site of interaction between 
the LDLR EGF motif and PCSK9 (16-19). However the predominant source of circulating 
PCSK9 in blood originates from the extracellular pathway in the liver and this correlates 
with the concentration of plasma cholesterol (18). 
PCSK9 is regulated at the transcriptional level by sterol regulatory element 
binding protein (SREBP)-2 (20, 21), possibly by SREBP-1c (22) and especially by 
hepatocyte nuclear factor-1 alpha (HNF-1 alpha) (23). PCSK9 expression is 
downregulated by cholesterol via SREBP-2 (24) and upregulated by statins via SREBP-
2 (25). The Liver specific Receptor, LXR and insulin also regulate PCSK9 (26, 27). 
126 
Therefore, mRNA levels of LDLR and PCSK9 are regulated by SREBP-2 and statins, 
inducing an upregulation of both LDLR and PCSK9 (28). The results obtained in the 
present study are consistent with this observation. The concept that the statin-mediated 
increase in PCSK9 may limit the efficacy of statins in human (13, 29), however, is not 
supported by the present study.  
  The effect of statins on PCSK9 has been inferred or documented in previous 
studies (11, 30-32). Here we show that rosuvastatin at a daily dose of 20 mg reduces 
LDL-C by approximately 50% on average and increases PCSK9 by 28% in men and 
34% in women. Baseline PCSK9 concentrations correlate with LDL-C (n=999; r=0.15 
P<0.0001). Although a statistically significant correlation between serum concentrations 
of PCSK9 and LDL-C is present at baseline (r=0.15), only ~2.25% of the variance in 
LDL-C concentrations is explained by PCSK9 concentrations. On rosuvastatin, this 
correlation is no longer observed (n=498; r=-0.01; p=0.84) (see online Supplemental 
Fig. 1, A and B). Similar findings with the drug atorvastatin have been reported (31). 
The observation that the increase in PCSK9 concentrations with rosuvastatin is not 
associated with a blunted LDL-C response is counter-intuitive, based on the postulated 
mechanisms of action of PCSK9. In fact, the data presented here show a significant 
negative correlation between the percentage change in PCSK9 concentration on 
rosuvastatin and the percentage change of LDL-C (n=498; r=-0.15 P<0.0005) (Fig. 2D). 
This observation warrants further mechanistic explanation. Based on these data (Fig. 2, 
A and B), However, plasma PCSK9 concentrations cannot be used to predict individual 
response to statin therapy. It remains to be determined whether the measurement of 
PCSK9 concentration in blood aids in diagnosing patients who are refractory to statins. 
The development of PCSK9 inhibitors may require such measurement if it can be 
demonstrated that measuring PCSK9 concentrations influences the choice and success 
of treatment.   
  The R46L allele frequency in our study was 2.5%, similar to that of the general 
population, leading to approximately 8% lower LDL-C than non-carriers (6, 33). Given 
the ethnic heterogeneity of our population, we cannot, however, perform meaningful 
statistical comparisons without a much larger sample size. Nonetheless, the presence or 
absence of this single nucleotide polymorphism was not associated with a difference in 
the response to rosuvastatin (see online Supplemental. Fig. 2B); therefore, knowing the 
R46L variant would not likely guide therapy in our population. 
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  We confirm the observation that statins increase PCSK9 (23, 25, 29). While 
individual LDL-C response to rosuvastatin can not be predicted by PCSK9 
concentrations (Fig. 2, A and B); there is a significant association between the 
magnitude of change in LDL-C and changes in PCSK9 concentrations (see online 
Supplemental Fig. 1C). A possible explanation is that the transcriptional regulatory 
protein SREBP-2 mediates the coordinate expression of the LDLR and PCSK9 in 
response to cellular cholesterol deprivation (24).  
As a biomarker and a therapeutic target, PCSK9 is appealing (12), but because 
of stoichiometric interactions between the EGF-A region of the LDLR and PCSK9, it has, 
to date, not been amenable to be targeted by small molecules. Several approaches have 
thus been examined to decrease PCSK9 concentrations and are at an advanced stage.  
One such approach is the use of antisense mRNA that modulates the expression of 
PCSK9 mRNA leading to reduced PCSK9 production (34-36). Another approach is the 
inhibition of PCSK9 binding to the LDLR by using antibodies against PCSK9 leading to 
inhibition of LDLR degradation mediated by PCSK9 (19, 37). These approaches require 
the manufacture of biological substrates (antisense oligonucleotides or antibodies) and 
are likely to entail production costs that will restrict their application to patients in whom 
statins at maximally tolerated doses still do not allow target levels to be reached as 
proposed in national guidelines (38,39). Given this interest, several monoclonal 
antibodies to PCSK9 are already in phase two clinical trials (see www.clinicaltrials.gov) 
giving clinicians a potentially effective add-on treatment alternative. A strategy based on 
the measurement of LDL-C response and PCSK9 concentrations may help identify those 
statin-resistant subjects who may benefit from PCSK9 modulation for therapeutic 
benefits and those smaller proportions of subjects unable to tolerate statins (40). 
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5. Foreword:  
The LDLR deficient mouse as a model for aortic calcification was proposed by 
our group, and thus a novel method to objectively quantify calcium by micro-computed 
tomography (micro CT) was established. The mechanism of aortic wall calcification is 
poorly understood unlike the mechanism in aortic valve calcification, given the unique 
population of cells in each tissue. Once thought to be a passive process following 
atherosclerosis, now it is considered a tightly regulated process mediated by osteoblast 
like cells differentiation under the dysregulated interplay of shear stress, metabolites and 
inflammatory cytokines. 
By studying the progression of atherosclerotic calcification in aorta and modifying 
the disease progression there is hope for FH patients to not only live beyond CVD but to 
surpass the premature aortic calcification process that contributes to lifelong morbidity.  
Thus, using relevant animal models, an atherogenic diet, methods designed to 
objectively promote calcification ex vivo and pharmacologically intervention, much can 
be applied to humans in a translational manner.  The timing of this project cannot be 
overemphasized since large clinical trials are being conducted to prevent secondary 
CVD from recurring in the context of secondary prevention. Conducting animal studies 
and applying new biology will steer the investigators on how to better utilize this huge 
effort effectively to look for relevant biomarkers of vascular health.    
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5.1 Abstract: 
  Once thought to be a passive process of calcium accrual in arterial vascular 
beds, vascular calcification is considered to be a tightly regulated process mediated by 
osteoblast-like cells under the dysregulated interplay of shear stress, metabolites, 
cytokines and transcription factors. Unfortunately, without effective medical interventions 
to prevent or regress vascular calcification, this process directly contributes to 
cardiovascular morbidity and mortality. We have previously shown that patients with 
familial hypercholesterolemia (FH) have severe, premature aortic calcifications and 
calcific aortic stenosis. We showed an age-related gene-dosage effect of deletion of the 
low-density lipoprotein receptor (LDL-R) gene on aortic calcifications in human subjects 
with FH. The LDL-R deficient mouse and transgenic mice overxpressing the LDL-R 
degrading protein PCSK9 also exhibit aortic calcifications, not fully explained by 
increased LDL cholesterol levels. Taken together, these data suggests a novel role for 
the LDL-R in the inhibition of vascular calcification. Understanding the molecular role of 
the LDL-R and its signaling partners in vascular calcification will be instrumental in 
identifying novel therapies for a common age-related process associated with a large 
burden of disease.   
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5.2 Abbreviations: 
 
ANK: ankyrin family 
AoCS: aortic calcium scores 
BMP: bone morphogenetic proteins 
Cbfa1: core binding factor alpha1 
DKK1: Dikkopf protein 
ESRD: end-stage renal disease  
FH: familial hypercholesterolemia  
GSK3B: glycogen synthase kinase 3 B 
HSP: heat shock protein  
LDL-R: low-density lipoprotein receptor protein 
Ldlr-/-: low-density lipoprotein receptor gene knockout in mice  
LRP: low-density lipoprotein receptor-related protein 
MGP: matrix gla protein 
NPP I: ectonucleotide pyrophosphatase/phosphodiesterase I 
OPG: osteoprotegerin  
PEBP2: polyoma enhancer binding protein 2  
PPARγ: peroxisome proliferator-activated receptor gamma  
Pi: inorganic phosphate 
PPi: inorganic pyrophosphate 
RANKL: receptor activator of nuclear factor kappa-B ligand 
Runx2: runt-related transcription factor 2  
TGF: Transforming growth factor  
TNFα: Tumor necrosis factor-alpha  
VSMC: vascular smooth muscle cells 
Wnt: a hybrid of Wg (wingless) and Int1 (integration1) genes in Drosophila  
Hox8: Homeobox protein 8, now known as Msx2 
Msx2: MSH homeobox 2, formerly Hox-8 
Sox9: SRY (sex determining region Y) box 9  
Osterix: Zinc Finger-Containing Transcription Factor  
CCAAT: enhancer-binding proteins 
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   It is estimated that one third of individuals over age 60 years have a progressive 
increase in calcium deposits in major arteries (1).  As a consequence of calcium build-up 
in the vasculature, aortic and arterial elasticity is reduced and cardiovascular 
hemodynamics becomes compromised. The clinical impact of vascular calcification is 
widespread and contributes to arterial hypertension, aortic valve stenosis, limb ischemia, 
myocardial infarction and congestive heart failure (2). Calcific aortic stenosis is the 
leading cause of aortic valve replacement in Europe and North America and the third 
leading cause of cardiovascular disease (3-6). In the western world, 3% of adults over 
75 years of age are affected by calcific aortic stenosis (7). Histologically, vascular 
calcification can occur in distinct layers of the blood vessel. Intimal calcification is 
associated with atherosclerosis whereas medial calcification (Monckeberg’s sclerosis) is 
associated with age, diabetes and end-stage renal disease (ESRD). In ESRD, calcium 
and phosphate disorders are typically present (8). Both intimal and medial calcifications 
are markers of increased cardiovascular morbidity and mortality. Calcification of 
coronary arteries is an independent biomarker of atherosclerosis and myocardial 
infarction (9). Diffuse medial calcification can lead to decreased arterial compliance and 
increase cardiac after load contributing to the development of left ventricular hypertrophy 
and decreased cardiac perfusion (8). Arterial calcification in ESRD is considered a 
predictor of cardiovascular mortality (10).  In dialysis patients, calciphylaxis represents a 
third form of vascular calcification; a systemic vascular calcification associated with 
calcific skin necrosis and global mortality (11).   
 
  The potential role of the low-density lipoprotein receptor (LDL-R) in the 
pathogenesis of intimal calcification was highlighted in a careful study of subjects with 
homozygous familial hypercholesterolemia due to mutations at the LDL-R gene locus 
(12, 13). Atherosclerotic intimal calcification appears to result from an interaction 
between inflammatory factors produced within an atherosclerotic plaque and a 
subpopulation of vascular cells that undergo osteogenic differentiation. Many of the 
conventional risk factors for coronary artery disease, namely hypercholesterolemia, 
hypertension, diabetes and tobacco use, have been linked to intimal calcification. It is 
thought that these pro-inflammatory agents induce oxidative stress in the milieu of the 
vascular endothelium that leads to atherosclerosis and calcification. On the basis of 
recent observations, this view is challenged.  
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5.3 Origin of cells involved in vascular calcification 
The key regulatory mechanisms involved in vascular calcification have been 
described and many excellent reviews have already been written on this topic (5,14,15). 
Fig.1 illustrates the proposed signaling pathways involved in vascular calcification.   In 
the current model, vascular calcification is a process of active bone formation by 
osteoblast-like cells. Two types of lipid vesicles have been identified that nucleate 
vascular calcification; the apoptotic bodies of dead or dying cells and mineralizing matrix 
vesicles. The latter process appears to predominate in aortic calcification.  
  The origin of the cells that calcify the underlying matrix is a matter of continuous 
debate. Transdifferentiation of vascular smooth muscle cells (VSMC) in the vascular wall 
by reprogramming mature VSMCs to osteochondrocytic cells or calcifying vascular cells 
has been postulated as a process occurring in response to cytokines and oxidative 
stress stimuli (16).  A second hypothesis, based on observation, suggests that nascent 
pericytes are involved in the process of calcification. Like calcifying vascular cells, 
pericytes form calcified nodules in culture (16). Pericytes play a role in skull wound 
repair, a process dependent on bone morphogenetic proteins (BMPs) (17).  A third 
possibility, based on the finding of osteogenic cells in peripheral blood (18), is that the 
osteoblast-like cells responsible for vascular calcification arise from bone marrow-
derived mesenchymal stem cell precursors. These stem cells have the ability to 
differentiate into osteoblasts, chondrocytes, myocytes and even adipocytes (19) (Fig. 2). 
5.4 Regulation of vascular calcification 
The signaling molecules that mediate vascular bone formation have been 
gradually elucidated. These include a variety of transcription factors, inflammatory stimuli 
and metabolites. The role of bone morphogenetic protein-2 (BMP2) in vascular 
calcification was elucidated at the time of its identification in human atherosclerotic 
plaques (20).  To date, over twenty bone morphogenetic proteins have been discovered 
and belong to the Transforming growth factor-β (TGF β) superfamily of proteins. Since 
then, endothelial cells, foam cells and smooth muscle cells have all been found to 
express BMPs (16, 20). Mechanistically BMP2 acts through the transcription factor runt-
related 2 (Runx2), which induces expression of type I collagen and alkaline phosphatase 
(Fig 1).  
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  The other key genomic target of BMP signaling is the Wnt canonical pathway. 
This pathway involves signaling via the Frizzled (Fz) receptor and LRP 5/6 coreceptors. 
In the presence of Wnts, a ternary complex is formed at the cell surface that prevents 
glycogen synthase kinase 3 (GSK3B) from phosphorylating the transcription factor β-
catenin. As a result, β-catenin can translocate to the nucleus. Once in the nucleus, β-
catenin binds to proteins of the T-cell factor/lymphoid-enhancer factor-1 family and 
modulates the expression of several target genes including cyclin D, Cbfa 1 and Sox9. In 
the absence of Wnt, β-catenin is phosphorylated by GSK3B. Phosphorylated β-catenin 
undergoes ubiquitination and proteasomal degradation (19, 21, 22). Thus, via the 
canonical Wnt pathway, BMP2 promotes osteoblast differentiation and bone formation.   
 
In addition to the canonical pathway, several Wnt proteins activate 
osteoblastogenesis through non-canonical pathways. Of the 19 Wnt family members, 
Wnt10b, Wnt7b and Wnt3a in particular have been shown to be involved in bone 
homeostasis in mice (19). Wnt10b promotes osteoblast differentiation through induction 
of the osteoblastogenic transcription factors Runx2 and Osterix and suppression of the 
adipogenic transcription factors CCAAT/enhancer binding protein alpha and peroxisome 
proliferator-activated receptor gamma (PPAR-γ) (19). Runx2 (also known as Cbfa1 or 
polyoma enhancer binding protein 2 (PEBP2), is thought to initiate osteoblast 
differentiation through activation of Osterix.   
 
A protein upstream to Wnt signaling called Msx2 (Hox8), is a homeodomain 
transcription factor involved in craniofacial bone mineralization and trabecular and 
cortical bone formation. In murine models of vascular calcification, Msx2 expressing cells 
in the adventitia were found to control osteogenic differentiation of neighboring 
progenitors in the media via the vasa vasorum. Further work identified that Msx2 
upregulates aortic expression of Wnt3a and Wnt7a (23). We have recently shown that 
Wnt5a and its co-receptor LRP5 are highly expressed in calcifying vessels in the 
absence of LDL-R in a mouse model of aortic calcification (24). 
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  Two key players in bone biology that have great relevance in vascular 
calcification are the receptor activator of nuclear factor NB ligand (RANKL) and its 
inhibitor osteoprotegerin (OPG) (Fig.1). RANKL, a member of the TNF superfamily, 
signals via its receptor on monocyte/macrophage progenitors to promote the formation 
of bone-resorbing osteoclasts (14). OPG serves as a decoy receptor in osteoblasts and 
antagonizes RANKL. In the setting of vascular inflammation, RANKL is expressed by T 
cells, macrophages and endothelial cells near atherosclerotic lesions, promotes 
mineralization of VSMCs and aortic valve interstitial cells in vitro and upregulates BMP4 
expression via its receptor. The role of RANKL’s in vascular biology was further 
supported by the findings of severe medial and intimal vascular calcification in OPG-
deficient mice (25). Interestingly, many of the same stimuli that induce cardiovascular 
disease in our aging population, namely inflammation (TNFα), reactive oxygen species 
and mechanical damage also upregulate these signaling pathways. Hydrogen peroxide, 
for example, promotes osteochondrocytic differentiation of VSMCs by upregulating 
Runx2 (15).  
Interleukin-1b has been implicated in the stimulation of alkaline phosphatase (26) and 
may be a critical factor in the transdifferentiation of smooth muscle cells into an 
inflammatory phenotype (27, 28). 
 
 
5.5 Inhibition of vascular calcification 
Several circulating proteins have been discovered that normally inhibit vascular 
calcification (Fig. 1). Osteoprotegerin (OPG), for example, competes with RANKL for its 
receptor. Inorganic pyrophosphate directly inhibits hydroxyapatite formation and calcium 
deposition. While it serves a substrate for alkaline phosphatase, its activity is maintained 
by ectonucleotide pyrophosphatase/phosphodiesterase I (NPPI) and the cellular 
pyrophosphate exporter ankyrin (ANK) (13). The actions of BMP are inhibited by several 
proteins; including noggin, chordin and matrix gla protein (MGP). MGP functions as a 
noggin-like protein by inhibiting BMP-BMPR2 interactions as well as by binding and 
inhibiting BMP2 directly. It is the quantitative ratio of BMP2 to MGP that modulates 
BMP2 activity and osteogenic calcification (16). Interestingly, MGP is activated by 
151 
vitamin K-dependent gamma carboxylation. Therefore, non-gamma carboxylated MGP is 
associated with vascular calcification. The importance of MGP in vascular calcification 
has been confirmed in vivo by gene deletion studies in mice. In the absence of MGP, 
mice develop extensive vascular calcifications without atherosclerosis (26). The interplay 
between the BMP and MGP pathways of vascular calcification was elegantly illustrated 
in experiments showing that heat shock protein (HSP) 70, an endogenous MGP binding 
protein and antagonist of MGP function found in atherosclerotic plaques is upregulated 
by IL-6, an inflammatory cytokine important in diabetic vascular disease (14,30). 
 
 Fetuin (also known as alpha Heremans-Schmid glycoprotein) is a protein 
synthesized by the liver. It belongs to the cystatin superfamily of cysteine protease 
inhibitors (5). Its mechanism of action appears to be twofold. First, fetuin directly inhibits 
calcium phosphate crystal formation by binding amorphous calcium phosphate. Second, 
fetuin, along with MGP, have been shown to mediate VSMC-mediated uptake and 
clearance of matrix vesicles (29). As a result, the scaffold for matrix mineralization is 
removed and mineralization cannot take place. The clinical relevance of fetuin’s 
protective role is supported by studies showing an inverse relationship between fetuin 
levels and mortality in end stage renal disease (31). 
 
    5.6 Familial hypercholesterolemia and aortic calcifications 
Patients with familial hypercholesterolemia (FH) exhibit an age- and gene-
dosage dependent increase in aortic calcification (Fig. 3). FH is a relatively common 
monogenic co-dominant Mendelian disorder (the allele frequency is often quoted as 1 in 
500 in the general population) and is caused predominantly by mutations in the LDL-R 
gene (12, 13, 32, 33). In populations with a founder effect, such as the French 
Canadians, the prevalence of LDL-R mutations is much higher and reaches 1 in 80 in 
certain parts of the province of Quebec (34). The LDL-R is a cell surface glycoprotein 
that regulates plasma cholesterol via endocytosis of LDL particles (32, 33). Three other 
genes have been found to cause a phenotype similar to FH include the apolipoprotein 
(apo) B gene (APOB), the proprotein convertase subtilisin/kexin type 9 gene (PCSK9) 
and the adapter protein autosomal recessive hypercholesterolemia gene (ARH, encoded 
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by the Ldlrap1 gene).FH is phenotypically characterized by markedly elevated levels of 
cholesterol, cutaneous xanthomas and xanthelasmas, corneal arcus, premature 
atherosclerosis and cardiovascular disease (12, 34-36). Before the advent of lipid 
lowering therapy, mortality was common in homozygous subjects before the second or 
third decade of life and cardiovascular disease developed in the third to fourth decade of 
life in heterozygotes. The development of selective LDL extracorporeal removal 
techniques (LDL apheresis) and lipid-lowering medication over the past few decades has 
resulted in prolonged survival and improved quality of life (12, 37-39).   
 
  Patients with homozygous FH develop premature aortic calcifications as 
determined by computed tomographic (CT) scan (12). A strong correlation was found 
between calcification scores and age but not with total cholesterol. Aortic calcifications in 
homozygotes and severe heterozygotes often lead to the development of a “porcelain” 
ascending aorta. In those patients with concomitant calcific aortic stenosis, resection of 
the entire ascending aorta under deep hypothermic circulatory arrest is often necessary. 
Thus coronary and aortic valve surgery presents unique challenges (40-42). 
Complications from such extensive surgery include calcific embolization, patient-valve 
mismatch and early coronary graft failure from proximal anastomotic occlusion and 
increased surgical mortality. Aortic calcifications were also observed in patients with 
heterozygous FH, though they tended to be less extensive and showed up 2 decades 
later than their homozygous counterparts (13) (Fig. 3).  It is interesting to note that aortic 
calcifications developed despite appropriate medical therapy, including the combination 
of LDL apheresis, statins and ezetimibe, resulting in marked sustained reductions in LDL 
levels. In contrast, the progression of coronary artery disease was markedly reduced 
and tissue cholesterol deposits, including xanthomas and xanthelasmas, often regressed 
with lipid-lowering therapy in FH patients (12, 13).  
  
These clinical observations suggest that the calcification process may proceed 
independently of cholesterol levels, once sub-endothelial damage has occurred. Based 
on these clinical observations, we proposed a two hit hypothesis of vascular calcification 
in FH: first, intimal injury due to the initiation of an inflammatory reaction and early 
atherosclerosis. Second the deposition of calcium on matrix proteins in the intimal wall of 
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genetically susceptible individuals. This hypothesis establishes a timeline wherein 
athereosclerosis progresses to accelerated vascular calcification. This clinical course is 
also consistent with the results of several trials in humans that have failed to show a 
benefit of statins in the progression of calcific aortic valve stenosis (43). By the time 
vascular calcification is detected, lipid lowering therapy to prevent or reverse calcification 
appears to be of limited clinical benefit. While statins may considerably slow down or 
even regress the process of atherosclerosis, they do not stop the calcification process.  
 
 Similar observations were found in experimental animals. Aged Ldlr-/- mice 
expressing ApoB100 developed extensive oxidative stress with aortic valve calcification 
and functional valvular disease (44).  In addition, older rhesus monkeys and Maccaca 
mulatta fed high cholesterol diets developed atherosclerosis and vascular calcifications. 
When plasma cholesterol decreased on a regression diet, atherosclerosis but not 
calcification diminished (45). 
 
5.7 Low-density lipoprotein receptor superfamily and osteogenesis 
While statins and other LDL-lowering therapies markedly diminish the 
progression of atherosclerosis in patients with FH, aortic valve and aorta calcifications 
are minimally affected (13). This apparent dissociation between the process of 
atherosclerosis and intimal calcification is further emphasized in murine models of aortic 
calcification. Using the chow fed C57Bl/6 Ldlr-/- mouse model, Awan et al. have shown 
that extensive aortic calcifications occur in a distribution similar to that found in humans 
(24). Conversely, wild-type mice fed a high-cholesterol, high-fat diet have serum levels 
of cholesterol similar to the chow-fed Ldlr-/- mouse but do not develop calcifications (Fig. 
4).   These observations strongly support the concept that the LDL-R modulates vascular 
calcification independent of serum LDL. Our hypothesis is that osteogenic signaling 
pathways are modulated by an intact LDL-R protein. As a result, mutation at the ldlr 
gene locus results in dysregulated calcification signaling pathways in osteoblasts-like 
cells (Fig. 2).  
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  The roles of LRP1, LRP5 and LRP6, proteins belonging to the LDL-R superfamily 
of proteins, are becoming increasingly important in vascular calcification. LRP1 
expression levels are higher in mature chondrocytic cell lines suggesting a specific role 
of LRP1 in cartilage formation (46). Interestingly, Lrp1-/- mice were found to develop 
chondrogenesis of the vascular wall emphasizing the regulatory role of this LDL-R family 
member in cell differentiation (47-49). Both LRP5 and LRP6 are large single-pass 
transmembrane receptors also part of the LDL-R superfamily. Their role in the canonical 
Wnt signaling pathway has been extensively investigated in Drosophila, Xenopus and 
mice and is briefly described above. Although LRP5 has an established role in bone 
development, murine knockouts on a western diet showed both osteoporosis and 
dyslipidemia thanks to its putative roles in binding apolipoprotein E-containing 
lipoproteins and chylomicron clearance (51, 52). Human mutations in LRP6 have been 
identified in the context of severe osteoporosis and premature cardiovascular disease 
(49). Finally, LRP6 can bind and regulate the function of the LDL-R (50). This raises the 
possibility of molecular cross-talk between the LDL-R and LRP6. Given the role in LRP6 
in the mineralization process, the possibility that the LDL-R modulates its function must 
be considered.  
 
  Ldlr-/- mouse aortic tissue exhibits abundant LRP5 and Wnt5a expression (24) 
(Fig. 5). This may be partly explained by the requirement of LRP pairing for LDL-R-
clearance. LDL-R internalization is severely diminished when LRP6 is knocked down 
(50). Therefore in the absence of LRP6 and possibly LRP5 (48, 49), LDL-R cannot leave 
the membrane surface and intracellular signaling becomes disrupted.  
 
  The identification of oxidized lipoprotein particles in tissues such as bone has led 
to the concept that lipid oxidation products directly inhibit osteoblast differentiation and 
induce osteoclast differentiation further supports this concept (15, 52, 53). Whether 
vascular calcification develops as a consequence of increased bone resorption and 
serum calcium remains unclear. A study by Awan et al addressed this question by 
studying biomarkers of bone turnover in 19 patients with heterozygous FH (54). Mean 
bone mineral density (BMD) at the femoral neck in these patients was not found to differ 
from age-, and sex-matched mean BMD. However, negative correlations (r=-0.64, 
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p=0.0034) were seen between the aortic calcium score and serum concentrations of 
osteocalcin, a marker of bone formation. Despite the absence of significant bone loss in 
these patients, diminished levels of serum osteocalcin compared to controls suggest that 
bone formation in FH may be subtly altered, although the clinical significance of this 
observation remains uncertain. Lack of an LDL-R might modulate osteoblast function 
either locally in the vasculature, in bone or in both tissues simultaneously. This would 
provide a molecular explanation for the marked vascular calcifications seen in patients 
with nonfunctional LDL-R.      
 
5.8 Conclusions: 
  The finding of accelerated vascular calcifications in patients with familial 
hypercholesterolemia that occurs independently of blood cholesterol levels coupled with 
data from mouse models of aortic calcifications supports a role for the LDL-R protein in 
the process of arterial mineralization. While statins, drugs that are known to increase 
LDL-R density and function at the cell surface, have markedly decreased the process of 
atherosclerosis, arterial calcifications remain unperturbed by this approach. Other 
avenues aimed at modulating the LDL-R signaling pathway may help identify novel 
therapeutic approaches to prevent vascular calcification.  
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5.9 Discussion: 
The evolution of vascular calcification appears to be, at least in part, independent 
of LDL-cholesterol levels (24) and once osteoblast-like cells differentiate; the process 
may become only poorly reversible. Conventional treatment modalities may lower 
cholesterols level and prevent coronary artery disease but do not necessarily stop 
vascular calcification. If FH patients survive coronary artery disease, they encounter 
morbidities associated with premature calcification of the aorta, such as hypertension or 
embolizing calcified lesions. The intriguing finding that diet-induced 
hypercholesterolemia in mice to levels that of homozygous FH (LDL-R-/-) alone does not 
lead to vascular calcification, may change established paradigms in the concept of 
arterial calcification (Fig. 4). Therefore we consider that vascular calcification requires 
two factors; one for initiation in the form of endothelial insult (oxidized LDL, angiotensin 
II, cytokine release and mainly intimal inflammation) and other factors for maintenance in 
the form of genetic predisposition (lacking cell surface receptors, lacking inhibitors of 
calcification). In turn, these factors are expected to trigger BMP2 activation of Msx2 and 
the Wnt/Lrp5/β-catenin signaling pathways, as well as the Runx2/Cbfa1 pathway and 
mediate activation of osteoblast transformation (Fig. 2).  
LDL-R-deficient mice developed calcium deposition in the intimal space of the 
aorta similar to humans with FH (12). This implies that early sub-endothelial damage 
caused by foam cell formation during the atherosclerosis process results in accumulation 
of structural matrix (collagen). Therefore early screen and detection with a sensitive 
method like CT scan in human is essential for disease understanding, monitoring 
treatment response and planning for future surgical interventions.  
Vascular intimal calcification stands in sharp contrast with the disturbances in 
calcium and phosphate metabolism in ESRD. Even when extracorporeal LDL-cholesterol 
filtration techniques (LDL aphaeresis) are used to normalize plasma LDL-cholesterol, 
patients do not suffer calcium levels alterations (54). Despite apparently normal levels of 
calcium, phosphate and bone mineral density, a negative correlation between 
osteocalcin levels and calcification merit further investigation. Therefore it would be of 
interest to examine bone metabolism in established animal models.  
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Unfortunately, at the present time, we have little in the way of medical therapy to 
halt or reverse vascular calcification. Anti-inflammatory agents, pyrophosphate inhibitors, 
chelating therapy, vitamin K, selective estrogen receptor modulators and calcium 
channel blockers all hold promise as potential therapies (55). The ideal agent would 
modulate the pathological calcification process –occurring at sites of tissue injury or 
inflammation, as seen in atherosclerosis, while leaving normal bone formation intact. 
Modulating inflammation is fraught with potential adverse effects; choosing an agent that 
leaves the immune defenses intact and decreasing inflammation would represent a 
potential therapeutic avenue. Interestingly, a randomized phase III (56) clinical trial is 
studying the role of subcutaneous canakinumab (an IL1β inhibitor) in stable post 
myocardial infarction patients. The purpose of this trial is to test the hypothesis that 
canakinumab treatment in patients with cardiovascular disease on lipid lowering drugs 
will prevent cardiovascular recurrence. It will be interesting to follow these patients for 
the development of calcific aortic stenosis and aortic calcification. This will help confirm 
the two hit hypothesis that is required to develop aortic calcification beyond cholesterol 
lowering.  
It is interesting to note that the relationship between age and cholesterol levels has 
previously been observed in patients with homozygous FH [57]. This simple measure 
was seen as an index of “cholesterol burden” during lifetime. In our studies in patients 
with homozygous FH in whom premature aortic calcifications was determined by 
computed tomographic (CT) scan, a strong correlationwas found between aortic 
calcification score and age (r = 0.73, p = 0.0001), but not with total cholesterol (r =-0.36, 
p = 0.0715) [12, 13]. This suggests that age remains the most important factor in 
vascular calcification.  
Based on the clinical trial evidence of statins on the progression of calcific aortic 
stenosis [43], and of trails showing that statins do not reduce the rate of progression of 
coronary calcifications despite a beneficial effect on the progression of atherosclerosis 
[58], it appears important not to solely reduce cholesterol markedly, but to do so early in 
order to prevent the calcification process. As statins increase the LDL-R on the cell 
surface, this should modulate osteocyte activity. Yet, this does not appear to be the case 
in the clinic. The molecular basis for this observation remains to be explained.  
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5.11 Legends and figures: 
 
Figure 1. 
 
 
 
 
 
Figure 1. A schematic representation of the signaling pathways in vascular calcification in relation 
to known stimulatory and inhibitory factors 
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Figure 2. 
 
 
 
Figure 2. A proposed model linking the LDL-R and the Wnt canonical pathway. In this scheme, 
the inflammatory environment created by atherosclerosis lesions in the FH mouse model leads to 
differentiation of osteoblast precursors cells to osteocytes. The absence (complete or partial) of 
the LDL-R contributes to translocation of the β-catenin to the nucleus.  
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Figure 3. 
 
 
 
Figure 3. Age- and gene dosage-dependent increase in aortic calcification obtained by 
computed tomography in patients with homozygous (n = 22) heterozygous (n = 17) 
patients with known mutations at the Ldlr gene. Controls (n = 50) were patients 
undergoing virtual computer-tomography assisted colonoscopy. 
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Figure 4. 
 
 
 
 
Figure 4. The effect of diet on serum cholesterol in wild type (WT) C57BL/6 background mice on 
both normal diet (chow) and high cholesterol, high fat diet (Western diet WD) in comparison to 
Ldlr-/- mice on a chow diet. Despite nearly comparable serum cholesterol levels, the degree of 
calcification was over 70 fold more in the Ldlr-/-  mice fed a chow diet than in the WT fed a WD. 
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Figure 5. 
 
 
 
 
Figure 5. The immunohistochemical expression of LRP5/6 and Wnt5a in the aortic root of WT 
and Ldlr-/- mice. This sections indicating the involvement of the Wnt canonical pathway in the 
aortic calcification of Ldlr-/- mice via LRP5/6 signaling. 
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6. Foreword:  
Inflammation predates atherosclerosis and aortic calcification. In this last article, 
we examine the effects of interleukin-1β inhibition on the process of arterial calcification 
in two animal models.  There is a strong translational aspect of this work to prevent the 
severe and premature aortic calcification in familial hypercholesterolemia and other 
chronic diseases.  
 
Familial hypercholesterolemia is predicted to be affecting at least 70,000 
individuals in Canada. Confirmed FH subjects are at a higher risk of premature CVD and 
thus at risk for premature aortic calcification. Despite intensive medical therapy, arterial 
calcification is currently not amenable to medical therapy. 
 
 As a proof-of-concept, it is experimentally possible now to modulate vascular 
calcification in mice by inhibiting interleukin-1β, a key inflammatory mediator involved in 
atherosclerosis and vascular calcification. Moreover, we showed that LDL-receptor-
deficient (Ldlr-/-) mice have a twofold higher level of interleukin-1β than LDL-receptor-
attenuated Pcsk9(Tg) mice and this may contribute significantly to the difference in the 
degree of calcification seen in both models. 
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6.1 Abstract:  
Objective: Given the link between cholesterol and activation of inflammation via 
interleukin-1β, we tested the effects of IL-1β inhibition on atherosclerotic calcification in 
mice. 
Background: Patients with familial hypercholesterolemia (FH) develop extensive 
aortic calcification and calcific aortic stenosis. Although statins delay this process, LDL-
cholesterol lowering alone is not enough to avert it. Data suggests that vascular 
inflammation initiated by hypercholesterolemia is followed by unchecked mineralization 
at sites of atherosclerotic plaques. LDL-receptor-deficient (Ldlr-/-) and LDL-receptor-
attenuated Pcsk9(Tg) mice are available animal models for pharmacological testing. 
Methods and Results: A mouse monoclonal antibody (mAB) against IL-1β or placebo 
was administered subcutaneously to Ldlr-/- and Pcsk9(Tg) models fed a Western diet. 
Drug level, anthropometric, lipid and glucose profiles were determined. PCSK9, SAA1 
and cytokine expressions were measured by ELISA. Aortic calcification was determined 
by micro-CT and X-Ray densitometry and aortic flow velocity was assessed by 
ultrasound. Circulating levels of IL-1β in Ldlr-/- mice were significantly greater (2-fold) 
than observed in Pcsk9(Tg) mice. MAb- and placebo-treated mice did not differ in their 
growth, lipid, glucose profiles and other cytokines while plasma SAA1 levels were lower 
in mAb-treated mice. Calcifications were significantly diminished in mAb-treatment Ldlr-/- 
mice (a reduction of 75% by X-ray and 96% by micro-CT) and reduced insignificantly in 
mAb-treatment Pcsk9(Tg) mice, whereas aortic flow velocity was unchanged in both 
models. 
Conclusions: Herein, we demonstrate that aortic calcifications can be inhibited by an 
IL-1β mAb in LDL-receptor deficient mice. These results have a translational component 
to prevent vascular calcification in human and represent new evidence to rationalize 
targeting inflammation in cardiovascular disease. 
 
Key Words: Familial Hypercholesterolemia, LDLR, PCSK9, IL-1β, Aortic Calcification. 
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6.2 Abbreviations: 
 
AoCS  = aortic calcium scores 
FH   = familial hypercholesterolemia  
hsCRP  =high-sensitivity C-reactive protein 
IFNγ  = interferon gamma  
IL-1β  = interleukin-1beta 
iNOS  = inducible nitric oxide synthase  
Ldlr  = low-density lipoprotein receptor gene in mice 
Ldlr-/-  = Ldlr knockout mice 
Micro-CT = micro-computerized tomography  
NLRP3 = NOD-like receptor family pyrin domain containing 3 
PCSK9 = proprotein convertase subtilisin/kexin type 9 
SAA1  = serum amyloid A1 
Pcsk9  = proprotein convertase subtilisin/kexin type 9 gene in mice 
Pcsk9(Tg) = Pcsk9 transgenic mice 
TNFα  = tumor necrosis factor-alpha  
WD  = western-diet  
Wnt  = a hybrid of Wg (wingless) and Int1 (integration1) genes in Drosophila  
WT  = wild-type  
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6.3 Introduction: 
Patients with familial hypercholesterolemia (FH) as a result of mutations in the low-
density lipoprotein receptor (LDLR) gene experience severe and extensive vascular 
calcification in an age dependent fashion.1 Using computerized tomography (CT) scans 
of the thoraco-abdominal aorta, revealed that this phenotype involves the entire aorta by 
the second decade of life in homozygous FH.1  In heterozygous individuals, a similar 
degree of vascular calcification is seen 20 years later.2 This stands in marked contrast 
with non-FH subjects in whom vascular calcification is not seen until the 7th decade of 
life. Interestingly, all relevant clinical and laboratory parameters in relation to bone and 
calcium homeostasis are within reference values.3 We recently recapitulated this 
phenotype in two mouse models and validated a micro-computed tomography (micro-
CT) technique.4 Using this method it was established that Ldlr-/- mice develop aortic 
calcification in a pattern similar to that seen in human. Furthermore, similar findings were 
obtained in Tg(Pcsk9), mice that transgenic for proprotein convertase subtilisin/kexin 
type 9 (PCSK9)5, a protein known to promote the LDLR degradation.6 Intriguingly at a 
comparable levels of serum cholesterol, an adult Ldlr-/- mouse fed a normal Chow-diet 
develops 70-fold greater calcification in comparison to a wild-type (WT) mouse fed a 
Western-diet (WD). This led us to postulate a model in which vascular inflammation due 
to early hypercholesterolemia is followed by dysregulated mineralization of 
subendothelial tissues.7 
 
The importance of vascular calcification in man is increasingly recognized in an 
aging population and in patients with FH. It is estimated that 30% of individuals over 60 
years of age have increased calcium deposits in major arteries.8 The hemodynamic 
consequences of calcium buildup in the vasculature include a reduction in aortic and 
arterial elastance, and cardiovascular hemodynamic response becomes compromised. 
Clinically, the impact of vascular calcification contributes to arterial hypertension, aortic 
valve stenosis, limb ischemia, myocardial infarction and congestive heart failure.9 
Furthermore, calcific aortic stenosis is the leading cause of aortic valve replacement in 
Western countries and the third leading cause of cardiovascular disease.10-13 It is 
estimated that in the Western world approximately 3% of adults over 75 years of age are 
affected by calcific aortic stenosis.14 Unfortunately, at the present time no efficient 
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therapy exists to stop or reverse vascular calcification.15 Amongst the many potential 
targets to prevent vascular calcifications, several interfere with bone formation, an 
undesirable side effect in an aging population. Anti-inflammatory agents, pyrophosphate 
inhibitors, chelating therapy, vitamin K, selective estrogen receptor modulators and 
calcium channel blockers are a short list of potential drugs.15-16 
 
In the present study, we investigated whether inhibition of the inflammatory cytokine 
interleukin-1β (IL-1β) prevents vascular calcification. Interleukin-1β plays an essential 
role in triggering an inflammatory response to injury and mediating the calcification 
process via the actions of IL-1β on Wnt signaling.17 Current data implicates cholesterol 
micro-crystals as being the initiating factor in the release of IL-1β through the activation 
of the NLRP3 inflammasome.  Inflammasomes are large, multimeric protein complexes 
that connect the metabolic stress sensing with proteolytic cleavage of prointerleukin-1β 
into bioactive IL-1β. Inflammasomes are thus responsible for activation of inflammatory 
processes, and have been shown to induce cell pyroptosis.17 Stimulation of the IL-1 
receptor on vascular endothelial cells leads to upregulation of iNOS, endothelin-1, 
chemokines/cytokines, adhesion molecules, endothelial and smooth muscle proliferation 
and macrophage activation, processes that contribute to endothelial dysfunction and 
progression of atherosclerosis.18 The targeted inactivation of IL-1β decreased plague 
size in a mouse model of atherosclerosis (apoe-/-/IL-1β -/-) fed a high cholesterol diet.19 In 
addition, lack of IL-1β decreased the severity of atherosclerosis in apoe-/-mice while 
prolonged treatment with IL-1β promotes arterial intimal thickening in the porcine 
coronary artery.20 In addition, IL-1β has been implicated in atherothrombosis and plaque 
rupture in several pre-clinical and clinical studies.21 Apparently, IL-1β inhibition 
modulates both a pro-inflammatory mediator that is not absolute for host defense and a 
signaling process that is not critical to innate immunity. Furthermore, IL-1β inhibition 
does not modify plasma level of lipids and lipoproteins, thus making it a perfect addition 
to more classical lipid lowering agents.  Herein, we tested the hypothesis that inhibiting 
the early inflammatory process with a murine monoclonal antibody against IL-1β 
(01BSUR, Novartis), will lead to a marked reduction in vascular calcifications in mice.   
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6.4 Methods 
Animal protocol. Mice were fed a WD (Harlan Teklad # TD 88137) from weaning 
until euthanasia. The colony of Ldlr-/- mice (C57BL/6J background; stock 002529) (n=31) 
were purchased from The Jackson Laboratories (Bar Harbor, ME, USA). Pcsk9(Tg) mice 
overexpressing the PCSK9 gene (n=27) were backcrossed to C57BL/6J for 10 
generations.5 Mice were kept in a pathogen free facility under 12 hour light/dark cycles 
and fasted for 3 hours prior to euthanasia and a total of 58 adult mice were used in this 
study. All procedures were approved by the animal care committee of the Clinical 
Research Institute of Montreal. The protocol for genotyping and the sequence of used 
primers can be found in supplementary materials and (Supplementary Table 1). The 
murine anti-mouse IL-1β monoclonal antibody (IgG2a/κ mAb)22 was administered 
subcutaneously for 6 months. The half life of the antibody in mice is approximately 14 
days. The 1st and 2nd doses were 10 mg/kg and subsequent injections were 7.5 mg/kg 
every other week for the remainder of the study. The study design is shown in 
Supplementary Figure 1.  Conceptually, genetically modified mice deficient in LDLR or 
transgenic for Pcsk9 respectively simulate homozygote and heterozygote FH 
phenotypes observed in humans. A treatment with either 01BSUR (treatment, + mAb) or 
NaCl 0.9% (placebo) was administered every two weeks after weaning and after the 
start of the Western diet (WD). Thus, 4 groups were analyzed: (1) Ldlr-/- on placebo (n= 
15), (2) Ldlr-/- on anti-IL-1β mAb (n= 16), (3) Pcsk9(Tg) on placebo (n= 13) and (4) 
Pcsk9(Tg) on  anti-IL-1β mAb (n= 14).  
 
Tissue sampling and plasma analysis. Mice went for primary (4 month) and final 
(6 month) assessments. Blood was collected at the induction of anesthesia by puncture 
of the left ventricle, and then transferred immediately to heparin anti-coagulated tubes on 
ice. Whole blood was used to measure glucose via a commercial glucometer (Bayer 
Diabetes Care, USA). Plasma was separated by centrifugation (20 minutes at 850xg and 
4°C) and kept at –20°C until assayed. Total cholesterol and triglyceride were measured 
by commercial kits Infinity (Thermo Fisher Scientific Inc, MA) and Wako (Pure Chemical 
Industries Ltd. Osaka, Japan), respectively. Mouse inflammatory cytokines were 
measured in two independent pools in each group by an expression ELISA array 
(SABiosciences, QIAGEN Company). SAA1 (main inflammatory marker in mice) and 
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PCSK9 levels were measured by a quantitative ELISA kit (MyBioSource and Cayman, 
respectively) according to the manufacturer's recommendations. An in-house ELISA 
assay was developed by Novartis to measure the level of circulating IL-1β mAb 
(01BSUR) given that measuring IL-1β in injected mice with anti-IL-1β mAb would be 
misleading (interference with IL-1β assay). Thus circulation levels of IL-1β mAb were 
determined by a competitive ELISA using highly purified goat anti-idiotypic antibodies 
raised against the Fab fragment of the mouse anti-IL-1β mAb. The ELISA is based on 
capture of a biotinylated anti-IL-1βmAb by plate-bound anti-idiotypic antibody and 
competition of this interaction by anti-IL-1β mAb present in the mouse serum. Serum 
concentrations of the antibody in mice were derived from standard curves generated 
with graded concentrations of the mouse anti-IL-1β mAb in mouse serum. 
 
Aorta isolation and analysis. Under general anesthesia, mice were perfused and aorta 
fixed in-situ as previously reported.23 Fine dissection of the excised aorta was done 
under microscopic inspection and each intact aorta was embedded in a single paraffin 
block for evaluation. For more details on surgical technique and histology protocol, see 
online (Supplemental Material & Methods). Vascular calcification in humans can be 
detected on a standard X-Ray or quantified more precisely on a computed tomography 
(CT) scan.2-4,24 Thus, we applied a miniaturized version (Skyscan-1072, TomoNT version 
3N.5, Belgium) to detect and quantify aortic calcification in mice with a resolution of 5-20 
μm. A three-dimensional (3D) reconstruction image and video were produced using 
commercial software to evaluate calcification. For details on X-Ray and micro-CT 
settings and the assessments of aortic valve size using ultrasound and flow velocity, see 
online Supplemental Material & Methods, Supplementary Figure 2.  
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6.5 Results: 
Inflammatory cytokine expression in aortic tissue of Ldlr-/- mice. Advanced 
atherosclerotic lesions were prominent in the aorta of Ldlr-/- mice. Expression of IL-1β, 
TNFα, and Mac2 (a marker of macrophages) was examined by immunohistochemistry 
(IHC) in WT and Ldlr-/- mice both fed a WD for 6 months. As described in Supplemental 
Material and Methods, aortic tissues were stained with appropriate primary and 
secondary antibodies. No expression of IL-1β (Figure 1A), TNFα, Mac2 was seen in WT 
control mice (data not shown). Note the intense subendothelial staining for IL-1β, TNFα 
and Mac2 (Figure 1B, C & D), reflecting complex atherosclerotic lesions.  
Anti-IL-1β mAb treatment did not alter growth, glucose and lipid profiles in 
comparison to placebo groups. Similar growth rates (data not shown) and organ 
profiles were seen after 6 months of WD in both arms. There were no significant 
differences between liver, kidneys, spleen sizes (expressed as % of body weight) or 
glucose levels between IL-1β mAb-treated and placebo-treated mice (Table 1). Lipid 
parameters were also not significantly changed between the two groups, including 
circulating PCSK9 levels between the Ldlr-/- mice groups (3,287±378 vs. 3,793±251 
ng/mL; mAb-treatment vs. placebo, respectively; p=0.28) and between the Pcsk9(Tg) 
mice groups (35,273±3,201 vs. 29,899±2,084 ng/mL; mAb-treatment vs. placebo, 
respectively; p=0.44). As expected, Ldlr-/- mice had higher total cholesterol and 
triglyceride levels than Pcsk9(Tg) mice. Circulating plasma cholesterol levels were ~2.5-
fold higher in Ldlr-/- mice relative to Pcsk9(Tg) mice (Table 1), consistent with a previous 
report.3  
Circulating levels of endogenous IL-1β were two-fold higher in Ldlr-/- mice than 
Pcsk9(Tg) mice. During the treatment phase, groups did not suffer major skin reactions 
or death related to repeated injections with anti-IL-1β mAb. To determine the efficacy of 
mAb-treatment, levels of the anti-IL-1β mAb (01BSUR) were determined by an ELISA at 
6 weeks (prior to initiation of treatment), then at 4 and 6 months (during the trough 
window of treatment). As seen in Figure 2A, therapeutic levels of 01BSUR were 
maintained throughout the course of the treatment.   
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Previous reports have shown that endogenous IL-1β levels increase by two-fold in Ldlr-/- 
mice compared to WT, post stimulation.25 Inflammatory cytokines therefore were 
measured by an expression ELISA array (SABiosciences, QIAGEN Company). 
Endogenous levels of IL-1β were determined at 6 months in placebo-treated Ldlr-/- and 
Pcsk9(Tg) mice maintained on WD diet. Intriguingly, endogenous levels of IL-1β in 
Pcsk9(Tg) mice, were half those observed in Ldlr-/- mice (p<0.010) (Figure 2B). Other 
than IL-1β, plasma levels of IL-1α, IL-2, IL-4, IL-6, IL-10, IFNγ or TNFα were not 
significantly different between Ldlr-/- and Pcsk9(Tg) mice on placebo nor between mAb-
treated and placebo-treated on the same background (Figure 3A). Interestingly, the 
level of serum amyloid A1 (SAA1, the major systemic marker of inflammation in mice) 
between mAb-treated and placebo-treated groups was 30% lower in Ldlr-/- mice and 
15% lower in Pcsk9(Tg) mice (but not reaching significance p=0.44 and p=0.59, 
respectively) (Figure 3B). Considering the plasma levels of cholesterol, triglycerides and 
IL-1β, the Ldlr-/- mice fed a WD show a more pro-atherogenic and pro-inflammatory 
profile than the Pcsk9(Tg) mice at 6 months of age. 
Significant reduction in aortic calcification in IL-1β mAb treated Ldlr-/- mice. 
Ldlr-/- mice fed a WD developed extensive atherosclerotic lesions, as seen previously.4 
Compared with placebo-treated Ldlr-/- mice, IL-1β mAb-treated mice exhibited a marked 
decrease in aortic calcification, as measured by X-Ray densitometry and by micro-CT 
aortic calcium scores (AoCS) (Figure 4).  As shown from X-Ray densitometry, Ldlr-/- 
mice on anti-IL-1β mAb showed a marked attenuation of vascular calcification by 4.3-fold 
(-75%) (0.17± 0.05 in mAb vs. 0.70±0.19 in placebo, P=0.007) and by 27-fold (96%) 
based on micro-CT scan quantification (0.12± 0.10 in mAb vs. 3.34±1.42 in placebo, 
P=0.043) (Table 1). 
As previously seen, the level of calcification in the Pcsk9(Tg) mice was lower and 
showed a later onset compared to Ldlr-/- mice.4 In Pcsk9(Tg) mice, the effect of the IL-1β 
mAb treatment on parameters of aortic calcification was not significantly different 
between placebo- and mAb-treated groups at 6 months on WD (Figure 5). Pcsk9(Tg) 
mice on anti-IL-1β mAb showed a trend towards attenuation of vascular calcification by 
55% as shown from X-Ray densitometry (0.07±0.03 in mAb vs. 0.16±0.04 in placebo, 
P=0.09) and micro-CT scan quantification (0.00±0.00 in mAb vs. 0.0015±0.001 in 
placebo, P=N.S). Interestingly, Pcsk9(Tg) mice had levels of plasma lipids and IL-1β 
markedly lower than that of the Ldlr-/- mice (Table 1, Figure 2A). 
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Flow velocities were unchanged between anti-IL-1β mAb and placebo. Because 
human subjects with familial hypercholesterolemia develop severe and premature aortic 
calcification, calcific aortic stenosis is often seen in FH patients, especially in 
homozygous FH. We thus examined aortic flow velocity in Ldlr-/- and Pcsk9(Tg) mice by 
Doppler ultrasound. At 6 months on a WD, IL-1β mAb-treatment had no effect on aortic 
valve size in either model (data not shown). The difference in flow velocity across the 
valve in Ldlr-/- mice on anti-IL-1β mAb showed no significant difference from placebo 
(1.44 ±0.34 in mAb vs. 1.22 ±0.30 in placebo, P=0.15) (Supplementary Figure 1D). 
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6.6 Discussion:  
FH is a relatively common monogenic co-dominant Mendelian disorder and is 
caused predominantly by mutations in the LDLR gene,26 coding for a cell surface 
glycoprotein that regulates plasma cholesterol via endocytosis of LDL particles.27 A 
phenotype similar to FH can be caused by mutations in the LDLR ligand, apolipoprotein 
(apo) B gene (ApoB) and the regulatory protein produced by the proprotein convertase 
subtilisin/kexin type 9 gene (PCSK9).28 At least in FH, the calcification process proceeds 
independently of cholesterol levels once subendothelial inflammation and 
atherosclerosis has occurred.1 This supports the two-hit model of vascular calcification,7 
were the first hit consists of intimal injury caused by lifelong hypercholesterolemia 
leading to accumulation of inflammatory cells, including monocytes/macrophages. The 
uptake of oxidized LDL by macrophages of the innate immune system is a critical step in 
the initiation of the atherosclerotic plaque and subendothelial inflammation. Recent data 
from Duewel et al29 and Rajamäki et al30 shows that micro-crystals of cholesterol are 
taken up by macrophages in the subendothelial layer of the arterial wall and activate the 
NLRP3 inflammasome, leading to the cleavage-activation of pro-IL-1β and its release in 
plasma. The contemporary view of vascular calcification has been extensively 
reviewed.7,8,15,31-34   
The second hit involves the calcification process by which calcium is deposited on 
matrix proteins in the intimal wall of genetically susceptible individuals. The involvement 
of inflammation in the calcification process has been shown previously.18,30 Importantly, 
IL-1β acts as a proximal amplification mechanism, causing the release of TNFα and the 
activation of the Wnt pathway35. Furthermore, IL-1β has been implicated in the 
stimulation of alkaline phosphatase36 and likely critical in the transdifferentiation of 
smooth muscle cells into an inflammatory phenotype.21,37 Therefore subsequent events 
leading to dysregulated mineralization have been postulated to involve a multi-step 
pathway, which include subendothelial injury and release of IL-1β, activation of the Wnt  
canonical pathway of osteoblasts and the decreased cross-talk between the LRLR and 
LRP5 cell surface receptors on osteoblasts7. This hypothesis establishes a link between 
atherosclerosis initiation and progression, and accelerated vascular calcification. 
Furthermore this is also consistent with the results of several trials that have failed to 
show a benefit of statins in the progression of calcific aortic stenosis.38 By the time 
vascular calcification is detected, lipid lowering therapy to prevent or reverse calcification 
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appears to be of limited clinical benefit. While statins may considerably slow down the 
process of atherosclerosis, they do not directly alter calcification. Conversely, elevated 
cholesterol seen in the WT mouse on a WD, does not lead to aortic calcifications per 
say, in sharp contrast to in the Ldlr-/- mouse model of aortic calcification.4 Moreover, 
aged Ldlr-/- mice expressing ApoB100 developed extensive oxidative stress with aortic 
valve calcification and functional valvular disease.39 Thus, our data indicated for the first 
time the potential role for IL-1β immune modulation in preventing vascular calcification. 
In addition, to the associate presence of IL-1β and TNFα in atherosclerotic aortic wall on 
Ldlr-/- mice (Figure 1), the plasma levels of IL-1β were shown to be markedly higher in 
the Ldlr-/- mice compared to Pcsk9(Tg) mice (Figure 2). The reasons for this observation 
have not yet been elucidated. This may explain why, Ldlr-/- mice develop extensive aortic 
calcifications at 6 months on WD, while Pcsk9(Tg) mice develop severe aortic 
calcifications only at 12 months of  WD.4 However, a milder calcification process was 
also observed in the current report at 6 months on WD (Figure 5).  
Most importantly, subtle changes (non-significant and less than 15%) in plasma 
levels of IL-1α, IL-2, IL-4, IL-8, IL-10, Interferon-γ, or TNFα, in mice treated with IL-1β 
mAb and placebo, suggesting that selective IL-1β inhibition does not result in a major 
alteration of innate immunity signaling (Figure 3).However the trivial positive changes in 
cytokine profile seen in Ldlr-/- IL-1β treated mice was not anticipated and may reflect the 
IL-1β-mAb complex retained in the blood, that was not seen in Pcsk9(Tg) mice at 6 
month (Figure 2A). Notably these changes were both in proinflammatory and anti-
inflammatory suggesting a desirable balance and a neutral net effect. After 6 months of 
treatment, Ldlr-/- mice with anti-IL-1β mAb reported a marked reduction in aortic 
calcification determined by X-ray densitometry (4.3-fold reduction) or by AoCS 
determined by the precise micro-CT scan (27-fold reduction), compared with saline-
treated mice (Figure 4). Although Pcsk9(Tg) showed a trend toward reduced 
calcification upon mAb treatment, those results did not reach statistical significance, 
perhaps due to lower basal calcification in those mice compared to Ldlr-/- mice (Figure 
5). The Pcsk9(Tg) mouse model is characterized by lower levels of cholesterol and IL-1β 
than the Ldlr-/- mouse and serves as a model of heterozygous familial 
hypercholesterolemia.4 This observation parallels that observed in human, where aortic 
calcifications in heterozygous familial hypercholesterolemia lag approximately 2 
decades, compared with homozygous FH.2  
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In conclusion, as a proof-of-concept, the murine IL-1β monoclonal antibody 
(01BSUR) represents a potential therapy to prevent vascular calcifications. We 
demonstrate that aortic calcifications can be prevented by selective inhibition of the 
inflammatory cytokine IL-1β and to a lesser extent by the reduction of the systemic 
marker of inflammation, SAA1. Interestingly, a randomized phase III clinical trial is 
currently underway to investigate the effect of subcutaneous injections of a fully 
humanized antibody directed against IL1β, canakinumab,40 in stable post myocardial 
infarction patients showing elevated levels of the inflammatory biomarker hsCRP. A 
translational component of this study therefore may apply to the overall treatment of 
homozygous and severe heterozygous FH patients by initiating immune modulating IL-
1β agents to decrease aortic calcification. The incidence of FH is often quoted at 1:500 
in the general population and it is much higher (1:80) in some communities with a 
founder effect, such as in the Lac St. Jean area of Quebec. These patients are at 
potential risk of premature aortic calcification and late aortic complications that are 
associated with impaired functional status and survival. Individuals with gain of function 
mutation in PCSK9 gene that promotes the LDLR degradation can similarly benefit from 
this approach.  
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6.9 Legends, figures and tables:  
 
Figure 1. 
 
Figure 1. Tissue expression of inflammatory cytokines in the aortic tissue of Ldlr-/- mice. 
(A&B) Immunohistochemistry (IHC) expression of IL-1β in subendothelium area of ascending 
aorta in the WT mouse (above) and the Ldlr-/- mouse (below) both fed a WD for 6 months.  (C) 
IHC expression of TNFα and (D) Mac2 in subendothelium area of ascending aorta in Ldlr-/- mouse 
fed a WD for 6 months. 
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Figure 2. 
 
 
Figure 2. Drug levels and endogenous circulating levels of IL-1β. (A) Levels of anti-IL-1β 
mAb (01BSUR) at 6 weeks (before treatment), 4 and 6 months in treated animals. (B) Circulating 
IL-1β levels in Ldlr-/- and Pcsk9(Tg) on WD at 6 months.  
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Figure 3. 
 
 
 
Figure 3. Cytokine levels and serum amyloid A1. (A) Placebo-treated and anti-IL-1β mAb-
treated (+ mAb) plasma levels of IL-1α, IL-2, IL-4, IL-6, IL-10, IFNγ or TNFα in both Ldlr-/- (top 
panel) and in Tg (PCSK9) mice (bottom panel). (B) Plasma levels of SAA1 in both placebo-
treated and anti-IL-1β mAb-treated (+ mAb) Ldlr-/- (top panel) and Pcsk9(Tg) mice (bottom panel). 
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Figure 4. 
 
 
 
Figure 4. Significant reduction in aortic calcification in IL-1β mAb-treated Ldlr-/- mice. 
Aortas from placebo-treated (panel A) and anti-IL-1β mAb-treated (panel B) Ldlr-/- mice. The top 
panel shows the thoracic aorta, removed en bloc, the middle panel shows the X-ray of the aorta 
and the lower panel shows the 3 dimensional micro-CT reconstituted aortas; arrows points toward 
sites of calcification progression and resolution (Panel C) shows the X-Ray densitometry 
quantification (top) and aortic calcium score (AoCS) expressed in arbitrary unit (A.U). 
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Figure 5. 
 
 
 
Figure 5. Attenuation of aortic calcification in IL-1β mAb-treated Pcsk9(Tg) mice. Aortas 
from placebo-treated mice (panel A) and anti-IL-1β mAb-treated (panel B) Pcsk9(Tg) mice. The 
top panel shows the thoracic aorta, removed en bloc, the middle panel shows the X-ray of the 
aorta and the lower panel shows the 3 dimensional micro-CT reconstituted aortas; arrows points 
toward sites of calcification progression and resolution (Panel C) shows the X-Ray densitometry 
quantification (top) and aortic calcium score (AoCS) expressed in arbitrary unit (A.U). 
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Table 1. 
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6.10 Supplemental Material: 
 
Genotyping. The Ldlr and Pcsk9 genotyping was performed by polymerase chain 
reaction amplification on genomic DNA isolated from mouse tails. Polymerase chain 
reaction products were then separated on a 3130Xl Genetic Analyzer (Applied 
Biosystems) and identified on the basis of fragment size and expected fluorescence, 
according to the manufacturer’s instructions and as previously described (1). Primers 
used for the genotyping are in (Supplementary Table 1). 
 
Aorta isolation and fixation. At term, under general anesthesia, mice were 
perfused fixed in-situ as previously reported (2).  Isoflurane at rate of 2% in 1L of oxygen 
was administered and blood was evacuated through an intact diaphragm intracardiac 
puncture and the systemic circulation was flushed with 5mL phosphate buffered saline 
(PBS) through the left ventricle at a pump rate of 0.4mL per minute for 10 min, followed 
by in-situ 4% phosphate-buffered paraformaldehyde (PBP) fixation. Organs were 
isolated and weighted in each animal while the heart and aorta was extracted as a whole 
by opening the chest wall and gently lifting the heart and excising posterior to the 
thoracic and abdominal aorta until the renal artery, where it was cut. The apex of the 
extracted heart was excised and the aortic tissue was further submerged ex-vivo in 4% 
PBP at 4qC overnight. Finally a fine dissection under microscopic inspection was 
performed and each intact aorta was embedded in a single paraffin block for evaluation. 
 
Histochemistry. Immunostaining for IL-1β (Abcam, Cambridge, MA), TNFα (Abcam, 
Cambridge, MA), and macrophage markers, Mac2 (Santa Cruz Biotechnology, Santa 
Cruz, CA) of WT and Ldlr-/- mice sections taken at the level of the ascending aorta were 
carried out according to the manufacturer’s protocol. Deparaffinized sections were 
incubated overnight at 4°C with anti-mouse IL-1β, TNFα and macrophage Mac2 
antibodies (1:20, 1:50 and 1:50, respectively). Sections were subsequently 
immunostained using an avidin-biotin-peroxidase kit (Vectastain,Vector Labs, CA). 
Nuclei were counterstained with hematoxylin (Sigma). After the end of the treatment 
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protocol, sections were performed at 6-month-old mice fed a WD and stained with Fast 
Green and Alizarin Red S solution (25 mg/l alizarin red S in 1% potassium hydroxide) to 
confirm calcium deposition in regions corresponding to calcified segments on micro-CT 
(data not shown) as previously published (3) Images were acquired using a Retiga EXi 
camera (Q-Imaging) mounted on a Leica DMRB microscope. Normalized total grey 
values from labeling monochromatic images (8 bits - 256 greyscale values) were 
obtained using Matlab R2010a (The MathWorks Inc.). 
 
Calcification and lesion analysis. We applied X-Ray and micro computed 
tomography (micro-CT), a miniaturized version, to detect and quantify aortic calcification 
in mice with a resolution of 5-20 μm. After dissection, the entire aorta was exposed to 
digital imaging capture. Aortas were then embedded in paraffin blocks as previously 
published (3). The whole cohort underwent X-Ray densitometric evaluation of 
calcification while representative samples underwent detailed and precise micro-CT 
evaluation. The radiological images of the entire aorta and aortic valve were acquired by 
digital X-Ray densitometry and then calcified areas were quantified by imageJ software 
(http://imagej.nih.gov/ij/, 1997-2012). Three independent reading were done blindly on 
two axes, averaged and expressed as % of calcification to whole aorta in arbitrary unit 
(A.U). Micro-CT evaluation was done on the scanner (Skyscan-1072, TomoNT version 
3N.5, Belgium) adopting the following parameters: 40 kV voltage; 248 μA current; 50 X 
zoom; 5.63μm pixel size; no filter applied; 0.9° rotation step, 2.2 second between frames 
at a 10 micron slice thickness. The calcium score was determined using dedicated 
software (CTAn v.1.8.1.2). Aortic calcification score (AoCS) was expressed as the ratio 
of calcified volume (mm3) over aorta volume (mm3) multiplied by 100 and expressed in 
arbitrary unit (A.U). While being rotated on a vertical axis, a three-dimensional (3D) 
reconstruction image and video were produced using commercial software (ANT 3D 
creator v.2.4 and NRecon v.1.4.4).  
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Ultrasound and flow velocity assessment. Animals were maintained under 
anesthesia with 2% isoflurane in oxygen during the whole procedure while monitoring 
the heart rate and body temperature as previously described (4). A commercial hair 
remover cream was used to clean the mouse chest, and echography transmission gel 
was applied before scanning (Aquasonic-100 from Parker Laboratories). Flow velocities 
were determined in the "Power-Doppler" mode ultrasonography with a Vevo 770 
apparatus (Visual Sonics, Toronto, Canada) equipped with a 30-MHz probe, with a 
depth focus at 12.7 mm. Three-second cine- loop movies were recorded for further 
offline analysis. A left parasternal long-axis view was used to visualize the aortic valves, 
aortic root, and ascending aorta (Supplementary Figure 2A&B) in order to position the 
probe. All measurements were performed by an operator blinded for genotypes. 
Velocities were expressed as meters per second (m/s) and the differential velocity was 
calculated by subtracting upstream from downstream velocities (Supplementary Figure 
2). 
Statistical Analysis. Categorical variables are expressed as mean ± stander error of 
the mean (SEM). Commercially available software (GraphPad Prism software, La Jolla, 
CA) was used for statistical analysis and graphs. Two-way analysis of variance (between 
treatment status, IL-1β mAb or placebo), are examined at any given time by Student’s t 
test for significance. A P value < 0.05 was considered statistically significant.  
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Supplementary Tables 
Supplementary Table 1: Primers used for the genotyping of mice. 
 
Gene Sense Primer sequence Allele Fragment 
size 
Ldlr Forward VIC – CCATATGCATCCCCAGTCTT   
Reverse           
AATCCATCTTGTTCAATGGCCGATC 
WT  167 bp 
Reverse           GCGATGGATACACTCACTGC  KO 350 bp 
Pcsk9 Forward  FAM– ACTCCCCACAACTACGGACTGT   
Reverse            ATCTTTCAGGATGCTGCATTT WT 213 bp 
Reverse            CATCCCTTTAGGCACAGAGCTT KO 338 bp 
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Supplementary Figure 1 
 
 
 
Supplementary Figure 1: Protocol and study design. A total of 58 mice were used in the 
present study. Mice were weaned for 6 weeks. Baseline measurements were obtained with 
additional matching 12 mice. At the 4-month time-point, 3-5 mice were sacrificed to determine 
plasma levels of anti-IL-1β mAb. At 6 months, aortic ultrasonography and later plasma levels for 
lipid and glucose were collected in 10-11 mice before euthanasia. 
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Supplementary Figure 2 
 
 
 
Supplementary Figure 2: Doppler ultrasound echocardiography of the aortic valve was 
performed in the aortic outflow track and downstream of the aortic valve. (A) Image 
showing the positioning of the Vevo 770 scanhead on a mouse. (B) Suprasternal view and close 
up along the long axis of the left ventricle and aortic root. (C) Pulsed-wave Doppler (PW Doppler) 
taken from upstream and downstream to the aortic valve. (D) Flow velocity across the aortic 
valve, the difference in flow velocity was calculated and represented in a histogram for IL-1β 
mAb-treated and placebo Ldlr-/- mice at 6 months. No significance in flow velocity across the 
aortic valve was seen. 
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CHAPTER 7: CLOSING REMARKS 
 
7. General discussion 
 
Familial hypercholesterolemia (FH) is the most frequent genetic lipoprotein 
disorder associated with premature cardiovascular disease (CVD) and vascular 
calcification. As an autosomal dominant genetic disorder, the transmission of the 
affected allele is 50%. If left untreated, CVD develops in men in the third to fourth 
decade of life and in women ten years later (Simon et al. 1999, Hansen et al. 1997, 
Jansen et al. 2005). Unfortunately, the majority of identified new cases are made in 
patients with advanced atherosclerosis or sudden cardiac death. Treatment options 
include lifestyle modification and administration of a potent statin, often in combination 
with other lipid-lowering agents. In some individuals, statins alone are not sufficient to 
lower lipoproteins to the recommended levels or are associated with serious side 
effect(s). Furthermore, genetic background and life-long exposure to cholesterol can 
foster an unhealthy vasculature that is chronically inflamed and prone to ectopic 
calcification as inflammation induces the differentiation of vascular cells to an osteoblast-
like phenotype. The hope for primary prevention in CVD lies in its earlier identification 
combined with the administration of new classes of anti-PCSK9 and anti-inflammatory 
drugs. A Canadian registry of FH patients would provide an invaluable tool to determine 
health outcomes, resource allocation and health economic issues. 
 
7.1. A need for a FH registry (and earlier screening) 
The purpose of creating a registry of subjects with FH is to capture clinical, 
biochemical and demographic information. Patient specimens (plasma/serum and DNA) 
are usually collected for bio-banking in order to perform specialized lipid and genetic 
testing. This registry would, on one hand, help clinicians collaborate in patient 
management and identify relatives for screening and treatment (cascade family 
screening). On the other hand, the registry would provide advice to general practitioners 
and support collaborative studies in biomedical, clinical and health economics research. 
Access to anonymized data from this registry would be available to researchers, 
clinicians, biopharmaceutical industries and government agencies through a peer-
reviewed process.  
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Undoubtedly, using data from referral centers and small FH registries has 
already led to many advances. The identification of the APOE mutation associated with 
FH from Italian and French families represents one example of the potential benefits in 
terms of novel gene discovery (Awan et al. 2013, Marduel et al. 2013). Furthermore, the 
identified APOE mutation was discovered following next-generation exome sequencing 
(a second level of genetic screening) after a candidate gene approach failed to identify a 
mutation in genes known to be causal in FH or autosomal recessive 
hypercholesterolemia. The discovery of the APOE mutation emphasizes the role of novel 
techniques in exploring phenotype-associated genes, which are not possible using 
traditional methods. Confirming the molecular basis of FH may be required in many 
instances since FH individuals with a molecular diagnosis (Wang et al. 2005) are known 
to have premature CVD and develop aortic calcifications (as confirmed by CT scan) 
(Awan et al. 2008), making early and aggressive treatment mandatory. Indeed, FH 
patients with a confirmed DNA diagnosis (definite FH) on statin regimens have a higher 
survival rate as compared to FH patients without treatment (Versmissen et al. 2008) 
(Figure 1). 
 
 
Figure 1: Kaplan-Meier survival curve for FH patients: FH patients on statin treatment 
have a better prognosis than FH patients without statin treatment. The survival rate is 
represented on the vertical axis and follow-up time is represented on the horizontal axis 
(adopted from Versmissen et al. 2008). 
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Accordingly, our reported proband with the APOE mutation was a 43 year old 
man at the time of presentation and had classical and biochemical features of FH. Sadly, 
he was not recognized for being at risk for CVD prior to his hospitalization, even though 
more than one individual in the family died from a CVD event (which argues strongly in 
favour of cascade screening). Nonetheless, the use of cascade screening of this 
proband family was successful in identifying one asymptomatic carrier (the proband’s 
sister) who was also heterozygous for the same APOE mutation and would ultimately 
benefit from close follow up in a specialized lipid clinic.  Thus, APOE mutations should 
be screened together with the classical LDLR, APOB and PCSK9 genes in individuals 
with an FH phenotype. This will help disseminate the finding that the APOE gene is in 
fact the forth loci implemented in FH and possibly a causative gene in many of the FH 
negative-LDLR/APOB/PCSK9 patients (Figure 2). 
 
 
Figure 2: Contribution of known mutations in FH. The 3 genes implicated in FH are LDLR 
(FH1), APOB (FH2) and PCSK9 (FH3); the contribution of mutations in these three genes 
ranges from 67%, 14% and 2%, respectively. However, there are a considerable number 
(17%) of unknown mutations, which could be attributed to APOE mutations. Therefore, 
expanding the candidate gene approach to include screening for the APOE gene may help 
decrease the percentage of unknown mutations (adopted from Seidah 2013). 
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From a basic science point of view, the understanding of how a mutation in 
APOE actually causes an isolated increase in LDL-C (in spite of absence of LDLR, 
APOB and PCSK9 mutations) is not completely understood.  Initial work by Marduel et al 
has shown a decreased catabolism of LDL particle using a cell-based assay. These 
findings suggest a new role for apoE in enhancing LDLR binding. However, with the help 
of properly implemented FH registries and systematic screening for mutations in the 
APOE gene, it would be possible to identify a patient homozygous for an APOE mutation 
and eventually test in vivo the LDLR binding capacity. The latter test would determine if 
the poor binding of the ligand (LDL) to the LDLR is indeed the mechanism or if an 
alternative mechanism exists. By analogy to apoB (Sun et al. 2012, Kosenko et al. 
2013), one could hypothesize that wild-type apoE may be required to prevent PCSK9 
from targeting the LDLR to degradation and mimicking a FH phenotype. 
 
We are anticipating that this report will have a positive impact on the creation of 
large registries for FH patients and ultimately allow access to specialized medical care 
for these patients. The diagnosis is critical to give patients access to novel and costly 
therapies that are given only to FH patients with a DNA diagnosis. Examples for such 
therapies are extracorporeal LDL filtration, anti-PCSK9 therapy, Lomitapide (an oral 
inhibitor of MTP), Mipomersen (anti-apoB antisense oligonucleotide), and, in the future, 
anti-inflammatory therapy. Furthermore, identifying additional genes associated with FH 
negative-LDLR/APOB/PCSK9 patients will advance cascade family screening and thus 
allow for efficient identification of more individuals at risk, which ultimately translates into 
CVD prevention.  
 
The close patient follow-up in specialized centers will ensure the identification of 
metabolic signs of harm, and trigger rapid action to prevent disease progression and 
provide optimal care. These complications will be entered into the FH registry and allow 
quality performance reviews comparing with national standards. Cardiometabolic 
aspects that modulate cardiovascular disease in FH will contribute to improve treatment 
modalities. Clinical and metabolic signs of harm include: elevated blood pressure related 
to aortic calcification or anemia related to chronic LDL-aphaeresis therapy or statin-
related muscle toxicity (rhabdomyolysis), renal toxicity (elevated creatinine), liver toxicity 
(elevated alanine aminotransferase), and glucose intolerance related to statins or, 
conceivably, infection related to anti-inflammation modulation. Monitoring and 
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recognizing all these metabolic signs of harm require dedicated teams and proper 
facilities. In the end, patients, caregivers and society will benefit. 
The establishment of national registries has proven to be a valuable asset in 
nations that have implemented them for many years (e.g.; Netherlands) (Al-Sarraf et al. 
2013). The challenges of implementing a national FH registry includes convincing 
governmental institutions to provide the required funding while ensuring a return on 
investment in terms of reduced rates of mortality, morbidity and health care costs. 
Fortunately, a Canadian FH registry has recently been initiated and I was delighted to be 
invited in there first assembly at the time of this thesis (http://clinicaltrials.gov - 
NCT02009345). This database will hopefully encompass all the new findings and 
discoveries related to patient care and thus prove itself useful in the very near future. For 
example, DNA diagnosis confirmed FH should be evaluated by CT scan prior to aortic 
valve surgery since associated calcification may increase intra-operative mortality 
(Grenon et al. 2007). Furthermore, the number of surgical procedures in this group will 
decrease once alternative therapy is made available (Chapter 6). 
 
Prospective from screening and following-up Familial Hypercholesterolemia (FH) 
patients and maintaining an FH registry: 
x Encourage the wide spectrum of FH recognition and the multiple associated genes. 
We included one of two simultaneous reports that confirm that FH can be caused by 
mutations within the APOE gene and represents the 4th locus causing FH.  
x Information from GWAS and next-generation exome sequencing should supplement 
our findings and therefore should be examined in selected FH individuals, since in 
many cases the current candidate gene approach will fail to identify a significant 
number (~20%) of FH patients.  
x This genetic approach should encourage lipid specialist to strive for confirmation of a 
molecular diagnosis in an individual with a FH phenotype so that extended family 
members of the affected index may benefit from early detection. Genetically 
confirmed FH patients have a higher risk for premature CVD and thus should be 
managed closely.  
x It would be interesting to screen FH negative-LDLR/APOB/PCSK9 cohorts for APOE 
mutations and report the prevalence of FH due to APOE mutations in these cohorts.  
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x The criteria by which the entry into a FH registry needs to be simplified to capture the 
whole range of FH. It should include a lipid profile (isolated increases in LDL-C / 
apoB) and at least one of the following:   
1) Family history of premature CVD.  
2) Skin stigmata of dyslipidemia (Xanthoma / Xanthelasma).  
3) Molecular diagnosis / dominant mode of inheritance. 
4) Functional analysis of LDLR (skin fibroblast). 
x Unrecognized phenotypes are easily captured in FH registries and specialized lipid 
centers. This was the case for the French-Canadian mutation that was ultimately 
associated with a severe form of aortic calcification that prompted us to study this 
phenomenon further (Awan et al. 2008, Alrasadi et al. 2009). 
x Study of long-term data in FH indicates that despite marked LDL-C lowering by 
statins, aortic calcification persists in a gene- and age-dependent manner and 
contributes to significant lifelong morbidity. Hopefully, this will encourage more 
biomedical researcher to examine the underlying mechanism (Awan et al. 2011). 
x It should be emphasized that vascular calcification was found to stand in sharp 
contrast with disturbances in bone metabolism and ectopic calcification as seen in 
end-stage renal disease. In fact, Bone Mineral Density (BMD) does not appear to be 
significantly disturbed in FH human subjects (Awan et al. 2010). The ectopic 
calcification on a background of normal bone calcification is intriguing and deserves 
more investigation since the bone is the main calcium reservoir. 
x It should be emphasized that early screening and monitoring of calcification in FH 
using a sensitive method like either CT scan (in human) or micro-CT scan (in 
animals), will help optimize disease detection (Awan et al. 2011), evaluate treatment 
responses (chapter 6) and plan future surgical interventions (Grenon et al. 2007).  
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7.2. PCSK9 is a “cause” and “cure” for FH (as anti-PCSK9 therapy) 
The PCSK9 gene has been established as the 3rd locus for FH since 2003 and is 
thought to decrease LDLR activity at the cell surface. Soon after the discovery of PCSK9 
and its critical role in regulating hepatic LDLR, it became a therapeutic target for LDL-C 
lowering and CVD prevention. Although PCSK9 is considered a member of the PC 
family, little is known about its potential substrate(s). Apart from cleaving itself and 
targeting the hepatic LDLR to the degradation pathway (and possibly other candidate 
receptors implicated in lipid and fat metabolism), there is very little known about its 
function in extrahepatic tissues. Therefore, before inhibiting PCSK9 on a large scale in 
man, we need to study situations that simulate an environment of low PCSK9 
availability. Hence, the purpose of the two cohort studies (reported in chapters 3 and 4) 
was to address the yet undisclosed human biology of PCSK9. In addition, an increasing 
number of reports (chapters 1) are exploring the role of PCSK9 by examining the state of 
PCSK9 protein deficiency in animals or LOF mutations in humans under different 
conditions. This will simulate how a PCSK9 inhibitor would function in vivo and predict 
potential side effects. Until more is known about PCSK9 function(s) and its potential 
partner(s), health providers cannot recommend PCSK9 inhibitors as a first line of lipid 
lowering medication. In certain health circumstances (e.g.; liver disease or pre-diabetic 
state), medical doctors could even prohibit treatment with a lipid lowering medication that 
targets PCSK9. Large-scale clinical trials with PCSK9 inhibitors are currently underway 
and will help physicians determine the appropriate patient for this new class of 
medications. 
 
The first population we studied was the homogeneous French-Canadians of 
Quebec. Four centuries ago 3,000-5,000 individual founders shaped the French-
Canadian community. Thus, this small genetic pool is an ideal population to study genes 
contributing to both Mendelian monogenic traits and complex traits. One common lipid 
determinant is the apoE phenotype, known to influence lipoprotein profiles in the French-
Canadian as well as the general population (Robitaille et al. 1996). There is a well-
known relationship between apoE genotypes and LDL-C levels, namely apoE2 is 
associated with lower cholesterol levels compared to the prevalent apoE3 isoform (Sing 
et al. 1985, Eto et al. 1986, Wilson et al. 1995, Xhignesse et al. 1991). However, only 
5% of the individuals possessing a homozygous apoE2/E2 genotype will develop a 
severe hyperlipidemia phenotype (type III dyslipidemia), which is characterized by 
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tuberous xanthoma, palmar creases and premature CVD (Johansen et al. 2011). In 
addition, PCSK9 gene mutations contribute further to the wide variability seen in plasma 
lipids.  
Prior to this report, there were no published reports of an interaction between the 
ApoE and PCSK9 genes on the modulation of plasma lipids. We found that the carrier 
rates of the PCSK9 natural LOF p.R46L variant is surprisingly enriched in certain 
regions, such as Saguenay-Lac-Saint-Jean and Québec City, reaching frequencies 
between 1:12 and 1:8. These two regions also have a high frequency of FH mutations 
(Vohl et al. 1997). The high prevalence of mutations causing low LDL-C (PCSK9 LOF) in 
areas enriched for LDLR mutations causing FH may seem counter-intuitive. One 
potential explanation may be that gene selection would favour the survival of protective 
genes to overcome deleterious ones. The likelihood of a founder effect for the p.R46L 
mutation will need to be addressed by co-segregation analysis in family members. 
However, due to the nature of the study, the identity of the patients was beyond our 
reach and thus family studies were not possible.   
 
Interestingly, when we combined the analysis of APOE and PCSK9 variants, we 
observed for the first time an intriguing phenotype associated with the combination of 
apoE2 genotype and p.R46L mutation that was characterized by higher HOMA-IR, 
insulin and leptin, which are known markers of insulin and leptin resistance. This is an 
alarming finding that warrants further investigation, and points out the importance of 
gene-gene interactions. The mechanism of insulin and leptin resistance with the 
combination of APOE and PCSK9 LOF may be partially explained by the increased 
density of LDLR (mainly in the liver) and VLDLR (mainly in non fat tissue) as a result of 
lower circulating PCSK9 levels. Furthermore, the additional LOF in APOE gene is 
suggested to further concentrate the elevated cholesterol and TG rich particles in many 
tissues that express VLDLR, including adipose tissue and the pancreas, since the apoE2 
isoform has a weaker affinity to LDLR. To explain further these observations, additional 
in vivo studies are necessary. In fact, one would anticipate that expressing both apoE2 
and p.R46L variants in transgenic mice may elucidate the underlying mechanism.  
Current in vivo data confirms that even modest elevations in free fatty acids and glucose 
could cause lipotoxicity and glucotoxicity, respectively. This may represent an important 
mechanism leading to failure of β-cell mass adaptation in the pre-diabetic state (Pascoe 
et al. 2012). It will be interesting to investigate if this anti-adaptive effect is observed in 
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older patients carrying the apoE2 genotype and PCSK9 p.R46L mutation (or PCSK9 
inhibitor). However, this remains a cross-sectional observation with its limitation, thus 
confirmation in other cohorts is necessary. Caution should be exercised when confirming 
the findings of this study in older cohorts by adjusting for waist and hip circumferences 
between groups, as they correlate better with visceral adiposity. As seen in the Pcsk9 
(KO) animal model, there is a tendency to accumulate visceral fat without total weight 
gain (Roubtsova et al. 2011). This visceral adiposity can contribute to insulin resistance, 
glucose intolerance and pre-diabetes.  
 
Diabetes mellitus was also associated with statin in many clinical trials, while 
statin-induce PCSK9 elevation is apparently contradictory to our finding with LOF in 
PCSK9 gene leading to insulin resistance,  the mechanism of diabetes in statin is 
unknown and is thought to be very different in each case. Indeed a small but significant 
increase in the rate of physician-reported diabetes was reported with rosuvastatin in the 
JUPITER study, as well as a small increase in the median value of glycated hemoglobin. 
Increases in glucose and glycated hemoglobin levels and the incidence of newly 
diagnosed diabetes have been also reported in many statin trials (Ridker et al. 2008). 
Nevertheless, the small increase in the rate of physician-reported diabetes in the 
JUPITER study (270 reports of diabetes, vs. 216 in the placebo group; P=0.01) could 
have been a random observation. Hence, further studies are needed before any 
causative effect can be established between statin or the related increase in PCSK9 
levels and diabetes. 
 
Collectively, overexpressing Pcsk9 in mice leads to hypercholesterolemia and 
aortic calcification, while both animal and human studies confirm signs of insulin 
resistance in Pcsk9 (KO) mice and in human PCSK9 LOF mutations. Therefore we 
believe that the normal PCSK9 values have a bell-shaped curve distribution, where at 
the high end they lead to hypercholesterolemia and promote atherosclerosis and 
vascular calcification, while at the lower end they lead to hypocholesterolemia and may 
promote visceral obesity and insulin resistance in high risk individuals (Figure 3).  
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Figure 3: PCSK9 GOF and LOF and the risk of cardiometabolic disease. PCSK9 GOF 
mutations leads to less LDLR/VLDLR on the cell surface of tissues and this will contribute to 
hypercholesterolemia, atherosclerosis and arterial calcification. PCSK9 LOF mutations (or 
use of inhibitors) leads to higher LDLR/VLDLR accumulation on the cell surface and 
contribute to hypocholesterolemia, visceral adiposity and insulin resistance. Therefore, 
targeting PCSK9 should be a balance between benefit and harm (adapted from Awan et al. 
2011, Roubtsova et al. 2011 and candidate private collection). 
 
In an attempt to further understand PCSK9 biology, we turned to a second 
population with a completely different mixed genetic background. The p.R46L allele 
frequency in this adult population is 2.5%, which is half of that seen in the French-
Canadian population and similar to that of the general population, leading to ~8% lower 
LDL-C than the non-p.R46L allele carriers (Benn et al. 2010, Kathiresan et al. 2008). 
Given the ethnic heterogeneity of this population, we cannot perform reliable subgroup 
statistical comparisons without a much larger sample size. Nevertheless, the presence 
or absence of the p.R46L variant was not associated with a difference in the response to 
statin, as one might expect, and therefore knowing whether the patient is a p.R46L 
carrier would not likely alter therapeutic decisions. The criteria to include patients based 
on low cholesterol levels (less than 3.4 mmol/L) could have been a confounding factor 
(selection bias) leading to a blunt response to rosuvastatin. This raises the question of 
whether or not p.R46L carriers could have showed a stronger response to rosuvastatin 
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in a hypercholesterolemia cohort. However, in the same study we examined 1,000 
patients at two time points and established that plasma PCSK9 concentrations are 
stable as a biomarker over time among those allocated to placebo, but increase by 
approximately 30 % among those allocated to 20 mg rosuvastatin.  
Not surprisingly, individual responses to statin were variable. However, we 
established a significant relationship between the magnitude of LDL-C reduction and the 
increase in PCSK9 concentrations on both the absolute and the relative scale. Across 
the entire group of patients, LDL-C reductions were associated with increases in plasma 
PCSK9 concentrations, an effect present across genders despite higher baseline 
PCSK9 concentrations in women as compared to men. The concept that a statin-related 
increase in PCSK9 level may limit statins efficacy (Seidah and Attie et al. 2005, Berge et 
al. 2006) was not supported by the present study. This can be explained by the 
presence of an intracellular pathway for PCSK9 (Poirier et al. 2009). The PCSK9 
intracellular pathway might exhibit a wide variation among individuals in a way that may 
confound meaningful correlations. Nevertheless, an approach based on the 
measurement of LDL-C response and residual PCSK9 concentrations may identify 
subjects with statin resistance (who may benefit from PCSK9 inhibitors) and subjects 
unable to tolerate statins. 
More common loss-of-function (LOF) mutations in PCSK9 gene are associated 
with lower circulating PCSK9 and reduction in both LDL-C and CVD. PCSK9-inhibition 
approaches are at phase III clinical trials and are reported to be powerful enough to 
lower LDL-C to levels seen in LOF mutations in PCSK9.  We sought to determine the 
effect of LOF mutations in this large registry hoping to be able to predict the LDL-C 
reduction by statin therapy from the initial PCSK9 levels. However, due to the effect of a 
statin on the transcription of both LDLR and PCSK9, a net result seams in favour of the 
LDLR elevation as suggested by the overall ~52% reduction in LDL-C (n=478). This is 
partially explained by the PCSK9 mode of action since it is mainly mediated by liver 
excretion and the protein-protein interaction in plasma, in comparison to the direct 
accumulation of LDLR on the surface of hepatocytes. In addition, we cannot exclude the 
co-expression of other PCSK9-inhibitors such as AnxA2 and apoB (Kosenko et al. 2013) 
or the co-regulation of other nuclear binding factors and receptors (HNF1α, HINFP, FXR, 
PPARs) by statin therapy. Nevertheless, in LOF R46L individuals after 20mg of 
rosuvastatin were associated with an overall ~56% reduction in LDL-C (n=25) and reflect 
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a non-significant additional 8% reduction in LDL-C compared to wild type PCSK9. This 
emphasizes that PCSK9-inhibition based therapy should exceed the 20% lower PCSK9 
plasma levels seen in LOF R46L in order to further lower LDL-C significantly.   
By observing the variation in the measured PCSK9 values in different 
populations, we conclude that PCSK9 exhibits diurnal rhythm and pubertal rhythm, but is 
stable over time as a biomarker, and has a skewed distribution toward higher values. 
PCSK9 is also higher in subjects with FH and subjects taking statin or fibrate drugs, 
females compared to males, and premenopausal and pregnant women compared to 
postmenopausal and non-pregnant women. PCSK9 is also higher postprandial and post 
systemic inflammation. PCSK9 is lower in a newborn compared to his mother, in women 
taking estrogen induction therapies for infertility, and in periods of overnight fasting. With 
more physiological and pathological conditions being reported, a better understanding of 
the biological functions PCSK9 may be obtained; this may influence the selection of 
candidates for this class of medications.   We can also predict populations at potential 
risk when treated with PCSK9 inhibitors by combining human and animal studies. Those 
who may be at risk includes: patients with acute or chronic viral hepatitis, pregnant 
women, individuals with insulin intolerance or diabetes mellitus, individuals with any LOF 
variants in PCSK9, individuals with neurological and psychiatric conditions, patients 
recovering from surgical operations (including liver resection) and individuals with 
cancer, metastasis and inflammation. Current on-going clinical trials will determine if 
these potential risks are seen in treated patients.  
Furthermore, the reason for the higher level of PCSK9 in premenopausal and 
pregnant women as opposed to postmenopausal and non-pregnant women is largely 
unknown. However, hormonal regulation is suggested to influence the level of PCSK9 
through different transcription factors and nuclear receptors. Candidate hormones 
include; estrogen, progesterone, gonadotropin-releasing hormone (GnRH) and growth 
hormone as suggested by infertility hormonal induction medications (Persson et al. 
2012). Furthermore, higher PCSK9 levels in premenopausal than postmenopausal 
women may reflect central regulation (Lakoski et al. 2009), while higher PCSK9 levels in 
pregnant than non-pregnant women may reflect higher cholesterol demand of the fetus 
(Peticca et al. 2013). Nevertheless, in vivo studies in animal models are required to 
further elucidate this relationship.  
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Prospective from studying populations with PCSK9 LOF mutations to predict the 
biological effect of a PCSK9 inhibitor: 
x Cardiometabolic risk required close monitoring in patients taking PCSK9 inhibitors.  
Screening should include weight, blood pressure, glucose levels and insulin levels. 
As statins treatments may tend to increase the incidence of diabetes in subjects with 
the metabolic syndrome, obesity or insulin intolerance, PCSK9 inhibitors may have a 
similar effect.   
x Testing for the apoE genotype is another consideration. The observation of insulin 
and leptin resistance associated with PCSK9 LOF mutations and the apoE2 isoform 
provides an interesting hypothesis and a research question that needs to be 
addressed. 
x Inhibition of PCSK9 may lead to visceral obesity, in Pcsk9 (KO) animal models. The 
complete absence of PCSK9 in animal models (likely not achieved by any drugs in 
human), is associated with visceral obesity and glucose intolerance but does not 
affect inflammatory biomarkers (data not shown).  
x LDL-C response to statin treatment could not be predicted by measuring circulating 
plasma PCSK9 levels, possibly due to the intracellular pathway of PCSK9 action. 
However, PCSK9 levels could probably still be used in predicting the best responder 
to PCSK9 inhibitors. Thus, PCSK9 levels should be measured before and after 
administration with a PCSK9 inhibitor and analyzed for an associated LDL-C 
response in large-scale clinical trials. This will determine the clinical usefulness of 
PCSK9–guided lipid-lowering therapies. 
x Interestingly, PCSK9 LOF mutations are more common than GOF mutations. 
Depending on the population, GOF mutations may account for ~2% of mutations 
causing FH, while LOF mutations may reach ~24% in some isolated populations of 
Québec associated with FH (as a survival gene selection). 
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7.3. Immunomodulation in FH management (anti-inflammation therapy)
We have shown that FH patients with LOF mutations in LDLR (or GOF mutations 
in PCSK9 as predicted in mice) develop premature calcification of the aorta 
approximately 25-30 years earlier than subjects without FH. Conventional treatment 
modalities lower cholesterol levels and slow down the progression of atherosclerosis, but 
do not prevent the development of aortic calcification. Thus, there is a residual risk 
beyond lipid lowering and it is manifested as increased risk of vascular calcifications 
even when plasma levels of LDL-C have been normalized.  
 
Accelerated vascular calcifications in patients with FH occur independently of 
blood cholesterol levels in adults. These findings, coupled with data from mouse models 
of aortic calcification, support a role for the LDLR and its downstream targets. In 
particular, the osteogenic Wnt canonical pathway is implicated in Ldlr (KO) mice (Awan 
et al. 2011). Targeting elements in this pathway might bring about unwanted side effects 
since the Wnt pathway is involved in a wide range of cellular functions including cell 
differentiation. An alternative approach is to modulate the local and upstream 
inflammatory stimulus, which is in line with recent data showing that micro-crystals of 
cholesterol are taken up by macrophages in the subendothelial layer of the arterial wall 
and activate the NLRP3 inflammasome (Duewell et al. 2010, Rajamäki et al. 2010), 
leading to the cleavage-activation of pro-IL-1ȕ and its release. After its release, IL-1ȕ 
acts as a proximal amplification hub causing the of the Wnt pathway implicated in 
calcification (Shao et al. 2010). Furthermore, IL-1ȕ has been shown to be involved in 
downstream stimulation of alkaline phosphatase essential to calcification (Lencel et al. 
2011) and was linked to a possible role in smooth muscle cells transdifferentiation in an 
inflammatory phenotype (Alexander et al. 2012, Keuylian et al. 2012).  
In Figure 4, we summarize our current mechanism for aortic calcification. This 
mechanism includes the uptake of oxidized LDL and cholesterol crystals by 
macrophages, a key step in the initiation of the atherosclerotic plaque and vascular cell 
transdifferentiation to an osteoblast-like phenotype. 
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Figure 4: Targeting IL-1β to inhibit aortic calcification: Anti-inflammation drugs may 
enhance vascular health in FH. Abbreviations – RBC: red blood cells, NLRP3: NOD-Like 
Receptor family Pyrin domain containing 3, SAA1: serum amyloid A1, CRP: C-reactive 
protein (adopted from chapter 6). 
 
In Figure 4, the aortic calcification process probably precedes atherosclerotic 
plaque accumulation by many years. In hypercholesterolemia, micro-crystals represent 
an endogenous danger-signal for the macrophages of the innate immune system in the 
subendothelial layer of the arterial wall (Figure 4A). Thus, micro-crystals promote the 
NLRP3 inflammasome assembly and the release of IL-1β in subendothelium and 
plasma. This results in the differentiation of aortic cells to an osteoblast-like cell and the 
release of inflammatory markers by the liver (Figure 4B).  Therefore, micro-crystals and 
IL-1β serve to maintain the state of chronic subendothelial inflammation; leading to 
dysregulated mineralization, which is postulated to involve a multi-step pathway that 
includes activation of the Wnt canonical pathway of osteoblast differentiation (Figure 
4B). Indeed, immunohistochemical analyses revealed an increased expression of the 
receptor LRP5 and Wnt ligand in aortas of Ldlr (KO) and Pcsk9(Tg) mice at 6 months of 
age as compared to wild type mice (Awan et al. 2011). This observation establishes a 
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link between inflammation, atherosclerosis initiation and progression of vascular 
calcification. Anti-IL-1β mAb selectively targets this critical step. 
 
The model shown in Figure 4 supports the two-hit model of vascular calcification 
(Fantus et al. 2013), where the first hit consists of intimal injury caused by lifelong 
hypercholesterolemia (thus the rationale to start statin treatment as soon as the 
diagnosis of FH is confirmed) leading to accumulation of inflammatory cells, including 
monocytes/macrophages. The uptake of micro-crystals and oxidized LDL by 
macrophages of the innate immune system is a key element in the initiation of the 
atherosclerotic plaque and the maintenance of chronic subendothelial inflammation. The 
second hit involves the calcification process, where calcium is deposited on matrix 
proteins in the intimal wall of genetically susceptible individuals including individuals with 
a hyperactive immune response (thus the rational to combined statin and 
immunomodulation). 
 
Activation of cytokine IL-1β will induce systemic inflammation, reflected by the 
hepatic secretion of CRP and SAA-1 (Figure 4B). Furthermore, transdifferentiation of 
aortic tissue occurs when cholesterol remains elevated and inflammation remains active, 
and with time leads to osteoblast-like differentiation and accelerated arterial calcification. 
Therefore, measuring both CRP and cholesterol may help in predicting the development 
of arterial calcification in comparison to cholesterol alone.  
 
Primary prevention strategies in newly diagnosed FH without a CVD should 
include a potent statin together with lifestyle modification. The FH population is at high 
risk to develop atherosclerosis and aortic calcification (immunization against 
atherosclerosis may be available in future). Secondary prevention with a history of 
CVD in FH should include a high dose of a potent statin (PCSK9 inhibitor, if indicated), 
and likely immunomodulation therapy if clinical trials confirm long-term safety (Figure 5).  
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Figure 5: Management of cardiometabolic disease in FH. A statin (and in future 
immunization methods) is proposed for the CVD primary prevention in asymptomatic 
molecularly-confirmed FH individuals. High dose statin in combination with 
immunomodulation is proposed as a secondary prevention in FH individuals (adapted from 
Klingenberg et al. 2009). 
 
An ideal agent that prevents vascular calcification should modulate the 
pathological calcification process occurring at the level of the subendothelium, as seen 
in atherosclerosis, while leaving normal bone formation intact. Moreover, modulating 
inflammation is fraught with potential adverse effects (increase risk of infection, cancer, 
etc.). Choosing a target that leaves the immune defenses intact and decreases 
inflammation would represent a potential beneficial therapeutic class. IL-1β targeting fits 
this category since it is not critical for innate immunity. Our data indicates for the first 
time the potential role for IL-1β immune modulation in the prevention of vascular 
calcification, as seen by lower X-ray intensity and lower micro-CT calcium scoring, and 
the prevention of vascular calcification in Ldlr (KO) mice taking anti-IL-1β mAb.  
 
Conversely, Pcsk9(Tg) mice did not significantly benefit from IL-1β immune 
modulation, possibly due to the lower burden of calcification in this model and/or lack of 
drug efficacy, since the mAb levels declined over time. It would be interesting to examine 
the kidney pathology in this animal model since the mAb-PCSK9 complex may have 
altered the filtration capacity of the nephrons, which is a general but theoretical concern 
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in therapeutic approaches using mAbs. A limitation to our study was that the kidneys and 
bone were not evaluated and the immune system was not challenged with a pathogen. 
 
However, the immune system in humans is more complex than in the mouse 
model. Nevertheless, these models are basic safety screens and the only guarantee of 
the success of these approaches is long-term outcomes in clinical trials. Screening must 
be meticulously done and it is important to pay attention to all of the data displayed in 
our animal models. Furthermore, immunomodulation approaches should be evaluated 
after the development of advanced plaques since this should simulate the real-life 
situation where the patient usually starts the medication after a CVD event has occurred 
or after a CT scan showing premature aortic calcification. Therefore, a mouse 
experiment where a Western diet is introduced first for a few months to accelerate 
atherosclerotic plaque formation, and then IL-1β mAb is administered in an escalating 
dose and frequency protocol, followed by micro-CT evaluation, would be very 
informative. Other anti-inflammatory approaches discussed earlier should also be 
evaluated in a similar protocol to demonstrate the superiority of one anti-inflammatory 
drug over the other (IL-1β mAb vs. low dose methotrexate, for example). 
 
Prospective from studying human and animal models to advance the understanding of 
arterial calcification and prevent disease: 
x By establishing mouse models with moderate to extensive vascular calcification that 
replicate the disease observed in humans, we can advance our understanding of the 
disease. These two animal models mimic absolute LDLR-deficiency and low LDLR-
availability. The latter phenotype is mimicked by over expressing Pcsk9. The two 
models should facilitate the studies of both the pathophysiology of vascular 
calcification as well as other metabolic risk. 
x Having validated micro-CT as a sensitive technique to quantify aortic calcification in 
murine models, we can now begin to test different therapeutic approaches. Micro-CT 
allows us to measure changes in calcification in a precise, quantifiable and 
informative manner and hence the efficacy of different treatment regimens can be 
compared.  
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x The mice used in our study demonstrate that aortic calcification is multifactorial and 
is associated with aging, LDLR-deficiency and is accelerated by Western diet. 
Pcsk9(Tg) confirmed the possible role of LDLR in calcium deposition. The role for the 
LDLR protein needs to be further examined. 
x The mechanism of aortic calcification in human FH could not be elucidated from this 
work. However, macrophage markers, TNFα and IL-1β were highly expressed in 
calcified aorta. Furthermore, the canonical Wnt pathway was induced, at least in 
mice, suggesting an inflammatory proliferative and remodeling mechanism. 
x We demonstrate that aortic calcification can be inhibited by IL-1β mAb in LDL-
receptor deficient mice. These results may be applied to the prevention of vascular 
calcification in humans. Future therapeutic approaches may include a combination of 
a statin with an anti-inflammation agent. Further testing in aortic calcification is 
warranted using different drug doses and patterns of administration. 
x Interestingly, a randomized phase III clinical trial is currently underway to investigate 
the effectiveness of subcutaneous injections of a fully humanized antibody directed 
against IL1β, canakinumab (Ridker et al. 2011) in stable post MI patients (secondary 
prevention) with elevated levels of the inflammatory biomarker CRP. It would be 
interesting to evaluate coronary calcification before and after canakinumab in a 
subset of these patients to confirm the findings we obtained in mice. However, failure 
to regress aortic calcification in these secondary prevention patients is expected, 
whereas the reasonable expectation should be attenuation of calcification.    
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7.4. Conclusions 
The incidence of FH in the general population is approximately 1/500 and it is 
much higher in populations with a founder effect, such as in the Lac St Jean and 
Kamouraska regions of Quebec. Given the incidence of FH in the general population, it 
is predicted that FH affects at least 70,000 individuals in Canada. Without adequate 
screening and treatment strategies for FH, vulnerable individuals are missing a golden 
opportunity in preventive medicine. Cascade screening should be implemented and DNA 
analysis should now include the APOE gene. Long-term follow-up of FH subjects will 
help identify success and failure of new treatment modalities and will help provide 
patients access to novel treatments. While on therapy, some FH subjects may develop 
statin intolerance and many experience premature aortic calcification that is associated 
with impaired functional status and survival. Similarly, individuals with GOF mutations in 
the PCSK9 gene that promotes degradation of the LDLR might be at risk (as seen in 
animal models). 
 
Therefore, PCSK9 inhibitors are a very attractive class of medications that will 
become an add-on to statins or an alternative to statins in statin-intolerant patients due 
to its unique mode of action. Currently, several clinical trials using different approaches 
to inhibit PCSK9 have reached phase III and continue to report satisfactory responses. 
With PCSK9 inhibitors, used in assisted monotherapy or in combination with statins, 
safety and tolerability are a concern. Therefore, we and others are focusing on predicting 
the long-term effects of these drugs on cardiometabolic health. PCSK9 inhibition, as 
seen in natural LOF mutations, is successful in maintaining lower cholesterol; however, 
care should be taken in individuals with cardiometabolic risk, particularly insulin 
resistance. APOE genotyping may assist in identifying individuals at risk. 
 
Aortic calcification is currently under-diagnosed and unresponsive to existing 
therapies. Subendothelial inflammation may represent the missing link between 
cholesterol and calcification. Administration of a murine IL-1ȕ monoclonal antibody was 
successful in preventing vascular calcifications in mice. This study therefore indicates a 
potential means of treating homozygous and severe heterozygous FH patients to 
prevent aortic calcification.  
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